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Abstract
The central goal to engineer feline inmiunodeficiency viral (FIV) vectors into a more modular 
platform for long-term ocular gene therapy was accomplished collaboratively by separating 
envelope, packaging and transfer function, the latter of which I optimized. FIV mediated gene 
transfer to the aqueous humor outflow tract and to the retina was established and long-term 
vector function and biocompatibility were confirmed. Transduction of the outflow tract was 
highly efficient and resulted in genetic modification of nearly the entire trabecular meshwork.
For this purpose, I developed methods for administration and sensitive monitoring of FIV vectors 
in the anterior chamber and a novel subretinal injection teclmique.
Bicistronic FIV vectors generated high levels of two different transgenes eGFP and |3- 
galactosidase, which allowed live m vivo tracking and sensitive yet specific cell labeling in 
tissue specimen, respectively. An integrase mutant control vector that differed in only one amino 
acid resulted in no significant transduction while preserving all other biochemical properties.
I developed a novel protocol for scaled-up production FIV vectors using cell factories and large- 
volume concentration that proved useful in the animal studies of this thesis. Especially the results 
achieved in the larger animal model, the domestic cat, validated the protocol for large-scale 
production. Transient transfection of 10 times lessDNA into 293T cells within high surface area 
cell factories and high volume, fixed-angle ultracentrifugation resulted in liigh titer vectors.
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Hypothesis, Specific Aims
1. Hypothesis
Feline immunodeficiency viral vectors can be engineered into a modular platform that 
allows long-term ocular gene transfer to the ocular outflow tract and the retinal 
pigment epithelium and monitoring of function with standard ophthalmology 
techniques.
1.1.Specific Aims
1.1.1. Refinement of an FIV vector system for ocular gene 
therapy.
An FIV vector system will be engineered that has versatile, exchangeable components 
of envelope, packaging, and transfer, fulfills safety requirements, and allows 
simultaneous delivery o f several transgenes.
1.1.2. Development of scaled-up lentiviral vector production and 
concentration.
Higher titers and larger volumes of vectors are needed for in vivo or ex vivo organ 
culture than for in vitro applications. A method will be developed that allows scaled- 
up and efficient generation of several liters of vector and subsequent large volume 
concentration.
1.1.3. Establishment of in vitro and in vivo FIV-mediated gene 
transfer to the aqueous humor outflow tract with long-term 
assessment of vector function.
Gene delivery to ocular tissue will be established stepwise in vitro, in ex vivo organ
cultures of perfused anterior human eye segments and in the domestic cat. Efficiency
of gene delivery and toxicity will be assessed. Vector long-term function will then be
studied in the outflow tract and retina that constitute the target tissue for gene therapy
of glaucoma and retinal neovascularization, respectively. New techniques will be
developed for the microsurgical delivery of vectors to the anterior chamber and the
subretinal space and for monitoring of transgene expression.
-  8 -
Hypothesis, Specific Aims
1.1.4. Establishment of in vivo FiV-mediated gene transfer to the 
retinai pigment epithelium with long-term assessment of 
vector function.
Gene delivery to ocular tissue will be established stepwise in vitro, in ex vivo organ 
cultures and in animal models. Initial studies will adjust efficiency of gene delivery 
and assess toxicity. Vector long-term function will then be studied in the outflow tract 
and retina that constitute the target tissue for gene therapy of glaucoma and retinal 
neovascularization, respectively. New techniques will be developed for the 
microsurgical delivery of vectors to the anterior chamber and the subretinal space and 
for monitoring of transgene expression.
- 9 -
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Introduction: Eye Structure and Function
6. Introduction
At the center of this thesis was the realization that the current treatment modalities for 
several chronic eye diseases still resulted in progressive visual loss. These include 
glaucoma in particular and various degenerative but also vasoproliferative disorders 
o f the retina and choroid in general. The knowledge of the genetic defects and 
resulting molecular pathology of these diseases had dramatically increased in the 
preceding years. At the same time new tools had become available to manipulate 
cellular pathology on its most basic level in the form of viral vectors. When in 1998 
Dr. Eric M. Poeschla developed the first non-primate lentiviral vector that promised to 
combine both the power o f permanent genetic modification and safety o f being non- 
pathogenic in humans/ I decided to pursue my idea of lentiviral gene therapy for 
these diseases and moved from Germany to start my studies in Dr. Poeschla’s 
laboratory.
The following will introduce the reader to the structure of the eye, to glaucoma and 
choroidal and retinal diseases and to ocular gene therapy.
6.1.Eye Structure and Function
I will review the eye structure and function that is relevant to this thesis as well as 
diseases affecting them in the following. The ocular outflow tract for which I 
developed genetic long-term modification is situated in the anterior segment o f the 
eye. In contrast, the retinal pigment epithelium is situated in the posterior segment 
underlying the neuroretina. The most applicable diseases that affect these structures 
are glaucoma, a progressive optic neuropathy caused by intraocular pressure that is 
relatively too high for the affected eye, and degenerative as well as vasoproliferative 
diseases of the retina that originate in the retinal pigment epithelium.
Glaucoma is typically caused by a decreased outflow facility in the anterior segment 
but causes degeneration of retinal ganglion cell axons in the posterior segment. 
Degenerative and vasoproliferative eye diseases are for the most part limited to the 
posterior segment but may progress to engulf the anterior segment at advanced stages.
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6.1.1. Overview of the Mammalian Eye Anatomy
6.1.1.1. Tunicas of the Eye
The mammalian eye consists of three separate layers that serve different functions: the 
fibrous tunic, the vascular tunic, and the nervous tunic.
The fibrous tunic is the most outer layer of the globe and consists of cornea and sclera 
giving the eye its rigidity and spherical shape. It is composed of dense connective 
tissue that contains collagen as its main component.
The vascular tunic is the middle layer of the eye and includes the iris, the ciliary body 
and the choroid. The iris regulates the amount of light that enters the eye but is also 
coupled to accommodation to increase depth of field and image quality. As discussed 
in more detail below, the ciliary body produces the aqueous humor and serves 
accommodation by allowing the lens to change shape and. The choroid holds a dense 
vascular network that provides high blood flow to supply the retina with oxygen and 
metabolites but also to maintain a consistent temperature. The choroid has a high 
concentration of melanocytes to minimize light scatter.
The nervous tunic consists of the neuroretina that captures the light with the first 
neuron of the visual pathway, the photoreceptor, processes it as described below and 
further conducts these signals via the second neuron, the bipolar cell and the third 
neuron, the retinal ganglion cell, the axons of which form the optic nerve.
6.1.1.2. Anterior and Posterior Segment
Division of the eye into anterior and posterior segment is somewhat arbitrary but 
provides useful categories in ophthalmology. The anterior segment can be thought of 
as the active part responsible for focusing light and maintaining that function, while 
the posterior segment has a more passive function consisting of receiving and 
processing light.
The anterior third of the eye is called the anterior segment and includes the cornea, 
the anterior chamber, the trabecular meshwork, Schlemm’s canal, the iris, the lens and 
the posterior chamber, a space between the iris and the anterior vitreous face. The air- 
comea interface is the main refi*active part of the eye, while the lens adds to this and 
allows change of focal length by accommodation. The ciliary body and the outflow 
system are discussed in detail below.
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The posterior segment comprises the posterior two-thirds of the eye from the anterior 
hyaloid membrane onward and includes the vitreous, retina, choroid, sclera and optic 
nerve.
6.1.2. Aqueous Humor Production and Outflow
Intraocular pressure is dependent on aqueous humor production and its outflow. 
Aqueous humor is produced by the ciliary body.^ The trabecular meshwork is the 
principal, pressure-dependent path for aqueous egress and represents the structure by 
whose resistance intraocular pressure is maintained. Flow is affected by the 
interaction of the ciliary body and its tendinous connections to the trabecular 
meshwork.
Besides production of aqueous humor other functions of the ciliary body are 
accommodation by interaction with the crystalline lens via zonular fibers 
and alteration of aqueous outflow through the trabecular meshwork.
Anatomically, the ciliary body can be subdivided into the pars plicata and pars plana. 
The pars plicata contains between 70 and 80 major and minor ridges on its inner 
surface that extend into the posterior chamber of the eye by about 1 mm. The pars 
plana has a flat inner surface and the ciliary body is much thinner and less 
vascularized than the pars plicata. Zonulae that hold the crystalline lens originate as a 
continuous layer on the surface of the pars plana and run into the valleys between the 
ciliary processes from where they are directed towards the lens equator where they 
insert directly at, anterior and posterior to it.
The ciliary body possesses ciliary processes with a fibrovascular core that is 
continuous with the ciliary body stroma and covered by a bi-layered epithelium. As a 
result of the invagination of the optic cup during embryogenesis, the ciliary epithelia 
consist of a double layer that is joined apically while the basement membrane of the 
inner, non-pigmented epithelium is facing the posterior chamber. The vasculature is 
connected to the major circle of the iris,^ and served by a set of anterior and posterior 
arterioles'^ which supply the large diameter capillaries (near the crest of the processes) 
and the smaller caliber capillaries deep within each process, respectively. Blood 
flows toward the network of choroidal veins to leave the eye via the vortex veins. A
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Sphincter-like system regulates blood flow that allows adjustment of filtration 
pressure and consequentially, aqueous humor production/'^
As other capillaries from the posterior arterioles, the capillaries o f the ciliary muscle 
are non-fenestrated and impermeable to plasma proteins. However, the capillaries 
from the anterior arteriole in the stromal core o f the ciliary processes lack tight 
junctions and are instead lined by fenestrated endothelial cells, allowing passage of 
macromolecules, ions and water. The ciliary non-pigmented epithelium serves as a 
selective barrier. It forms the blood-aqueous barrier in the ciliary body^ with zonulae 
occludentes, adhérentes and desmosomes.^’  ^Primarily the epithelium at the tip of the 
ciliary processes contains carbonic anhydrase, a pharmacological target in 
glaucoma^^'^^ and Na-K-ATPase to produce aqueous humor. Aqueous humor is a 
clear, water like fluid to provide good optical properties but it still has to provide 
nutrients to the avascular tissues of the eye. Although the total protein content of 
aqueous humor is less than 1% of that in plasma to prevent light scatter, the free 
amino acid levels are almost equivalent.'^ Disruption o f the junctional complexes that 
form the blood-aqueous barrier in intraocular inflammation results in leaking of 
macro-proteins and flare that can be observed at the slit lamp.'''
Despite the increased leakiness during inflammation, intraocular pressure is usually 
lower, not higher because gap junctions that serve intercellular metabolic and 
electronic coupling of ciliary epithelial cells disappear,'^’ resulting in reduced 
aqueous humor net production and decreased intraocular pressure.'''
Aqueous humor leaves the eye via two routes, the uveoscleral and the conventional 
outflow tract. It is estimated that under normal conditions about 10% of total aqueous 
outflow occurs via the uveoscleral pathway by absorption into uveal tissues'^’ which 
may increase to as much as 60% during intraocular inflammation or 
pharmacologically by analogous substances such as prostaglandins and prostamides. 
Ninety percent pass the trabecular meshwork into the circumferential Schlemm's canal 
and subsequently via circuitous channels toward the surface of the sclera where they 
join the circulation of the episcleral vasculature. Flow through the 
uveoscleral pathway is essentially pressure independent.'^"'^ Flow occurs from the 
posterior chamber through the pupil and anterior chamber directly into the ciliary 
muscle to follow connective tissue fascicles that collect toward the supraciliary space 
which is contiguous with the suprachoroidal space. From here, the aqueous exits the
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eye either by diffusing through the sclera or through the scleral emissaria o f the vortex 
veins. Prostaglandin analogues in the medical treatment of glaucoma increase the 
uveoscleral outflow through up-regulation of matrix metalloproteinases that break 
down extracellular matrix material facilitating fluid movement through the interstitial 
space of the ciliary muscle.^''’
In conventional outflow, aqueous drains through the trabecular meshwork of the 
iridocorneal angle. Because the flow occurs down a pressure gradient, any obstruction 
at the level of the trabecular meshwork such as blood or lens proteins or further 
downstream obstacles such as 360 degree encircling buckles used for retinal 
detachment repair, intentional episcleral vein cauterization for creation of glaucoma 
models or carotid-cavernous sinus fistulas can lead to increased intraocular pressure 
and glaucoma.
The trabecular meshwork is a wedge-shaped tissue band that bridges the anterior 
chamber angle connecting the peripheral edge of Descemet's membrane of the cornea 
(Schwalbe’s line) anteriorly and the scleral spur, ciliary body and iris stroma 
posteriorly. Iris processes are often seen that attach to the beams of the trabecular 
meshwork. The innermost trabecular meshwork is termed uveoscleral trabecular 
meshwork as its beams project into the stroma of the ciliary body and iris which are 
both part of the uvea. Trabecular meshwork posterior to an imaginative line between 
Schwalbe's line and the scleral spur is called corneoscleral meshwork. Contraction of 
longitudinal meshwork bundles of the ciliary muscle will pull the scleral spur 
posterior and consecutively stretch the uveoscleral and corneoscleral meshwork, a 
mechanism by which miotics can increase conventional outflow.
Cord-like beams of collagen and elastin that branch and connect to each other form 
the backbone of the uveoscleral meshwork and are coated by endothelial cells capable 
of phacocytosis.^^ Similar to the comeal endothelium, these cells are nondividing and 
subject to age related attrition.^^ It is not clear whether this contributes to the 
development of glaucoma.^''’ The larger spaces o f the most inner trabecular 
meshwork become smaller towards Schlemm's canal.^^ The juxtacanalicular 
trabecular meshwork directly overlying Schlemm's canal is fundamentally different 
consisting of an open connective tissue matrix with fibroblast-like cells rather than 
endothelial cells. Despite this difference, tendons from the longitudinal bundle o f the 
ciliary muscle extend also into the juxtacanalicular trabecular meshwork and system
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of elastic fibers that insert into the inner wall of Schlemm's canal termed the cribiform 
plexus/^ The juxtacanalicular meshwork is the main source of outflow resistance/^ 
Past suggestions that increase in outflow resistance in primary open angle glaucoma 
derive from accumulation o f extracellular matrix material in the open spaces of the 
uveal and corneoscleral trabecular meshwork have recently been shown to be 
problematic as the hyaluronans decrease with age and POAG/^'^' Aqueous humor 
passes through the juxtacanalicular trabecular meshwork and the inner wall of 
Schlemm's canal through micropores in unique giant vacuoles that form pressure- 
dependent^^’ and energy independent.
Around 30 external collector channels drain from the outer wall o f Schlemm's canal 
towards the scleral surface into a deep scleral plexus that leads to the deep scleral 
veins and eventually to the episcleral veins. Despite this small caliber vascular 
network and its ability to regulate flow^'' the vast majority of the conventional outflow 
resistance is the trabecular meshwork.^^ Several unique vessels termed the aqueous 
veins of Ascher bypass the deep scleral plexus directly into the episcleral veins that 
can easily identified during slit lamp exam by their dual string of blood and aqueous 
humor that yet has to mix.
6.1.3. Central Fundus and Optic Nerve Head in Glaucoma
The approximately 1 to 1.5 million axons that form the optic nerve from the retinal 
ganglion cells run towards the optic disc in a characteristic pattern. Axons that 
originate nasal from the fovea take a direct course toward the disc, while ones that 
originate more temporal to the fovea arc around the macula and enter the upper and 
lower pole of the optic nerve. The macula axons run directly to the temporal quadrant 
of the disc in the papillomacular bundle. Retinal ganglion cell axons are organized in 
a retinotopic pattern throughout the visual pathway.^^'^^ Axons are grouped together 
by sheets of Muller cells'"'’''^  which gives the retina a striated pattern''^ during 
funduscopic examination. This striation is most prominent near the nerve fiber layer is 
thickest. This is the most common site of the typical notching when retinal ganglion 
cell loss occurs in glaucoma. The polarizing properties of this striated fiber layer and 
its loss is utilized in nerve fiber analyzer strategies (retinal scanning laser 
polarimetry)."'^’ It can most commonly be observed at the inferior and superior
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arcuate b u n d l e s T h e  reflective properties is determined by the cylindrical nature 
and size of axonal microtubules producing a directional, spectral and polarization 
(retardation)/^’
Localized damage to retinal never fiber bundles or in the optic disc cause well 
circumscribed scotomas, while more diffuse pressure on the posterior optic nerve e.g. 
by a mass lesion or demyelinating disease produces a central scotoma and diffuse 
visual dysfunction of the macula such as impaired color vision and decreased visual 
acuity. Axons exit the eye through a chorioscleral canal that passes through the outer 
retina, the pigment epithelium, Bruch's membrane, the choriocapillaris, the outer 
choroid and the sclera. It is variable in size resulting in a cup-disc ration that is used 
clinically to quantify likeliness of axonal loss. A typical optic disc has a vertical size 
between 1.5 to 2 mm and a cup to disc ration that does not exceed 0.5 but varies 
depending on the relation of size of the chorioscleral canal and space required for 
axons, supporting glial cells and vessels.^^’ To accommodate the greater number of 
axons entering the superior and inferior pole the chorioscleral canal usually is taller 
than wide giving it an oval shape.^'' The neuroretinal rim is usually the greatest 
inferior, superior, nasal and temporal rim which has been termed the "ISNT" rule.^'
Increased intraocular pressure can result in increase of the physiological cupping or 
take on more focal changes at the neuroretinal rim in glaucoma. Conversely, lowering 
intraocular pressure can halt axonal loss^^’ although apoptosis may contribute to 
continuing fiber loss even if the initial trigger is removed.^'' There is considerable 
individual variation between actual height of intraocular pressure and anatomic and 
functional changes typical of glaucoma: while about half of eyes with an lOP greater 
than 35 mm Hg will develop glaucoma, others can suffer degeneration o f the optic 
nerve with lOP in the statistically normal range ("normal tension glaucoma").^^ 
Known risk factors for glaucomatous optic nerve damage include reduced central 
comeal thickness^^, family history of glaucoma and impaired microcirculation.^^'^'' In 
typical glaucoma, damage occurs over a prolonged period of time. Progression can be 
associated with splinter hemorrhages that appear at the optic disc.^'’ Typical axonal 
loss occurs in the upper and lower quadrants resulting in a vertical increase of 
the cup^'' with corresponding arcuate loss of retinal ganglion cells. However, when
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axonal loss is diffuse, the cup expands concentrically,^^ resulting in a generalized 
visual field depression.
In addition to change of visual threshold as measured in standard visual field 
testing, contrast sensitivity, acuity and color sense are among the functions lost.^'' 
Detection is more challenging with diffuse axonal loss unless a baseline has been 
established in that person with prior visual fields. Comparison to the opposite eye 
must take into account that this eye, too, may be affected by glaucoma. In contrast a 
circumscribed axonal loss with a well defined arcuate scotoma may be detected much 
earlier. The combination of visual field testing and funduscopic examination is 
usually able to detect glaucoma at a relatively early stage by corresponding visual 
field loss and cupping, asymmetry of age-adjusted field depression in upper and lower 
fields, asymmetry of cupping and field loss between the two eyes consistent with 
asymmetric intraocular pressure or simply by a change from baseline photography or 
threshold perimetry. Any interpretation must take other causes of visual depression 
into account such as amblyopia and different media clarity (e.g. cataracts), 
anisometropia.
6.1.4. Anatomy, Cell Biology and Function of the Retina
The following describes the anatomy, cell biology and function of the retina relevant 
to the use of lentiviral vectors for transduction of the retinal pigment epithelium and 
retina. This chapter includes the description of the human macula because of its 
relevance in leading causes o f blindness as it is the object of intense focus o f novel 
therapies including gene therapy. However, the murine eye that is used in this thesis 
as a model does not have a macula. The retinal histology is otherwise very similar.
The retina is derived from the optic vesicle that develops from the diencephalon in 
humans around 25 days of fetal development. The optic vesicle then invaginates in the 
fourth week to form a cup resulting in an inner and outer wall. The inner wall further 
differentiates into the multi-layered neurosensory retina, while the outer wall becomes 
the retinal pigment epithelium. The two walls can later separate again creating a 
retinal detachment from various causes such as vitreoretinal traction, subretinal 
exudation or a retinal hole that allows fluid to access this potential space. Surgically,
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this space can be used to subretinally inject vectors/^’ insert implants/^'^^ remove 
neovascular membranes^'' and to facilitate retinal translocation/'’
The retinal pigment epithelium (RPE) is a monolayer o f hexagonal cells that extends 
from the margin of the optic disc to the ora serrata, where it is continuous with the 
pigmented epithelium of the pars plana o f the ciliary body. The RPE cells are 
cuboidal in cross section and joined near their apical margins by junctional complexes 
that include maculae and zonulae adhérentes (intermediate spot and belt junctions, 
respectively), as well as zonulae occludentes (tight junctions). The zonulae 
occludentes between RPE cells form the outer blood-retinal barrier that is 
impermeable to water, ions and proteins. RPE cells are polarized cells that 
phagocytose shed outer segments with their long microvilli and provide the matrix 
surrounding the photoreceptor inner and outer segments. They also participate in the 
vitamin A metabolism and absorb l i g h t . R P E  cells are smaller and contain more 
melanin in the macula and are flatter and about 4 times wider with less pigment in the 
periphery. There is a relatively constant ratio of 45 photoreceptors per RPE cell 
throughout the retina.^''
RPE cells may accumulate lipofuscin granules over times which represent residual 
outer segment lipids that are incompletely digested. The highest density o f those can 
be found in the macula. Because of this association, it has been suggested to 
contribute to macular degeneration.^^ Ion pumps and passive ion channels cause water 
movement across the RPE towards the choroid, promoting adhesion of the 
neurosensory retina and RPE.^''
The potential space into which FIV vectors were injected in this thesis is delineated 
by the zonulae occludentes (tight junctions) of RPE cells and by the external limiting 
membrane formed by the intermediate junctions (zonulae adhérentes) between 
photoreceptor inner segments and Muller cell apical p rocesses .T h is  space is filled 
with various proteins, glycoproteins, enzymes, glycosaminoglycans and proteoglycans 
that surround the rod and cone inner and outer segments and are called the 
interphotoreceptor matrix. Vitamin a transport between photoreceptors and RPE is 
enabled by the interphotoreceptor-retinoid binding protein of the interphotoreceptor 
matrix. Matrix sheaths surround the individual photoreceptor outer segments to 
maintain outer segment orientation and to isolate individual photoreceptor segments 
but also contribute to the attachment of photoreceptors to RPE cells.^^
- 3 5 -
Introduction: Eye Structure and Function
Rods and cones are the two types of photoreceptors found in vertebrate retinas. Rods 
are used in low light (scotopic) and cones in bright light (photopic) vision and allow 
to discern colors as they contain different opsins (red (564 nm; L cones), green (533 
nm; M cones), or blue (437 nm; S cones)).^^ The minority of cones are blue-sensitive. 
Photoreceptors, external limiting membrane, outer nuclear layer and layer of 
photoreceptor axons and synapses constitute the outer retina. Rods have a long, thin 
outer segment that contains rhodopsin with an absorption maximum at 500 nm. 
Overall, there are 4.6 million cones with a peak foveal cone density of 199,00 
cones/mm2 and 92 million rods that have the highest rod density o f 150,000 rods/mm^ 
in a ring around the fovea with an eccentricity of the optic disc.^^ Blue-sensitive cones 
are most numerous (2000 cells/mm^) in a ring at 0.1 to 0.3 mm from the foveal center 
but absent in the fovea itself. They constitute only 7% of cones in the periphery.^''
Rod and cone outer segments consist of stacked membranes with rhodopsin or cone 
opsin. The inner segments of photoreceptors contain mitochondria, ribosomes, 
endoplasmatic reticulum and Golgi apparatus. Rhodopsin is continuously added into 
newly forming discs that pinch off from the outer membrane at the base of the rod 
outer segment. The turnover of the entire outer segment that involves RPE 
phagocytosis and lysosomal degradation of shed discs is approximately 2 weeks. In 
contrast, rod outer segment membranes are continuous with the surface membrane. 
Shedding of cone outer segments occurs stepwise when large parts are deposed off at 
night while regrowth happens during the day.^' Outer and inner segments are 
connected by the cilium that functions as a conduit for transport of newly made 
proteins and originates in the centriole of the inner segment. It accommodates nine 
microtubule doublets arranged in a ring that can be found in sensory cilia. However, 
the central pair of microtubules that is characteristic of motile cilia is absent.
6.1.4.1. Layers and cell types of the Neuro-Retina
Several layers of the neuroretina can be distinguished histologically and will be 
discussed in the following:
1. the outer photoreceptor layer,
2. External limiting membrane,
3. the outer nuclear layer (nuclei of photoreceptors).
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4. Middle limiting membrane,
5. the outer plexiform layer,
6. the inner nuclear layer (nuclei of horizontal, bipolar and amacrine cells),
7. the inner plexiform layer,
8. the ganglion cell layer.
6.1.4.1.1. Outer Photoreceptor Layer
The external limiting membrane at the level of the photoreceptor inner segments 
consists of intermediate junctions (zonulae adhérentes) between rod and cone inner 
segments and the apical processes of Muller cells. These junctions form the inner 
border of the subretinal space are form a diffusion barrier to large molecules^^ that 
may include viral vectors. This layer contains rods and cones, the number of which is 
equal in the macula while the overall ratio is 1:20 rods to cones (120 million rods to 6 
million cones). When dark adapted, rods are 1000 times more sensitive than cones 
when dark adapted. They are in a ring 20 to 40 degrees around the fovea. Fifty percent 
of cones are located in the macula and have the highest density in the fovea.
6.1.4.1.2. External limiting membrane
The external limiting membrane is situated external to photoreceptor nuclei and 
consists of fenestrated intercellular bridges. It interconnects photoreceptor cells to 
Muller cells and photoreceptors.
6.1.4.1.3. Outer Nuclear Layer
The outer nuclear layer consists of cells bodies and nuclei of photoreceptors. It 
contains 8 to 10 rows of nuclei that belong mainly to cones in the par fovea and 5 
rows of nuclei (single row of cone nuclei and 4 rows of rod nuclei internal to them).^^
6.1.4.1.4. Middle limiting membrane
The middle limiting membrane consists of synapses and is located between the outer 
nuclear layer and the outer nuclear layer. It forms the approximate border of the 
vascular inner portion and avascular outer portion of the retina whereas the central 
retinal artery supplies the retina from the internal limiting membrane to the middle
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limiting membrane and the choriocapillaris the external retina from middle limiting 
membrane to the retinal pigment epithelium. It has been described as diffusion barrier 
to fluids such as exudates and hemorrhages.^^
6.1.4.1.5. Outer Plexiform Layer
Synapses of rod and cone photoreceptors and dendrites of horizontal and bipolar cells 
are located in the outer plexiform layer. The outer plexiform layer is thickest in the 
macula where it forms the fiber layer o f Henle with its characteristic radially radiating 
axons. Rod and cone terminals are arranged as invaginating synapses and encompass 
two lateral processes from horizontal cells, and a single central process from a bipolar 
cell. Cone pedicles have further small flat synapses on their surfaces that originate 
from “o ff’ cone bipolar cells. Small lateral gap junctions also exist between rod and 
cone terminals but do not contain synaptic vesicles.
6.1.4.1.6. Inner Nuclear Layer
Bipolar cells, horizontal cells, Muller cells, interplexiform cells and amacrine cells are 
the five cell types can be found in the inner nuclear layer.
Dendrites of horizontal cells innervate the photoreceptor axon terminals in the 
outermost row in the inner nuclear layer. The two different horizontal cell types (HI, 
H2, H3)^'' form widespread syncytia. Horizontal cells generate receptive fields and 
color opponent properties of bipolar and ganglion c e l l s . H I  cells have a large cell 
body and receive input from M and L cones but have no input from S cones. Each HI 
cell has a long axon with a terminal arbor connected to rod spherules^^ H2 cells have 
smaller cell bodies and receive input from all three cone types. Their axons contact 
mainly S cones. They receive input from L and M cones and have a large and often 
asymmetric field. H3 are similar to HI cells but are only known in human retina.^'' 
They receive input from L and M cones and have a large and often asymmetric field.
Bipolar cells receive direct input from photoreceptors (15 to 20 in the central retina,
40 to 50 in the periphery) and connect to amacrine and ganglion in the inner plexiform 
layer with their axon.^^ There are only "on" rod bipolar cells but "on" as well as "o ff  
cone bipolar cells, the later ones terminating in the outer strata of the inner plexiform 
layer.^^ Cone bipolars connect to several or single cones (midget bipolar cells). L- and
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M-cone input occur to six diffuse cone bipolar types and each foveal cone synapses 
onto one “on” and one “o ff’ midget bipolar cell. In contrast, the “on” blue cone 
bipolar cell receives input exclusively from S cones.
The cell bodies of the interplexiform cells lie among amacrine cells and synapse with 
bipolar and amacrine cells in the inner nuclear layer. They gather input from several 
bipolar cells. Different from all other retinal cells, interplexiform cells are arranged 
centrifugally in that they send processes into the outer plexiform layer where they 
form synapses with cone pedicles and dendrites of rod and cone bipolar cells."''' Their 
function is to regulate receptive fields of horizontal cells.
The amacrine cells form the inner row of cells of the inner nuclear layer. There are 40 
types of amacrine cells that can be distinguished by morphology and 
neurotransmitter.^^’ The density of amacrine cells is similar 
in the central and peripheral retina. Amacrine cells receive lateral input from bipolar 
and other amacrine cells in the inner plexiform layer and synapse to those cells as 
well as to ganglion cells.
6.1.4.1.7. Inner Plexiform Layer
The inner plexiform layer consists of the synapses from inner nuclear layer cells, the 
outer part o f which contains layers SI and S2 and the inner layer contains S3, S4 and 
S5. "on" center ganglion cells that respond when light is turned on have dendrites in 
the inner layer and "o ff  center ganglion cells in the outer layer.
While many rods converge onto a single rod bipolar cell in the outer plexiform layer, 
fewer cones converge onto a cone bipolar cell or may synapse onto various cone 
bipolar cell types. The rod and cone circuits are separate. Rod bipolar axons terminate 
in sublamina b of the inner plexiform layer onto dendrites of amacrine cells.
Amacrine type II cells from chemical synapses with "on" ganglion cells whose 
dendrites branch in sublamina b. A ll amacrines further form gap junction (electrical) 
synapses in sublamina b with dendrites of "on" diffuse cone bipolar cells, whose 
axons connect to both "on" and "o ff  ganglion cells. As a result, rod signals reach 
both "on" and "o ff center ganglion cells.
In sublamina A some cone bipolars synapse with "o ff  ganglion cells, while others 
synapse in sublamina B with "on" ganglion cells. Overall, much fewer cones converge
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to one cone bipolar cell than the many rods that create an input to a rod bipolar and 
fewer cone bipolar cells converge onto a ganglion cell. In the fovea a single M or L 
cone synapses onto one "on" and one "o ff  midget bipolar cell that synapses onto two 
midget ganglion cells ("on" and "o ff)  to provide the highest resolution in the visual 
pathway. Amacrine cells modify the ganglion cell receptive fields and center response 
also for the cone system.
6.1.4.1.8. Ganglion Cell Layer
The ganglion cells that form the ganglion cell layer are the projection neurons of the 
retina that constitute the third neuron of the visual pathway. The total count of 
ganglion cells can vary between 0.7 to 1.5 million per retina."" Outside the central 
retina the ganglion cell layer has one single row of cells and up to 10 rows within the 
macula and the highest concentration in the parafovea."" More than 20 different 
classes of ganglion cells have been described based on different staining, molecular 
markers, electrophysiological behavior or central projections."'^ The different 
ganglion cells have a characteristic receptive field, receiving input from the inner 
plexiform layer and one single projecting axon.
The inner surface of the retina is covered by a basal lamina that is derived from the 
Müller glial cells. This 2 pm internal limiting membrane is closely associated with the 
Müller end feet and merges with collagen fibrils of the vitreous. Müller cells are 
radial glia that extend from the vitreal surface of the retina to the subretinal space, 
while their body and nuclei are in the inner nuclear layer. Their apical cell processes 
extends to the external limiting membrane forming microvilli that project into the 
subretinal space around the photoreceptor inner and outer segments. Müller apical 
processes and photoreceptor inner segments are connected by band o f intermediate 
junctions of the external limiting membrane. Müller cells have fine cytoplasmic 
processes that reach into the retinal parenchyma surrounding all neurons and their 
processes. Because of this, retinal neurons only contact each other at the synapses but 
are otherwise completely engulfed. Muller cells also surround bundles of ganglion 
cell axons and terminate against the basal laminae of blood vessels in the inner retina. 
Besides structural and metabolic support of retinal neurons, Muller cells regulate 
potassium levels, neurotransmitters, CO2, pH levels in the retina and are involved in 
angiogenesis, differentiation and gliosis (Loewen et al., submitted).
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Astrocytic glia are located mainly in the nerve fiber layer and a few in the ganglion 
cell layer. Their wide foot processes surround the walls of retinal vessels. These 
stellate cells with oval nuclei are abundant in the prelaminar portion of the optic disc. 
Microglia are derived from the bone marrow and function as tissue macrophages. In 
the retina these cells form regular mosaics between the nerve fiber and ganglion cell 
layers as well as the inner nuclear and outer plexiform layers.'"'' As they are closely 
associated with the retinal vasculature they are absent in the foveal avascular zone. 
Microglia become activated during repair in traumatized or degenerating retina. They 
scavenge debris and present antigens to T lymphocytes.'"^
RPE, photoreceptors and the outer retina receive supply from the choriocapillaris, 
whose endothelial cells are fenestrated and allow diffusion of variously sized 
molecules along the lateral walls of RPE cells. About 65 to 85% of ocular blood flow 
occurs through the choriocapillaris while the remainder enters the inner retinal 
circulation. Tight junction between RPE cells block diffusion of larger serum 
components into the subretinal space constituting the outer blood-retina barrier. In 
contrast, the inner blood-retinal barrier is formed by endothelial cells of the central 
retinal circulation that lack fenestrations entirely and have zonulae occludentes. The 
central retinal artery has four branches to supply all quadrants. Its main branches lie in 
the nerve fiber layer and send capillaries to all levels of the inner retina. The arterial 
branches have smooth muscle walls and an endothelium but lack an internal elastic 
lamina. The branches of the central retinal vein have thin walls of smooth muscle and 
an endothelium, and the walls of the venules and capillaries contain mural cells 
(pericytes) enclosed within a basal lamina continuous with that of the endothelial 
cells. Capillaries are absent in the fovea in an area 0.25 to 0.6 mm in diameter because 
the foveal pit contains only photoreceptors and RPE c e l l s . '""
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6.2.Human Ocular Diseases
6.2.1. Glaucoma
Damage to 
optic nerve
Pressure 
inside eye
Optic Nerve 
normal glaucomatous
Figure 1: Impaired outflow of aqueous humor may result in increased intraocular 
pressure (left) and glaucomatous optic neuropathy (right) (National Eye Institute, 
National Institutes of Health).
6.2.1.1. Overview
Glaucoma is a descriptive term that identifies a group of clinical conditions with 
different etiology and the final common outcome of degenerative optic neuropathy 
(Figure 1).'"  ^Categories are based upon whether increase of intraocular pressure 
(lOP) by aqueous humor outflow obstruction occurs in the presence of an open 
chamber angle (primary open-angle glaucoma, POAG) or a closed chamber angle 
(primary angle-closure glaucoma, PACG) and can further be subdivided into primary 
or secondary causes. The new American Academy of Ophthalmology (AAO) 
definition of primary open-angle glaucoma (POAG) states that the disease is 
multifactorial in origin but that it primarily affects the optic nerve. lOP is the most 
important cause of optic nerve damage, but not the only one. Characteristic findings 
include progressive thinning of the neurosensory retinal rim, notching, asymmetry, or 
nerve fiber layer defects. Because early glaucoma typically has no associated visual 
field loss (Figure 2),'" ’^ visual field function screening (perimetry) has the goal to 
detect already moderate to advanced states of glaucoma.'"^
Glaucoma afflicts 67 million people and is the leading cause of irreversible blindness 
worldwide."" Risk of blindness remains high despite the availability of several
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treatments.'" For patients treated and monitored for open angle glaucoma, Kaplan- 
Meier cumulative probabilities of monocular and binocular blindness at 20 years are 
27 and 9%, respectively."^ These risks are increased when damage to the optic disc is 
present at the time of diagnosis.
It is estimated that 15 million Americans would be classified as having glaucoma 
based on optic nerve head criteria."^ In 1992 direct and indirect costs exceeded $2.4 
billion in the U S."'' About 50% of people affected by glaucoma are unaware o f their 
disease.'"^ Age is a strong risk factor to develop glaucoma (30-fold increase)"^’ 
and so is race (10-fold)."^ Mathematical models indicate that at lOPs of over 28 to 30 
mm Hg chances of optic nerve damage exceeds 50%."^"'^^ Conversely, lowering lOP 
by 30% from baseline was associated with a 50% reduction in visual field loss 
over.'''’'"''
Even with treatment, long-term outcome of POAG is poor and may result in 
progression of visual field loss in up to 8% of patients a n n u a l l y . T h e s e  risks are 
increased when damage to the optic disc is present at the time of diagnosis. Glaucoma 
is the cause of blindness (best visual acuity of less than 20/200 or best visual field less 
than 20°) in 80,000 adult Americans.'"^ Impaired vision is associated with measurably 
decreased quality of life'^" '^' and increased risk of falls, hip fractures, and decreased 
physical m o b ility .D ecreased  vision is also directly related to difficulties in vision- 
related tasks.
The major causal risk factor in most forms of glaucoma is intraocular hypertension, 
which is caused by impaired outflow of aqueous humor from the anterior chamber,'^"’ 
'^^but low tension glaucoma with average or below average intraocular pressure also 
ex ists .M ain ta in in g  intraocular pressure in a narrow range (10-21 mmHg) is 
essential for viability o f the neuroretina. In the most common form of glaucoma, 
primary open angle glaucoma, as well as angle closure glaucoma, sustained higher 
pressures directly damage optic nerve axons and also may impair vascular supply, 
resulting in irreversible loss of retinal ganglion cells. There is experimental support 
that advanced axonal loss can lead to increased shear forces and disadvantageous 
biomechanical properties at the lamina cribrosa.'^""'" In addition, instead of a 
percentage attrition resulting in an asymptotic decay curve, the rate of retinal ganglion 
cell loss in glaucoma accelerates with progressive disease at least in animal models.'''^
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Aqueous humor is produced by the ciliary body and exits the eye primarily through 
Schlemm’s canal and its downstream tributaries, the collector channels and episcleral 
veins. To enter Schlemm’s canal, fluid must first traverse the trabecular meshwork 
(TM), a wedge-shaped reticulum of metabolically active, yet mitotically quiescent 
endothelial- like cells located in the angle of the anterior chamber (a and b). Although 
it is known that the TM generates most of the resistance to aqueous humor outflow,'^"’ 
the responsible cellular mechanisms are poorly understood. Nevertheless, progress 
has been made in identifying human genes that are involved in the pathogenesis of 
some forms of g l a u c o m a . A  glaucoma-specific gene expression profile has been 
identified in human TM.'^" Stable transcriptional reprogramming is suggested by the 
consistency of this abnormal profile in diverse forms and stages of the disease, and by 
its persistence in TM cells after primary subculture removes them from glaucomatous 
conditions in the eye.'
6.2.1.2. Aqueous Humor Outflow
Aqueous humor outflow occurs through several structures. Pores can be seen between 
Schlemm’s canal cells as well as within cells t h e m s e l v e s . E y e s  with higher 
outflow facility have a higher number of such p o r e s . G i a n t  vacuoles also contribute 
to outflow. These structures are pressure-dependent, energy-independent protrusions 
of canal cells that may sense pressure by stretching.
Through interactions with integrins and cell adhesion molecules that is produced by 
trabecular meshwork cells, the extracellular matrix contributes to regulation of the so 
called conventional outflow through the trabecular meshwork.'^'' Proteoglycans, 
laminin, fibronectin, collagen, matricellular proteins and glycosaminoglycans (GAGs) 
make up this extracellular matrix. Cell-matrix interactions are modulated by 
matricellular proteins such as thrombospondins, tenascin and secreted protein acidic 
and rich cysteine (SPAC), that are nonstructural adaptors p ro te in s .A lth o u g h  
matricellular proteins are generally seen during development and tissue repair, these 
proteins are found in abundance in the trabecular meshwork.'^"' At this point it is 
unknown how these proteins regulate outflow. The negatively charged GAGs are 
primarily found in the extracellular matrix and on the cell surface. Because of their 
size these molecules can increase the viscosity of fluids and play a role in retaining
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and releasing water e.g. in cartrilage.'^^ In eyes with primary open angle glaucoma 
more chondroitin sulfate and less hyaluronic acid is seen compared to healthy eyes.^'
A hydraulic-like system has been described that may influence the actin cytoskeleton. 
Ciliary muscle tendons and elastin fibers extend to the endothelium of Schlemm’s 
canal and transmit any tension resulting in a change of shape of the trabecular 
m e s h w o r k . I t  is thought that while cellular contraction can change the outflow 
acutely, the extracellular matrix is more likely to modulate resistance in the long- 
term.''^ »'""
A second route of aqueous humor outflow exists through the supraciliary space as 
well as across the anterior and posterior sclera through emissarial canals around 
vortex veins or into choroidal vessels. This outflow route is termed uveoscleral 
outflow and accounts for up to 60% in non-human primates'"' but this can vary 
considerably from e.g. 8% in rabbits to 80% in mice.'"^ In humans, uveoscleral 
outflow decreases with age'"^ and the conventional pathway becomes more important. 
A range from 4% to 60% has been reported in different studies.'^’
Although many differences have been identified between normal and glaucomatous 
eyes and changes during the course of the disease, the pathogenesis o f primary open 
angle glaucoma is not understood. It is known that normal trabecular meshwork cells 
become more sparse and altered behavior: proteomic studies identified a total o f 368 
proteins expressed in TM and differential expression of 52 proteins that were only 
seen in glaucomatous and 177 only in normal trabecular meshwork.'"" Vascular 
endothelial growth factor (VEGF),'"" tumor growth factor beta 2 (TGFp2),'"^ 
endothelin,'"^ plasminogen activator inhibitor (PAI)'"" and soluble CD44'^" are 
elevated in aqueous humor of glaucomatous eyes and may change the phenotype. 
TGF-B2 has attracted interest because it induces secretion of additional extracellular 
matrix molecules which increases the outflow resistance.'^'
Other factors might play a role in glaucoma pathogenesis but their role is less certain. 
Oxidative stress for instance has been identified in other eye diseases such as cataract 
formation and macular degeneration. Oxidative DNA damage can be demonstrated in 
the trabecular meshwork of glaucoma p a t i e n t s . Mo r e  evidence suggests that NF-kB 
release after oxidative stress causes up-regulation of ELAM-1 which has been 
suggested as a marker for glaucoma in the past.'"" Welge-Lussen et al. found that
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tissue transglutaminase is expressed in the HTM and can be induced by TGF-Bl or - 
B2 in cultured HTM cells/^" Tissue transglutaminase can polymerize fibronectin 
causing an increase of irreversibly cross-linked ECM proteins. This mechanism might 
play a role for the increased outflow resistance seen in glaucomatous eyes.
In 1997 involvement of myocilin in glaucoma pathogenesis was recognized.'''"’
Stone et al. identified point mutations in the olfactomedin domain, which is highly 
conserved among species, that are associated with and believed to be causative in 
primary open-angle glaucoma (POAG), including juvenile and adult forms of open- 
angle glaucoma.'"'" Research was further accelerated when the gene coding for 
myocilin, MYOC, was published.'^" Since then, a number of mutations associated 
with glaucoma have been confirmed in the third exon of MYOC'^" '^  ^although the 
process leading to the development of glaucoma remains unclear. The idea of 
physiologic as well as pathologic effects of changes in myocilin production, 
degradation, or binding is supported by findings that normal myocilin can contribute 
to outflow obstruction in the anterior segment perfusion model'^" and can interact 
with other myocilin molecules to form complexes.'^"'
Myocilin is a secreted 55-57 kDa glycoprotein with a myosin-like domain, a leucine 
zipper region and an olfactomedin domain.'^" It is highly expressed in the trabecular 
meshwork (TM), within the cytoplasm and in association with fibrillar extracellular 
matrix c o m p o n e n t s . S e c r e t e d  myocilin can be found in the aqueous humor'"' 
and is expressed in s c l e r a , c i l i a r y  body,'^^’ '""and iris,'^^’ '"" and at lower
amounts in the r e t i n a ' a n d  optic nerve head.'^^’ The expression in TM cells
is induced upon treatment with dexamethasone,'''"'’ '"^ transforming growth factor-p'''"' 
and mechanical stretch.'''''
6.2.1.3. Clinical Perspective
6.2.1.3.1. Intraocular Pressure is Causatively Linked to 
Glaucoma: A Brief History
Intraocular pressure (lOP) has been causatively linked to glaucoma development,
progression and treatment. From its very first description to contemporary
approaches lOP plays the most noteable role in glaucoma. However, this was not
always the case and its significance was passionately disputed as late as in the 1980s
in the dawn of evidence-based medicine.'"^
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The first time of glaucoma was described as a blinding disease associated with 
high lOP was by the Persian physician Ali ibn Rabban at-Tabari (810-861) in the 
writings Firdaws al hikma (Paradise of Wisdom).'"" This association was later pointed 
out by Richard Banister o f England in 1622: “A treatise of one hundred and thirteen 
diseases of eye“: “if  one feele the Eye by rubbing upon the Eie-lids, that the Eye be 
growne more solid and hard than naturally it should be.” "^" The Dutch 
ophthalmologist Franciscus C. Donders (1818-1889) coined the expression “simple 
glaucoma” for increased lOP occurring without any inflammatory symptoms. In 1973 
Drance provided for the first time the definition of glaucoma as an optic neuropathy 
caused by increased lOP and other associated risk factors.^"'
An association of lOP and open angle glaucoma was eventually confirmed in studies 
in the 1990s but still not in the form of a cause-result relationship: in the Baltimore 
Eye Survey' and the Barbados Eye Stud)/"^ lOP was found to be an important factor 
in glaucoma that correlated with increased prevalence and incidence.^"" It was not 
until the large randomized trials of the late 1990s that demonstrated 
beyond correlation that a true causal relationship existed by showing that lowering 
lOP can slow or prevent POAG progression. The two most noteworthy trials in that 
regards are the Ocular Hypertension Treatment Study (OHTS)^"'' and the Early 
Manifest Glaucoma Trial (EMGT).^"" These studies have direct practical implications 
for daily ophthalmic care today and are summarized in the following. While there are 
other risk factors for glaucoma, lOP remains the single most important modifiable 
variable used to prevent or delay progression. Other strategies, such as vascular^"",^"^, 
neuroprotective^"^'^'" or metabolic management^" appeared promising in animal 
experimentation and were recognized as risk factors (reviewed in^""’^'^) but influence 
on the course of manifest glaucoma could not yet be established in randomized 
clinical trials.
6.2.1.3.2. Elements of Intraocular Pressure
Intraocular pressure can be calculated using the Goldmann equation^'" which consists 
of four elements:
lOP = F / C + Pv - U
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whereas F is the aqueous humor formation rate in microliters per minute, C is the 
facility of outflow in microliters per minute per millimeter of mercury, Pv is the 
episcleral venous pressure in millimeters of mercury and U is the rate of outflow of 
aqueous humor via all channels that are intraocular pressure independent.
F, C and U are most commonly manipulated to alter lOP, while increased epivenous 
pressure might have to be addressed surgically.
Under physiological conditions, between 70% to 95% of outflow occurs through the 
trabecular meshwork and is pressure dependent'""’ but the pressure independent 
uveoscleral outflow can significantly increase during inflammation or second to 
prostaglandin analogues and very effectively lower lOP under those circumstances.
6.2.1.3.3. important Randomized Clinical Trials
6.2.1.3.3.1. Ocular Hypertension Treatment Study OHTS
The purpose of the Ocular Hypertension Treatment Study (OHTS)^"'' was to 
determine whether the medical reduction of elevated lOP can prevent glaucoma and 
to define risk factors for glaucoma development. Topical ocular hypotensive 
medication was effective in delaying or preventing onset of POAG in individuals with 
elevated lOP by about 50%. Results to date have shown an approximate 50% 
reduction in conversion from OHT to POAG with a 20% reduction in intraocular 
pressure (lOP)."" OHTS demonstrated that medical treatment of people with 
intraocular pressure (lOP) of > or =24 mm Hg reduces the risk of the development of 
primary open-angle glaucoma (POAG) by 60%.^'^
6.2.1.3.3.2. Early Manifest Glaucoma Trial (EMGT)
The Early Manifest Glaucoma Trial (EMGT)^"" compared how glaucoma progression 
was affected by immediate medical (betaxolol) or laser therapy for newly diagnosed 
POAG with normal or moderately elevated lOP versus late or no treatment. Treatment 
caused an average reduction of lOP of about 5 mm Hg (25%) which reduced 
glaucoma progression to 45% compared to 62% in the control group and occurred 
later.
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6.2.1.3.3.3. Collaborative Normal Tension 
Glaucoma (ONTO) trial
Before the Collaborative Normal Tension Glaucoma (CNTG) triaP^^ it was not
known whether lOP that was in the normal statistical range was at all involved in
glaucomatous optic nerve damage and visual field loss. During the study it became
apparent that - similar to simple POAG - participating patients had a slower glaucoma
progression (no progression in 5 years) when lOP was lowered by 30%.
6.2.1.3.3.4. Conclusion from Randomized Trials
These randomized clinical trials proved that lower intraocular pressure delays or 
prevents progression of POAG as evidenced by delay or complete prevention of 
development o f glaucomatous optic neuropathy from ocular hypertension, visual field 
defects from pre-existing optic nerve changes and reduced progression of existing 
visual field defects. However, another conclusion was that despite good lOP control 
in many actively treated patients, POAG can still progress and can result in blindness 
in an unacceptable large number of patients.
6.2.1.4. Current Status of Glaucoma Therapy
The site of the highest resistance to outflow of aqueous humor is the juxtacanalicular 
trabecular meshwork.^^’ This structure is the principal site of pathology in primary 
open angle glaucoma Current interventional approaches for
moderate to advanced POAG circumvent this resistance,^^^ induce remodeling^^^ or 
permanently disrupt the trabecular meshwork (TM).^^"  ^Pharmacotherapy either 
decreases aqueous humor production or increases uveoscleral outflow as the main 
mechanisms.^^^
Traditional therapies for advanced glaucoma attempt to lower intraocular pressure 
surgically by circumventing the outflow resistance of the TM by shunting aqueous 
humor to the subtenon space (e.g. trabeculectomy, glaucoma drainage device)?^^ 
These filtering procedures have a high rate of complication and failure^^^ despite the 
introduction of antimetabolites and improvement of drainage device design, 
respectively.
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Trabeculoplasty has been employed to lower intraocular pressure by inducing 
remodeling of the TM and extracellular matrix?^^ However, the extent o f pressure 
reduction is much smaller than in filtering procedures and can only be used in early 
stages of the disease.
Complete disruption o f the TM and wall of Schlemm’s canal has recently been 
achieved with the trabectome^^^ but this disruption is irreversible creating a 
permanently open connection to the downstream drainage system.
Pharmacotherapy has primarily been successful in reducing intraocular pressure by 
decreasing aqueous humor production (e.g. P-blockers, alpha adrenergic receptor 
agonist, carbonic anhydrase inhibitor) and improving uveoscleral outflow (e.g. 
prostaglandin analogues, alpha adrenergic receptor a g o n i s t ) . T h e  only medication 
that addresses the primary pathology of reduced conventional outflow, pilocarpine,^^^ 
has been abandoned because of its side effects and reduction of non-conventional 
outflow.
Little is known about the actual pathophysiology on a molecular level and the cause 
of failing TM regeneration. Both normal and POAG TM cells are non-dividing 
in situ but can be cultured and expanded in v i t r o A few studies have examined 
TM regeneration responses but these were limited to focal destruction with laser.^^ '^^^^ 
It would be desirable to ablate the entire tissue that creates outflow resistance yet to 
do so selectively in order to study cell turn over and regeneration.
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Figure 2: Gradual deterioration of the visual field from the periphery (A) and 
figurative representation of the effect on the visual field in a late stage of glaucoma 
(B) (National Eye Institute, National Institutes of Health).
6.2.1.5. Rational for Developing Gene Transfer to the 
Trabecular Meshwork
In the presence of poor long-term outcome of vision in glaucoma patients with current
strategies gene therapy may offer solutions to permanently correct aqueous humor
outflow. Lentiviral vectors have evolved as the only vector type that allows stable and
targeted genetic modification of the trabecular meshwork providing new tools for
development of glaucoma therapy and animal models through tissue specific
transgenesis. Permanent genetic reprogramming of anterior chamber outflow tract
physiology by gene therapy has attracted attention as an ideal solution in theory
because of the disease’s life-long chronicity and the emerging understanding of its
genetic b a s i s . T h e  trabecular meshwork (TM), is a key intraocular structure
to target since it controls lOP by controlling outflow of aqueous humor.
Strategies for gene therapy for glaucoma must not only consider the chronic nature of 
the disease but also the generally nondividing nature of the target cells. Two general 
approaches have emerged. One focuses on the intraocular pressure problem, and the 
other on blocking its sequelae, retinal ganglion cell death.^^^’ The accessibility of 
the anterior chamber and the restricted anatomic target are favorable for gene therapy
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directed at the TM. Gene therapy with retroviral vectors has appeal, because these 
vectors undergo reverse transcription of their single-stranded RNA genomes, 
generating a linear double-stranded DNA intermediate that that is subsequently 
integrated into the host genome in a reaction catalyzed by the retroviral integrase. 
Therefore, these vectors result in permanent transgenes and have potential to address 
the chronicity of glaucoma pathophysiology. However, an important consideration is 
that TM cells do not normally divide. Unlike conventional retroviral vectors based on, 
for example, murine leukemia viruses (MLVs), lentiviral vectors, such as those 
derived from HIV and FIV, integrate into the genomes of both dividing and 
nondividing cells.
Glaucoma is a particularly appropriate disease to investigate for corrective gene 
therapy because of its chronicity and anatomically restricted pathology. However, this 
approach would require stable expression of candidate genes in the aqueous outflow 
tract. Correcting the primary aqueous outflow pathophysiology, and the 
complementary aim of expressing antiapoptosis genes in retinal ganglion cells,^^^’ 
are both likely to require not only gene transfer to nondividing cells, but also 
transgene stability commensurate to the chronicity of the disease. Trabecular 
meshwork cells are highly metabolically active and display pronounced phagocytic 
and secretory function, but appear to undergo limited cell division in vivo; less than 
0.5% have been estimated to be mitotically active at any one time.^^^’ Although 
adenoviral and herpes simplex vectors transduce nondividing cells and can mediate 
gene transfer to the TM,^ "^ "^ ’ these vectors are best suited to short-term gene 
expression because they do not generate integrated transgenes. In addition, these 
vectors can trigger marked inflammatory responses. Oncoretroviral vectors, such as 
those derived from murine leukemia viruses (MuLYs), do achieve stable integration, 
but only in target cells that are proliferating at the time of t r a n s d u c t i o n . T h e  
latter requirement could hinder effective gene transfer to the trabecular meshwork, 
although this question has not been investigated.
In contrast to these vectors, lentiviral vectors integrate permanently into the genomes 
of both dividing and nondividing cells. This property, which enables the universal 
lentiviral strategy of propagating through tissue macrophages, has been attributed to 
multiple determinants in virion proteins^"^  ^and within the reversed transcribed DNA^"^  ^
that facilitate nuclear import o f lentiviral preintegration complexes. Envelope
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glycoprotein-pseudotyped lentiviral vectors have been derived from primate 
lentiviruses^"^^’ and from nonprimate animal lentiviruses/'^^^"^^^ Feline 
immunodeficiency virus (FIV) vectors exploit compartimentalized blocks to 
productive cross-species infection, because they complete the postentry stages o f the 
infection cycle in nondividing human cells despite blocks to viral transcription and 
other life cycle mechanisms that prevent productive replication.^’ Human 
immunodeficiency virus type 1 (HIV-1) vector systems have so far received more 
extensive validation and molecular engineering for vector optimization.^^^
Additional features make glaucoma an intriguing potential proof-of-concept disease 
for gene therapy. The small amount of tissue that would require targeting, and its 
accessibility, could enhance the feasibility of adequate levels of corrective gene 
transfer. In the absence o f a selective growth advantage for gene-altered cells, and/or 
a tissue that supports proliferation in vivo after ex vivo gene transfer,^^^ achieving 
permanent transduction of most of a relevant tissue has remained a major hurdle in 
most gene therapy situations. Specific tissue targeting is problematic if  the target cells 
cannot be isolated ex vivo (e.g., ref.^^^). The anterior chamber can also be visualized 
through clinically feasible imaging methods, suggesting a means to monitor the in 
vivo expression of an integrated transgene over time during gene therapy 
developmental studies.
Long-term, stable, high-grade, and properly targeted transgene expression in the 
trabecular meshwork has not been achieved. Liposomes,^^^ adenovirus,^"^" ’^ adeno- 
associated virus,^^^ and herpes simplex virus vectors^"^  ^have been limited by short 
duration, inflammation, or lack of sufficient, targeted transduction. In contrast to 
DNA virus- or plasmid-based vectors, lenti-retroviral vectors integrate permanently 
into the genomes of transduced cells as an obligate part of the life cycle.^^"  ^The 
advantage over conventional onco-retroviral vectors is their ability to integrate in 
nondividing cells.
Not only could long-term transgene expression in the trabecular meshwork be utilized 
to study therapeutic transgenes, it would also enable transgenesis that is selective to 
the outflow tract and technically more simple than the generation of entire transgenic 
animals. Prior to either therapeutic or experimental gene transfer, proof-of-principle 
has to be established with marker genes, the most common ones of which are beta- 
galactosidase that allows intensely blue staining of galactose breakdown products and
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fluorescent proteins such as the humanized, enhanced green fluorescent protein 
(eGFP), or a renilla reniformis green fluorescent protein (rGFP). The construction of 
these vectors is described below in detail. LacZ as a marker gene has the advantage 
that it can be detected with the beta-galactosidase assay after short fixation and the 
blue product of the assay is compatible with other conventional tissue staining 
techniques e.g. of paraffin sections. It can be detected even at low multiplies of 
infection (m.o.i.) or low enzyme activity. It can also be stained with 
immunohistochemistry staining techniques as numerous antibodies are commercially 
available. A disadvantage is that it cannot be visualized in vivo easily. In contrast, 
eGFP and rGFP can be visualized in vivo with a variety of techniques as long as the 
correct exciting wavelength is applied. E.g. standard cobalt blue light and observation 
with a slitlamp,^^ gonioscopic visualization with a histopathology microscope as 
described in the techniques section of this thesis or excitation and capture with a 
scanning laser ophthalmoscope^^^ are possible.
6.2.2. Retinal and Choroidal Diseases
A spectrum of chronic retinal diseases is suitable for gene therapy: vasoproliferative 
retinal and choroidal diseases that include retinopathy of prematurity, proliferative 
diabetic retinopathy and exudative age-related macular degeneration as well as 
degenerative retinal and choroidal diseases that include retinitis pigmentosa. Best 
disease, choroideremia and Favre Goldmann syndrome. All of these diseases fulfill 
criteria such as chronicity, identified genetic defect and limited or no available 
treatment options. These diseases are introduced in the following and the rational for 
gene therapy for retinal and choroidal diseases is discussed further below.
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6.2.2.1. Vasoproliferative Retinal and Choroidal Diseases
6.2.2.1.1. Retinal Neovascularization
Laser 
U  beam
Laser spots
Abnormal 
vessels
Figure 3: Simulation of normal visual field (A) and with diabetic retinopathy (B). 
Neovascularization, exudates and preretinal bleeding can be found in the proliferative 
state of diabetic retinopathy (C). The treatment consists of panretinal laser therapy 
and ablates healthy retina in the periphery (D) (National Eye Institute, National 
Institutes of Health).
Retinal neovascularization (e.g. in diabetic retinopathy, exudative macular 
degeneration and retinopathy of prematurity, Figure 3) is currently treated by ablating 
healthy retina to prevent release of growth factors that cause neovascularization. As in 
glaucoma, integrating vectors could provide a permanent cure because they allow 
expression of therapeutic genes for the whole life of a cell.
Ocular neovascularization is a central feature of retinopathy of prematurity, diabetic 
retinopathy and age-related macular degeneration. These conditions constitute a 
leading cause of blindness in infants, individuals of working age and the elderly, 
re sp ec tiv e ly .N eo v a scu la riz a tio n  is the final common pathway of these and 
several other disorders that are multifactorial in etiology and involve an imbalance 
between pro- and anti-angiogenic factors.^^^’ Visual loss is a result of increased
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vascular permeability that causes retinal edema, hemorrhage from vascular fragility 
and fibrovascular proliferation with tractional retinal detachment.^^^
Present therapies are of limited efficacy and adapt destructive measures with 
significant adverse effects in order to reduce production of angiogenic factors/^^'
As the pathophysiology is better understood, a number of new angiogenic and 
angiostatic molecules has been identified. While systemic angiostatic therapy would 
be problematic, local application in proximity to the affected tissue is promising. 
While effects of intraocular injection of angiostatic substances would be short-lived, 
gene transfer through vectors allows local and long-term delivery of therapeutic 
molecules.
Lentiviral vectors are attractive vectors for therapy of retinal and choroidal 
neovascularization (e.g. diabetic retinopathy, age related macular degeneration, 
retinopathy of prematurity) as well as of degenerative RPE diseases that do not 
involve neovascularization (dry age-related macular degeneration, Leber's amaurosis, 
choroideremia, atrophia gyrata. Best's disease, Stargardt's disease), because achieving 
long-term expression is a vital goal for these chronic conditions. Since transduction 
from subretinally injected lentiviral vectors is mostly limited to the RPE,^^ 
except when injected immediately after birth,^^^’^^  ^ these vectors would be similarly 
useful to AAV vectors for degenerative RPE diseases.
6.2.2.1.2. Retinopathy of Prematurity
Retinopathy of prematurity (ROP) is an ischemia-induced proliferative retinopathy, 
which affects premature infants with low birth weight. Retinal neovascularization in 
ROP may lead to traction, retinal detachment, and blindness. Infants bom at the 
gestational age of 31 weeks or less are at risk for ROP. O f these, 66% of infants 
weighing less than 1251 g at birth, and about 82% less than 1000 g develop this 
disease.^^^ Current treatments for ROP, using laser or cryotherapy, are only somewhat 
successful in preventing blinding sequelae.^^"  ^It is generally accepted that the 
pathogenesis of ROP is multifactorial. Documented risk factors include oxygen 
exposure, prematurity, and acidosis during the early neonatal period. One hypothesis 
implicates relative hypoxia of the peripheral retina.^^^ As with other instances of
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retinal neovascularization, vascular endothelial growth factor (VEGF), which can be 
counteracted by PEDF,^^^ plays a central role.^^ '^^^^
ROP is a two-phase process that occurs during the timeframe of early vessel 
development and maturation. In the first phase, developing retinal capillaries 
obliterate when exposed to hyperbaric oxygen concentrations, while under 
physiological conditions, there would be a balance between developing and 
degenerating capillary buds. When excess oxygen is removed, the acute ischemia 
leads to vascular proliferation. Newly formed vessels induced by VEGF break 
through the internal limiting membrane and grow into the subvitreal space. In the later 
healing phase glial-fibrocellular scar tissue develops that can cause significant visual 
loss, ectopia of the macula, as well as serous and tractional detachments of the retina. 
Although cryosurgery and laser retinal ablation of avascular retina improve chances of 
a favorable outcome, vision impairment still occurs in up to 44% of patients.
6.2.2.1.3. Proliferative Diabetic Retinopathy
Hyperglycemia in diabetic retinopathy Figure 3 is thought to cause ischemia through 
microvascular occlusion. Up-regulation of angiogenic growth factors results in vessel 
growth from the inner retinal surface into the vitreous.^^' Present treatment for 
proliferative diabetic retinopathy is retinal laser photocoagulation, a destructive 
procedure that can affect visual function adversely.^^^ 60% of diabetics develop 
retinopathy within 15 years of diagnosis.^^^ As in ROP, the blindness results from 
retinal detachment associated with pre-retinal neovascularization. It is hypothesized 
that hypoxia of the neural retina contributes to the pathogenesis. PEDF levels are low 
in diabetic retinopathy.^^^’
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6.2.2.1.4. Exudative Age-Related Macular Degeneration 
(AMD)
C D
Figure 4: Normal central fundus (A) and Amsler grid (C) and in wet age-related 
macular degeneration (B and D). Central vision is missing entirely or appears 
distorted (D) (National Eye Institute, National Institutes of Health).
Choroidal neovascularization in AMD Figure 4 is the result of retinal pigment 
epithelium hypoxia from thickening of Bruch's membrane or changes in choroidal 
p e r f u s i o n , w h i c h  leads to production of angiogenic growth factors.^^^’ Visual
loss is a consequence of hemorrhage from neovascular vessels extending from the 
choroidal vasculature through breaks in Bruch's m e m b r a n e . T r e a t m e n t  options 
include laser photocoagulation and photodynamic therapy, offering some short-term 
benefits to certain subgroups of p a t i e n t s . E x u d a t i v e  age-related macular 
degeneration (ARMD) typically occurs in individuals 60 years of age and older, and is 
responsible for blindness in 16,000 people in the US per year.^^^
6 2.2.2. Degenerative Retinal and Choroidal Diseases
The list of potential therapeutic target diseases for gene therapy is comprehensive but 
as with any therapeutic, development has to be guided not only by feasibility but also 
by socioeconomic relevance. As devastating as many hereditary fundus dystrophies 
are as challenging it would be to proceed through all steps from the drawing board to
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animal models, clinical trials and approval. It might be more applicable to focus on a 
common cause such as neovascularization in vasoproliferative disorders or on 
neuroprotective or anti-apoptotic strategies in degenerative disorders. In addition, an 
animal model is needed as a crucial step.
6.2.2.2.1. Retinitis Pigmentosa
Although the term retinitis implies inflammation it is a group retinal degeneration 
without inflammatory features. Retinitis pigmentosa is a term broadly applied to 
disorders in which nyctalopia and progressive peripheral vision loss occurs followed 
by late central vision loss. More than 100 genes have been identified that have a 
similar appearance on clinical exam but may affect primarily either the retina or the 
retinal pigment epithelium. Approximately 50% cases are sporadic while about 25% 
are autosomal dominant, 20% are autosomal recessive, 10% are X linked. In 30% of 
patients hearing loss can be observed as a systemic association known as Usher 
syndrome. Rods of the mid-periphery are primarily affected followed by cones. The 
frequency is about 1 in 3000 while the carrier state is about 1 in 100 in the USA with 
a worldwide estimated prevalence of I in 5000. On a genetic level, about 30% of 
autosomal dominant cases are caused by rhodopsin mutations and approximately 15% 
of those are single point mutations. RetNet, steadily growing online database is a 
collaborative effort to catalogue these (http://www.sph.uth.tmc.edu/Retnet/): the 
autosomal dominant form of RP can be caused by mutations in 12 different genes 
while more than 60 genes are identified for the autosomal recessive form and only 2 
for X-linked RP (75% of those in the RPGR gene (retinitis pigmentosa GTPase 
regulator)). Retinitis pigmentosa that is the result o f a retinal pigment epithelium 
defect (RPE65, RBP, RDH5) can be seen as a bystander phenomenon where 
photoreceptor death is the consequence. An exception is the ABCA4 gene that can 
cause both retinitis pigmentosa and Stargardt’s disease by primarily affecting the 
RPE. The mutation affects a flippase of the photoreceptor outer segments that moves 
photo-transduction molecules through the membrane that build up when defective and 
are phagocytosed by the RPE. Other noteworthy major genes are the RDS/peripherin 
gene and the beta-phosphodiesterase of the photo-transduction cascade.
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In the following hereditary fundus dystrophies are described that are rare but cause 
profound visual loss. Because the genetic defect is identified and animal models exist, 
these are amenable to a gene therapy approach in theory.
6.2.2.2.2. Best Disease
Juvenile Best disease has an AD inheritance. Vision is usually acceptable until the 
fifth decade after which there is a sharp decline due to macular scarring, choroidal 
neovascularization, geographic atrophy or hole formation. The course of the disease 
can be staged according to the fundus exam: stage 0 (pre-vitelliform) is characterized 
by a subnormal electrooculogram and normal fundus, stage 1 shows pigmentary 
macular mottling, stage 2 (vitelliform) presents in the first to second decades. Stage 3 
is characterized by a pseudohypopyon due to partial absorption of lipofuscin while 
stage 4 has the vitelliruptive ("scrambled egg") lesion with diminished vision. 
[5904376, 10737974] The most common mutation is found in VMD2 that encodes 
bestrophin, a multispan transmembrane protein preferentially expressed in the RPE 
that is localized at the basolateral plasma membrane and functions as an oligomeric 
chloride channel. VMD2 is highly and preferentially expressed in the RPE [9662395 
9700209]. Although accumulation of lipofuscin-like material within and beneath the 
RPE is also seen in age-related macular degeneration of patients with age-related 
macular degeneration show that VMD2 does not play a major role in this common 
disorder [10854112 10453731]. Guziewicz et al. suggested that canine multifocal 
retinopathy, an autosomal recessive disorder of multiple dog breeds that shares a 
number o f clinical and pathologic similarities with Best macular dystrophy may be 
used as an animal model for Best disease.[17460247] In this study two disease- 
specific sequence alterations were identified in the canine VMD2 gene: a C(73)T stop 
mutation in cmrl and a G(482)A missense mutation in cmr2.
The adult-onset vitelliform macular dystrophy is a rare autosomal dominant disorder 
with incomplete penetrance and highly variable expression that only causes mild 
metamorphopsias in the fourth to sixth decades. It is considered a subtype of patterned 
dystrophy of the retinal pigment epithelium (RPE).
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6.2.2.2.S. Choroideremia
Choroideremia is an x-linked recessive diseases in which female carriers have mild 
patchy peripheral RPE changes however in males nyctalopia already presents in the 
first decade.^®  ^Progressive, diffuse atrophy of the choroid and RPE occurs with 
consecutive photoreceptor death. The scotopic electroretinogram is non-recordable 
and the photopic is severely subnormal as is the electrooculogram. Second to the RPE 
atrophy on fluorescein angiography prominent filling of retinal and large choroidal 
vessels can be seen with central blockage at the fovea surrounded by 
hyperfluorescence. Most patients retain some useful vision up to the sixth decade after 
which very sever visual loss occurs.
The choroideremia gene encodes for a protein, the Rab escort protein-1 (REPl), 
which is involved in membrane trafficking and several point mutations have been 
described^that introduce a premature termination codon. Tomachova et al.^^  ^
created a knockout mouse model of the CHM gene in which heterozygous-null 
females display the features of choroideremia.
6.2.2.2.4. Favre Goldmann Syndrome
Favre-Goldmann syndrome is an autosomal recessive disease that causes nyctalopia 
already in childhood. Signs on exam are vitreous degeneration, congenital 
retinoschisis, pigmentary retinopathy and white, dendritiform, arborescent peripheral 
retinal vessels. The electroretinogram is reduced and the prognosis is poor. The 
genetic defect is located in the NR2E3 gene (nuclear receptor subfamily 2, group E, 
member 3 PNR, which encodes a retinal nuclear receptor that is a ligand-dependent 
transcription factor that regulates embryonic development and is required for regular 
maintenance in the adult. In early human NR2E3 disease demonstrates an S-cone 
hyperfunction in a thickened retina. Akhmedov et al. showed that in the rd7 mouse a 
deletion in a photoreceptor-specific nuclear receptor is responsible for the retinal 
degeneration ob served.
6.2.2 3. Rational for Gene Therapy for Retinal and Choroidal 
Diseases
Ocular gene therapy offers a novel approach to treating eye diseases characterized by 
retinal neovascularization (e.g. diabetic retinopathy, age related macular degeneration,
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retinopathy o f prematurity)/^^' 312-314 chronic retinal degeneration/^^’
Several different viral vector systems have been proposed, including lentiviral and 
adenoviral (Ad) vectors as used in this thesis. These vectors have markedly different 
biologic properties; lentiviral vectors, such as those based on the feline
I  0 * 7 0  1
immunodeficiency virus (FIV), ’ ’ require integration into the host genome as an
obligate part of the life cycle and have shown little direct immunogenicity or 
toxicity,^^ '^^^"  ^which may facilitate long-term expression.^^’ In contrast. Ad 
vectors remain episomal, persist variably, undergo dilutional attrition with cell 
division and are often immunogenic, which may result in shorter-term expression.^^^'
328
Parameters for lentiviral transduction efficiency were examined in the neonatal rat in 
particular because these animals have been used to study retinopathy of prematurity, 
and they are useful to investigate anti-angiogenic factors in Retinal and
subretinal neovascularization is common to a number of ocular diseases, many of 
which are leading causes of blindness, e.g. diabetic retinopathy, exudative age-related 
macular degeneration, and retinopathy of prematurity. These diseases are good 
candidates for RPE-targeted gene therapy since specific growth factors that modulate 
neovascularization are secreted by the RPE or neighboring cell types.^^^’^^  ^However, 
the tropism of lentiviral vectors within the rodent retina appears to depend on the 
route of injection, transgene promoter, age, and species.^^^’^^ ’^^^ ®’^^ ’^^^ '^ '^ ^^  In 
particular, age (injecting within the first five days post-natal) has been a critical factor 
favoring lentiviral transduction of photoreceptors.^^^
6.2.3. Mediators of Ocular Angiogenesis
The development of ocular neovascularization depends on the balance of angiogenic 
and angiostatic e l e m e n t s , b o t h  of which can be exploited in gene therapy. Relevant 
growth factors and inhibitors include vascular endothelial growth factor (VEGF), 
insulin-like growth factor-1 (IGF-l),^"^^’ "^^  ^pigment epithelium-derived factor 
(PEDF),^^^’^^ ’^ '^^ '^^ '^  ^matrix metalloproteinases (MMPs),^^ '^^^"  ^tissue inhibitors of 
MMPs (TIMPs),^’^  angiostatin,^^^’^^ ’^^^  ^endostatin,^^^’^^ ’^^^ ’^^^  ^ and others.
VEGF is a potent endothelial-cell-specific mitogen^^^’ expressed by pigment 
epithelial cells, pericytes, vascular endothelial cells, neuroglia and ganglion cells.^^^’
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359,361,362 pj^yg ^ crucial rolc during retinal development/^^ Expression of VEGF is 
up-regulated by hypoxia^^^’ through the hypoxia-inducible factor-1 (HIF-1) 
transcriptional e l e m e n t / V E G F  acts through high affinity receptor tyrosine kinases 
specific receptors, fins-like tyrosine kinase (Flt)-l and fetal liver kinase-1 (Flk- 
l)/kinase insert domain-containing receptor (KDR) phospholipating C /an d  other 
proteins to form diacylglycerol (DAG) activate protein kinase C (PKC) ultimately 
leading to endothelial cell proliferation, migration, and increased vascular 
permeability.
Patients with proliferative diabetic retinopathy, retinopathy of prematurity, vascular 
occlusion and choroidal neovascularization have increased levels of VEGF^^ '^^^^ that 
can be simulated in experimental models of retinal ischemia.^^^’ Many novel 
therapies target VEGF as a central molecule o f angiogenesis: neutralizing VEGF 
antibodies,^^^' 370,371 g^^^y^g VEGF-like receptors,^^^ oligonucleotides,^^^'^^^ VEGF 
receptor sFlt-1 (sequestrates VEGF),^^^’ inhibition of VEGF-specific protein 
kinase.^^^
Insulin-like growth factor 1 (IGF-1) mediates effects of growth hormone,^"^^ but can 
also induce angiogenesis directly.^^^ Inhibition of IGF-1 by a receptor antagonist was 
able to suppress retinal neovascularization in mice.^^^
Pigment epithelium derived factor (PEDF) is a new member of anti-angiogenic 
molecules successfully used in animals to inhibit neovascularization. A non-inhibitory 
member of the serine protease inhibitor (serpin) superfamily of p r o t e i n s , P E D F  was 
first described as a neurotrophic factor.^^ '^^ "^  ^The potent anti-angiogenic properties of 
PEDF, possibly promoted though endothelial cell apoptosis,^"^^ were only discovered 
much later.^^^ Imbalance between PEDF and VEGF have been proposed as a 
mechanism of action in retinal neovascularization.^^^’ Pigment epithelium-
derived factor (PEDF) was recently identified as an inhibitor of angiogenesis and is 
among the most potent in comparative s t u d i e s . P E D F  has specific inhibitory 
activity against VEGF, a substance thought to be responsible for OIR.^^ '^^^^ The 
physiologic source of PEDF in the eye is the RPE, from which it diffuses into other 
retinal layers. Normal roles of PEDF appear to be stopping retinal vascularization at 
appropriate points in development and inhibition of neovascularization in adult life.^^^ 
PEDF levels may be decreased in eyes with pathological neovascularization, e.g. 
diabetic retinopath)/^"^’ and age-related macular degeneration.^^^
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Angiostatin and endostatin, in particular, have yielded promising results in 
experimental m o d e l s , ^ a l t h o u g h  these inhibitors have yet to be 
evaluated in clinical trials for ocular neovascular disorders/^^
Subretinally expression of VEGF inhibitor sFlt-1,^^^ PEDF^*^ and angiostatin^'^ was 
also able to reduce neovascularization in models of choroidal neovascularization.
Finally, tissue inhibitors of matrix metalloproteinase^'"' and a soluble form of the 
Ang2 receptor^^'’ have been proposed as therapeutic molecules for gene therapy of 
retinal neovascularization.
6.2.4. Models of Retinal and Choroidal Neovascularization
/
Figure 5: Quantification of retinal 
neovascularization in a model of oxygen 
induced retinopathy. Flat mounted, stained
1
retina is divided into clock hours and 
pathological vessel buds (arrows) are 
counted.^^^
* The most common animal models for retinal
neovascularization are models of oxygen- 
induced retinopathy in the mouse^^"' or rat^^^’ 
that allow reliable induction of 
neovascularization and its quantification^^^ (Figure 5). In these models, newborn mice 
or rats that are exposed to cycling oxygen levels develop retinal neovascularization 
during the relative hypoxia on return to room air. In addition, newborn rats may be 
kept in expanded litters of n = 25 to mimic the low birth weight of premature human 
neonatals. I used this litter design in the experiments described below already to 
develop marker gene delivery as a basis for future gene therapy.^^’
Other models of neovascularization include choroidal neovascularization induced by 
rupture of Bruch’s basement membrane with laser^^^’ or the local application of 
VEGF^^^’ and basic fibroblast growth factor.^'"
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The neonatal rat model has the advantage that it is more established than these 
models, is widely used in various models of retinal neovascularization, particularly 
for retinopathy of prematurity and diabetic retinopathy/^^'^^^’
6.3.Gene Therapy
6.3.1. Definition
In gene therapy, diseases are treated by manipulating the genetic material in a targeted 
cell population to change its expression pattern. Genetic reprogramming requires 
detailed knowledge of the genetic basis of a disease. The most common and ethically 
accepted form of gene therapy is somatic gene therapy, which seeks to correct gene 
expression without propagation of this correction to the next generation. Treatment 
goals have a wide range from specific repair o f genetic defects to less specific 
amendment of or interference with nongenetic disease processes. Classically, the 
genetic material is delivered to a cell in the form of DNA or RNA for the expression 
of therapeutic proteins (
Figure 6), but recently discovered features of RNA (small interfering RNA,"'^ '^"'^  ^
reviewed in"'''  ^and ribozymes,"'''^"'” '' reviewed in'” ' ’'"^) have increased the options.
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Figure 6: Gene types transferred in clinical gene therapy trials (data from the online 
database provided by The Journal of Gene Therapy).
Fundamental goals in gene therapy are the specificity, efficiency, and safety of gene 
delivery. Vehicles that encapsulate therapeutic genes for delivery are called “vectors”. 
For chronic diseases, expression from these vectors should ideally persist for the 
whole life of the cell and lead to a permanent cure, while short-term function is 
sufficient for acute diseases.
Most vectors currently in use are based on attenuated or modified versions of viruses 
and exploit the highly efficient targeting and gene delivery that have evolved from the 
adjustment of a pathogen to its host, by abandoning their pathogenicity and 
effectively turning them into a Trojan horse. Commonly used viral vectors are derived 
from adeno-associated virus, type-C retroviruses, lentiviruses, adenovirus, herpes 
simplex virus, but other viruses such as measles, alphaviruses, and paramyxoviruses
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have also been engineered into vectors. A variety of non-viral gene delivery systems 
is available that are based on cationic, cholesterol-containing liposomes, peptide-lipid 
vectors, activated dendrimers (branched DNA-binding carbohydrates), bacteria, 
artificial chromosomes or artificial viruses (liposomes with viral components).
6.3.2. History
Ideas for the genetic reprogramming of cells appeared already in 1967, when Nobel 
laureate Marshall Nirenberg reflected on reprogramming cells with synthetic 
messages in an editorial in Science entitled "Will Society Be P r e p a r e d ? t h a t  
addressed the concerns raised by molecular geneticists. Nirenberg contended that the 
impulse to exploit molecular genetics could only be kept in check by sobriety and 
caution: "When man becomes capable of instructing his own cells, he must refrain 
from doing so until he has sufficient wisdom to use this knowledge for the benefit of 
mankind. [...] decisions concerning the application of this knowledge must ultimately 
be made by society, and only an informed society can make such decisions wisely." In 
a draft of his Nobel acceptance speech'"'' Nirenberg stressed that knowledge of the 
genetic code made it likely that "man eventually w ill... influence his own biological 
evolution. One can predict that a new area of research will emerge during the next 
twenty-five years, that of molecular evolution, in which the effects of synthetic genes 
upon the economy of the cell will be explored in a systematic fashion."
This prediction rapidly materialized, when Stanfield Rogers attempted to treat two 
patients suffering from hyperargininemia with the Shope papilloma virus (SPV) in the 
early I970s.'"^ Four years later first regulations of recombinant DNA research became 
available when the National Institutes of Health (NIH) created the Recombinant DNA 
Advisory Committee (RAC). The acceptance of gene therapy experienced a setback 
when in 1980 Martin Cline performed recombinant DNA transfer into bone marrow 
cells of two patients with hereditary blood disorders, but tried to avoid review by this 
body and conducted these studies abroad under questionable c i r c u m s t a n c e s . I n  
1984 the RAC created a new group, called the Human Gene Therapy Working Group 
(later called the Human Gene Therapy Subcommittee (HGTS)) to specifically review 
gene therapy protocols''^^, the first two of which it received in 1990. One protocol by 
Michael Blaese and French Anderson proposed treatment of SCID,^^^ a fatal and
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incurable childhood disorder that has become one of the greatest successes of gene
therapy/^^
6.3.3. Types of Gene Transfer Vectors
As obligate intracellular parasites, viruses are optimized gene transfer vehicles by 
design that have evolved mechanisms to enter and take reprogram the infected host 
with great specificity and efficiency. These mechanisms can be exploited by replacing 
non-essential genes with genes of interest that can be transferred for a therapeutic or 
experimental purpose. Non-essential genes that are still needed during vector 
production can be provided in trans from other plasmids the genetic information of 
which will not become part of the physical vector particle. Because of the intricate 
host-virus interaction of their parent virus vectors may elicit a similar immune 
response.
In the following the most commonly used vector types are briefly reviewed to help 
put lentiviral feline immunodeficiency viral vectors used in this thesis into context. 
The order of discussion follows the percentage of usage in clinical trials as listed 
above.
6.3.3.1. Adenoviral Vectors
Despite early short comings, adenoviral vectors are used in 25% (337 trials) of all 
clinical gene therapy trials. Adenoviruses have a large genome of 35 kb 30 kb of 
which can be replaced with foreign DNA allowing for an exceptionally large cargo 
among current gene therapy vectors. They are non-enveloped viruses that contain a 
linear double stranded DNA genome. Most of the 40 serotypes cause benign 
respiratory tract infections in humans. Subgroup C serotypes 2 and 5 are commonly 
used as vectors. Adenoviruses do not integrate into the host genome but replicate as 
episomes. As a result potential disadvantages are that patients often are pre­
immunized due to prior exposure, that permanent expression is difficult to achieve 
and that vectors can aerosolize during production.
Four early transcriptional elements (El through 4) have regulatory functions while a 
late transcript codes for structural proteins. In early adenoviral vectors either E l or E3 
were inactivated and supplied during the production process in trans as can be done
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with HEK293 cells/^^ Second generation vectors utilize an E2a temperature sensitive 
mutant''^^ or an E4 deletion/^'' More recent so called gutless vectors contain only the 
inverted terminal repeats and packaging sequence around the transgene while all other 
needed viral genes are provided in trans by a helper virus
A major advantage is the broad tropism and the relative ease compared to other 
vectors with which very high titers of adenoviral vectors can be achieved enabling 
injection of small volumes in restricted spaces or small species. However, expression 
is generally short lived, especially in earlier generation vectors with E l deletion. After 
intravenous administration up to 90 percent are already removed and broken down in 
the liver.''^^ Transduced cells are often eliminated by cytotoxic T cells (CTLs) within 
a short time and promoter shut down may follow in those that are not ablated by 
CTLs.''^'' Immune suppression''^^’ or oral induction of tolerance''^^ or administration 
of CTLA4Ig, which is known to block co-stimulatory signals between T cells and 
antigen presenting cells,''^^ can prolong transgene expression or permit repeat 
application. Occasionally, adenoviral vectors can induce an unpredictable toxicity the 
resulting inflammation of which has even resulted in a fatal outcome in one case in 
one patient.''^^ Adenovirus type 3, 4 and 11 more often results in toxicity compared to 
others''^^ (adenovirus type 5 was used in Jesse Gelsinger) but the mechanism is still 
poorly understood.
Later generation vectors contain fewer adenoviral genes or no adenovirally expressed 
genes (“gutless vector”''^ )^. However, even such gutless vectors may trigger an 
immune response to the viral proteins that engulf the transferred DNA. Clinical 
application is nevertheless limited because a large proportion of the population has 
already been exposed to adenovirus.'''"'
Adenovirus update occurs in a two stage process that involves interaction of the fiber 
coat protein with MHC class I molecules'''" and the Coxsackie virus-adenovirus 
receptor.''''^ The penton base protein then binds to integrins''''^ and is internalized via 
receptor mediated endocytosis. Most cells express primary receptors for the 
adenovirus fiber coat protein but the process of internalization is more selective.'''''' 
Uptake into target cells can be improved by stimulating expression of appropriate 
integrins,''''^ antibody targeting by conjugating vectors with antibodies''''^’ or by 
incorporating receptor binding motifs into the fiber coat protein.''''^
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Rosenfeld et al. were the first ones to transduce rat respiratory epithelium with human 
alpha lAT, the gene for alpha 1-antitrypsin deficiency resulting in functional 
secretion from analyzed lung tissue. The major shortcoming of adenoviral vectors, 
short-term expression and immunogenicity was noticed as expression could only be 
followed for one week.' '^'^
Other historically important studies include Akli et al.’s transfer of beta-galactosidase 
into rat brain using an adenoviral vector with E l and partial E3 deletion.''^'' For the 
first time the authors described adenoviral gene transfer to post-mitotic, neuronal 
tissue. A formidable target for gene transfer as type C retroviral vectors cannot be 
used for this purpose. The authors find that 3x10^  TU delivered in 10 microliters did 
not result in any tissue toxicity but note that this could be seen at 10  ^TU per 10 
microliter. This highlights the relative ease with which high titers of vectors can be 
generated. Similar results were quickly replicated elsewhere.''^' Adenoviral vectors 
experienced a surge of popularity
The first functional mammalian odorant receptor could be expressed in sensory 
neurons in the rat olfactory epithelium using adenoviral v e c t o r s . Z h a o  took an 
elegant approach to demonstrate receptor function and specificity by using 
recombinant adenovirus expressing a hybrid mRNA encoding the 17 odorant receptor 
and green fluorescent protein and introducing them into the nasal cavity of rats. 
Imaging of the GFP in the olfactory neuroepithelium revealed that up to 10% of the 
cells expressed GFP and that the virus selectively infected the neuronal cell 
population. The authors assessed the electrophysiological response of wild-type and 
infected epithelium to individual odorant application by a measurement of transient, 
induced electrical potential, the electroolfactogram. The use of real olfactory neurons 
to direct the expression of introduced G protein-coupled receptors circumvents the 
previous difficulties in protein translocation and receptor function. Those receptor 
receptors were difficult to study because no particular mammalian receptor had been 
definitely paired with a ligand.
An interesting idea of ameliorating telomere loss was accomplished by adenoviral 
vector mediated essential telomerase RNA (mTR) gene in telomerase-deficient mice. 
In these mice, telomere dysfunction is associated with defects in liver regeneration 
and accelerated development of liver cirrhosis in response to chronic liver injury. 
Adenoviral delivery of mTR into the livers of mTR(-/-) mice with short dysfunctional
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telomeres restored telomerase activity and telomere function, alleviated cirrhotic 
pathology, and improved liver function.
Recombinant, replication-incompetent adenovirus serotype 5 (rAd5) vector-based 
vaccines for human immunodeficiency virus type 1 and other pathogens have proved 
highly immunogenic in preclinical studies but are limited by the high prevalence of 
pre-existing anti-Ad5 immunity in human populations. Roberts et al. showed that 
recombinant adenoviral vectors serotype 5 can be engineered to circumvent anti-Ad5 
immunity.''^^ The authors constructed novel chimaeric Ad5 vectors in which the seven 
short hypervariable regions (HVRs) on the surface o f the Ad5 hexon protein were 
replaced with the corresponding HVRs from the rare adenovirus serotype Ad48.
These HVR-chimaeric rAdS vectors were produced at high titers and were stable 
through serial passages in vitro. HVR-chimaeric rAd5 vectors expressing simian 
immunodeficiency virus Gag proved comparably immunogenic to parental rAd5 
vectors in naive mice and rhesus monkeys. In the presence of high levels of pre­
existing anti-Ad5 immunity, the immunogenicity of HVR-chimaeric rAd5 vectors was 
not detectably suppressed, whereas the immunogenicity of parental rAdS vectors was 
abrogated. These data demonstrated that functionally relevant Ad5-specific 
neutralizing antibodies are focused on epitopes located within the hexon HVRs. 
Moreover, these studies showed that recombinant viral vectors can be engineered to 
circumvent pre-existing anti-vector immunity by removing key neutralizing epitopes 
on the surface of viral capsid proteins.
The opposite approach, taking advantage of the immunogenicity o f adenovirus is to 
use vectors to develop vaccines. Shiver et al. used a replication incompetent 
adenovirus type 5 vector expressing the SIV gag protein to illicit a protective immune 
response to infection with a pathogenic HIV-SIV hybrid virus.''^'' Ad5 vectors 
immunized animals exhibited the most pronounced attenuation compared to plasmid 
DNA or modified vaccinia Ankara (MVA) virus. A similar strategy was applied by 
Letvin et al''^  ^who immunized monkeys with E l deleted, E3-defective adenoviral 
vectors encoding SIV gag, pol and env. Although tested monkeys demonstrated a 
reduction in viremia only in the early phase of SIV challenge, this was associated with 
prolonged survival and preserved central memory CD4+ T lymphocytes.
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6.S.3.2. Retroviral Vectors
Retroviral vectors have been used for many years in clinical trials contributing to 22.6 
percent of clinical trials because they can easily be pseudotyped allowing for a broad 
host range, high titers can be achieved by ultracentrifugation and vector production 
cell lines can be made''^^ as these vectors integrate. In contrast to adenovirus, prior 
exposure to retroviruses in treated subjects is highly unlikely and pre-existing 
immunity is not expected.''^^ As described in the section reviewing AAV vectors, pre­
existing immunity has recently been found to be an unexpectedly grave problem with 
AAV vectors that can cause destruction of transduced cells although no AAV capsid 
proteins are synthesized de novo.''^^
In the following discussion “retroviruses” refers to both type C retroviruses and 
lentiviruses unless mentioned otherwise. Retroviruses are enveloped, single stranded 
RNA viruses of 7 to 11 kb and 80 to 100 nm size although pseudotyped particles may 
be slightly larger. After cell entry the RNA is reverse transcribed into a double 
stranded DNA that is eventually integrated into the host genome. Gag (group specific 
antigen, core protein), pol (polymerase, coding for reverse transcriptase and env 
(envelope) are the three genes that can be found in any retrovirus. These are usually 
replaced with transgenes with exception of the packaging signal that is contained in 
gag. Removal of non-essential genes and separation of packaging, envelope and 
transfer function to different plasmids has made vector production a lot safer. There 
are long terminal repeats (LTRs) at each end of the genome that contain promoter and 
enhancers for the integration. Several splice sites are responsible for the generation of 
the different RNAs during the viral life cycle and can complicate vector design.
Some retroviruses contain proto-oncogenes that must be removed in vector design. 
Retroviral genomic integration, a required step in the viral life cycle, is mutagenic by 
definition. Retroviral integration is usually well tolerated but may be oncogenic itself 
if  it occurs near a cellular proto-oncogene or by disrupting a tumor suppressor gene or 
alteration of transcription start sites which are favored integration sites for the 
Moloney murine leukemia virus (MLV).''^^ Most retroviral vectors are based on the 
Moloney murine leukemia virus, an amphotrophic virus that is capable of entering 
both mouse and human cells which allows production in mouse cells and transduction 
of human target cells. The packaging capacity is limited to about 7.5 kb which 
requires use of cDNA. Because transduced cells are permanently altered, retroviral
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vectors can be used to generate cell lines. This is usually accomplished by co-transfer 
o f a non-cap dependent, internal ribosomal entry site-mediated marker''^'' that can be 
selected for by resistance or visualized and sorted for instance by fluorescence- 
activated cell sorting (FACS). The tropism of the retroviral envelope is a key 
determinant determining the target cell range. Attempts have been made to retarget 
retroviral vectors (reviewed in''^') but often this interferes with efficiency of vector 
uptake.''''''
Pseudotyping is an easier approach to target transduction yet potentially less specific 
than direct modification of retroviral envelope proteins. Retroviruses can use a 
surprisingly wide range of envelope proteins from other viruses that are not at all 
related to the family o f retroviruses. The most commonly used pseudotype, vesicular 
stomatitis G protein, allows for a broad target range and provides high stability for 
concentration by ultracentrifugation.''^^ A well known example of altering the tropism 
by pseudotyping is use of the rabies glycoprotein in retroviral vector envelop which 
facilitates transduction of n e u r o n s . O t h e r s  are the Jaagsiekte sheep retrovirus,''^'' 
maedi-visna virus,''^^ gibbon ape leukemia virus,''^^ equine infectious anemia virus,''^^ 
avian leucosis-sarcoma virus,''^^ baculovirus,''^^ Lassa virus,''^® rabies v i r u s , M o k o l a  
virus,''^' filovirus,''^^'''^'' influenza,^^^ lymphocytic choriomeningitis virus,^^^ Ross
475nver virus.
Type C retroviral vectors, but not lentiviral vectors, require the target cell be dividing 
to access to the genome.^''^ As a result, gene therapy with type C retroviral vector may 
require removal of a patients resting cells (e.g. hematopoietic stem cells) and 
induction of cell division.''^^ Despite genomic integration, long-term expression can 
be difficult to achieve because of promoter interference of interferons, specifically 
IFNa and IFN-y, with viral LTRs''^^ and méthylation of the integrated retroviral 
genome and flanking host DNA sequences.''^^
Because of the need for cell division and for high multiplicities of infection per target 
cells, retroviral gene therapy typically requires extraction of the target tissue (e.g. 
harvesting of hematopoietic stem cells) and transduction ex vivo prior to re­
implantation. This adds the additional safety benefit of being able to select for desired 
characteristics of transduced cells before patient exposure to genetically modified 
material.
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Several breakthrough therapies have been developed using retroviral vectors to treat 
previously incurable diseases. Hacein-Bey-Abina et al. achieved a functionally 
adaptive immune system in patients with X-linked severe combined 
immunodeficiency (SCID)."^^  ^In this disease, a mutation in the gene encoding the 
common gamma chain is lethal unless an allogenic stem-cell transplantation is 
performed. The study authors infused autologous hematopoietic stem cells that had 
been transduced in vitro with the gamma gene using an MLV vector. Transduced T 
cells and natural killer cells appeared in the blood of four of the five patients within 
four months. The numbers and phenotypes of T cells, the repertoire o f T-cell 
receptors, and the in vitro proliferative responses of T cells to several antigens after 
immunization were nearly normal up to two years after treatment. Patients developed 
a normal sized thymus gland. Although the frequency of transduced B cells was low, 
serum immunoglobulin levels and antibody production after immunization were 
sufficient to avoid the need for intravenous immunoglobulin. Correction of the 
immunodeficiency eradicated established infections in some patients and allowed 
them to live a normal life. However, almost 3 years after gene therapy, uncontrolled 
exponential clonal proliferation of mature T cells occurred in two p a t i e n t s . B o t h  
patients' clones showed retrovirus vector integration in proximity to the LM 02 proto­
oncogene promoter, leading to aberrant transcription and expression of LM 02. 
Retroviral vector insertion triggered deregulated premalignant cell proliferation. The 
analysis showed that this was most likely driven by retrovirus enhancer activity on the 
LM 02 gene promoter.
Aiuti et al. used hematopoietic stem cell gene therapy for adenosine deaminase 
(ADA) deficient SCID."^^  ^The authors used an MLV vector to replace the defective 
ADA and achieved sustained engraftment of engineered HSCs with differentiation 
into multiple lineages resulted in increased lymphocyte counts, improved immune 
functions (including antigen-specific responses), and lower toxic metabolites. Both 
patients are currently at home and clinically well, with normal growth and 
development. These results indicate the safety and efficacy o f HSC gene therapy 
combined with nonmyeloablative conditioning for the treatment of SCID.
Morgan et al. demonstrated that regression of metastatic melanoma can be achieved 
using genetically engineered lymphocytes."^^^ In this study autologous lymphocytes
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were harvested from peripheral blood and transduced with a retroviral vector 
encoding the alpha and beta chains of the anti-MART-1 T-cell receptor. These genes 
were cloned from a tumor infiltrating lymphocyte clone obtained from a cancer 
patient who demonstrated a near complete regression of metastatic melanoma after 
adoptive cell transfer. Adoptive transfer of the transduced cells resulted in durable 
engraftment for at least 2 months after infusion and objective regression of metastatic 
melanoma lesions. Although this outcome could only be achieved in 2 out of 15 
patients it demonstrates the therapeutic potential of genetically engineered cells for the 
biologic therapy of cancer.
Different from the above trials that involved correcting a lymphoid 
immunodeficiency, Ott et al. successfully corrected and clinically improved subjects 
suffering from X-linked chronic granulomatous disease (X-CGD),"^^^ a primary 
immunodeficiency caused by a defect in the oxidative antimicrobial activity of 
phagocytes resulting from mutations in gp91(phox). Substantial gene transfer could 
be noted in the two participating children’s neutrophils that lead to a large number of 
functionally corrected phagocytes. A large-scale retroviral integration site-distribution 
analysis showed activating insertions in M D Sl-EV Il, PRDM16 or SETBPl that had 
influenced regulation of long-term hematopoiesis by expanding gene-corrected 
myelopoiesis three- to four-fold in both individuals. The risks associated with the use 
of retroviral vectors for X-CGD was estimated to be low because gp91^^°^ is not 
known to provide a survival or growth advantage to transduced cells, and abnormal 
hematopoiesis or leukemogenesis have not been observed in animal models of X- 
CGD transplanted with gp91^^°Vexpressing cells.
Alzheimer disease is characterized by loss of cholinergic neurons as one of its 
cardinal features. Nerve growth factor (NGF) stimulates cholinergic function, is able 
to prevent cholinergic degeneration in animal models and improve memory.
Tuszynski et al. transduced autologous skin fibroblasts with an NGF MLV vector in 
subjects with early probable Alzheimer."^^"  ^This trial is remarkable for several reasons: 
it involved subjects with a relatively early stage of the disease and addressed an 
ailment that is -  in contrast to the previously mentioned studies -  not lethal. In the 
contrary, several medical treatment options exist. After transduction, NGF production 
was measured, and cells were stereotactically injected into the cholinergic basal 
forebrain over a region of 1 cm in length in awake but sedated subjects. NGF induced
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cholinergic axon sprouting into the site of NGF delivery. At mean follow-up of 22 
months no long-term adverse effects of NGF occurred. Evaluation of the Mini-Mental 
Status Examination and Alzheimer Disease Assessment Scale-Cognitive 
subcomponent suggested improvement in the rate of cognitive decline. Serial PET 
scans showed significant (P < 0.05) increases in cortical 18-fluorodeoxyglucose after 
treatment. Brain autopsy from one subject suggested robust growth responses to NGF.
Junctional epidermolysis bullosa (JEB) is a devastating and often fatal skin adhesion 
skin disorder. In an Italian study/^^ a single individual with nonlethal JEB was treated 
with a retroviral vector expressing LAMB3 CDNA encoding LAM5-beta3, the 
basement membrane component that is defective in this disease. The patient was a 
double-heterozygous carrier of a null allele and a single point mutation (E210K) in 
the LAMB3 gene who had suffered from blistering skin occurring spontaneously or 
after minimal injury. Epidermal stem cells were transduced, expression of LAM5 was 
conformed and nine graft were transplanted onto surgically prepared regions. This 
skin remained stable at the 1 year follow up without blisters, infections or rejection.
6.3.3.3. Lentiviral Vectors
A subfamily of retroviruses, lentiviruses (lenti = Latin for slow) typieally cause 
slowly progressing diseases with incubation times that can amount several years. As 
lentiviruses, lentiviral vectors permanently integrate in both dividing and nondividing 
cells as Naldini et al. showed in their elegant study. "^^  ^Others have confirmed these 
results or applied those vectors to other hard to transduce cell types
Lentiviruses are considerably more complicated than type C retroviruses and -  in the 
case of HIV - contain the additional six genes tat, rev, vpr, vpu, nef and v if in addition 
to gag, env and pol. As for type C retroviral vectors, packaging cell lines can be 
generated"^^^ and the other afore mentioned advantages of retroviral vectors apply. A 
recent study by Yanez-Munoz et al. demonstrated that lentiviral integration is not 
always a requirement in order to obtain expression levels high enough to achieve 
therapeutic transgene levels when subretinal delivery of an integration-deficient 
HIVvector carrying a functional human RPE65 transgene led to expression of RPE65 
in transduced RPE with functional rescue as assessed by electroretinography for at 
least 8 w e e k s . F I V  vectors can express transgenes in non-dividing cells in the
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absence of a functional integrase but that expression is lost when growth-arrested cells 
are allowed to divide again.^^^ Transduction is negligible in dividing cells. The retinal 
pigment epithelium that Yanez-Munoz studied is non-dividing in vivo.
Replication-defective lentiviral vectors were originally derived entirely from the 
human lentivirus human immunodeficiency virus type 1 (HIV-l).'^^^’'^ ®^ Application of 
pseudotyping with broadly tropic, physically stable envelope glycoproteins"^^^ 
permitted efficient transduction of nonlymphocytes by HIV-1 vectors in vitro and in 
vivo. "^^ ’^ The first nonprimate lentivirus-based vector was derived from feline 
immunodeficiency virus (FIV).^ Subsequently, substantial improvements have been 
made in the design and capabilities of FIV vectors, and recently identified FIV 
elements (central polypurine tract, central termination sequence, and packaging 
signal) have been incorporated.'^^^’
6.3.3.3.1. Important Lentiviral Properties
Retroviral reverse transcription (Figure 7) yields a linear double-stranded DNA 
intermediate that is integrated into the target cell genome (Figure 8) in a reaction 
catalyzed by the viral integrase. Therefore, retroviral vectors generate permanent 
transgenes, a process that makes the former appealing for therapy o f chronic diseases. 
This capability was first demonstrated for vectors derived from simple 
oncoretroviruses, e.g., murine leukemia viruses. Oncoretroviral vectors have now 
been incrementally optimized to the point that clinical utility has been demonstrated 
for diseases that are recognized to be the targets most accessible to gene therapy. For 
example, children with common gamma chain deficiency, in which gene-altered cells 
have a marked survival advantage, have sustained clinical improvement.^^^’
However, it became apparent early on that oncoretroviral vectors achieve integration 
only in target cells that are proliferating at the time of transduction.^"^^’ This 
limitation, which precludes targeting many clinically relevant cell types, is a 
consequence of the fact that the reverse-transcribed linear DNAs (preintegration 
complexes) of these simple retroviruses cannot traverse the intact nuclear envelopes 
of interphase cells. Completion of the replication cycle instead depends on breakdown 
of the envelope during m i t o s i s . I n  contrast, the lentiviral preintegration complex 
is imported through the nuclear pore, permitting integration in nondividing cells. 
250,251,254 capacity to infect nondividing cells is fundamental to the universal
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lentiviral strategy of propagating through terminally differentiated macrophages and 
has been the principal motivation for engineering viral vectors from these highly 
pathogenic viruses. The mechanism of nuclear import remains controversial, but it has 
been attributed to multiple determinants in virion proteins^"^  ^and to a plus strand 
discontinuity, the central DNA flap, which results from lentiviral initiation o f plus 
strand synthesis at two locations.
While genomic integration is mutagenic by definition there are significant differences 
between type C retroviruses and lentiviruses. Montini et al. studied hematopoietic 
stem cell transduction of a tumor prone mouse model (Cdkn2a-/- mice)."^^  ^In a 
comparison of integration site selection and tumor development in transplanted mice 
retroviral vectors retroviral vectors caused dose-dependent acceleration of tumor 
onset dependent on long terminal repeat activity. Insertions at oncogenes and cell- 
cycle genes were enriched in early-onset tumors suggesting cooperation in 
tumorigenesis. Surprisingly, tumorigenesis was unaffected by lentiviral vectors and 
did not enrich for specific integrants, despite a higher integration load and robust 
expression of lentiviral vectors in all hematopoietic lineages. Unlike the gamma- 
retrovirus MLV, ELAY and HIV-1 vectors do not integrate preferentially into the 
promoter region or the 5' end of the transcription unit."^ ^^
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6.3.3.3.2. FIV and FIV Vectors
Three groups of lentiviruses infect primates, ungulates, and felines respectively. 
Feline immunodeficiency virus infects 10-20% of domestic cat populations 
worldwide, as well as many free-roaming, nondomestic Felidae, but is pathogenic 
only for the domestic cat. Figure 12 (Top) illustrates the genomic structure of FIV 
34TF10,"^^  ^the clone used as the substrate for replication-defective FIV vector work 
to date. FIV has typical lentiviral morphology and genetic structure, although only 
three nonstructural genes (vif, rev, and orf2) are encoded in comparison to the six 
encoded by the primate lenti viruses. Other peculiarities are a Rev response
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element (RRE) that overlaps the 3’ end of env rather than the SU-TM junction and a 
pol-encoded dUTPase, which may facilitate reverse transcription under conditions of 
low nucleotide tension.
6.3 3.3.3. Primate versus Nonprimate
No lentiviral vector system will proceed to clinical use without documentation of 
effective mechanisms to prevent and to screen for the most recognized threat: 
generation of replication-competent retroviruses. Other, theoretical considerations can 
be marshaled for and against use of lentiviral vectors, but empirical data are lacking. 
Nevertheless, there are some reasons to hypothesize that FIV vectors could eventually 
have higher acceptability for a broad range of applications. A practical consideration 
for vector workers and for potential gene therapy recipients is that FFV lacks any 
capacity to generate immunological cross-reactivity with HIV, for example in 
diagnostic HIV antibody enzyme-linked immunosorbent assays (ELISAs)."^^^’ In 
addition, there is an extensive record of a lack of human infection or disease despite 
widespread human exposure to wild-type FIV via its principal and very efficient 
natural mode of interfeline transmission, biting (which fi*equently transmits other 
pathogens to humans), and despite the ability of the wild-type virus to use a human 
chemokine receptor for entry.^’^^ ’^^^  ^This epidemiological record of prevalent, direct, 
and efficient human inoculation without sequelae is unique among the lentiviruses. 
Another consideration is that FIV vectors can be tested in an animal model that is 
susceptible to disease causation by the parental virus.
FFV vectors efficiently complete the postentry stages of the infection cycle in 
nondividing human cells despite a severe block to transcription from the FIV long 
terminal repeat (LTR) and to other life cycle mechanisms that prevent productive 
replication.^’ The replication-defective FIV vector^derived from the 
infectious clone FIV34TF10^^^ was the first demonstration of the feasibility of using a 
nonprimate lentivirus as a substrate for vectors. The negligible FFV expression 
observed in human cells^^' was an initial obstacle to transfer vector production. This 
was overcome by substitution of the 5' FFV U3 (but not the 3' U3) with a heterologous 
promoter by a fusion at the TATA box just upstream of the R repeat.^^^ The change 
enabled expression of high levels of FFV proteins and FFV vectors in human cells, 
revealing that previously suggested blocks to other productive phase functions, e.g.,
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do not exist, at least in the relevant human cell lines. Use of a human cell line 
for clinical vector production (such as 293 cells, which have been approved for 
adenoviral vector production by the Food and Drug Administration, FDA) is 
important since feline vector producer cells would be unacceptable for human clinical 
application because of the risk o f known and unknown adventitious agents. For 
example, feline cells harbor multiple copies of an inducible, xenotropic, replication- 
competent type C endogenous retrovirus (RDI 14) that can replicate in human cells, 
resists inactivation by human serum complement, and is related at the nucleotide 
sequence level to a primate retrovirus (baboon endogenous virus).^^ '^^^^
The transcriptional silence of the FIV U3 in most human cell types provides a first 
level self-inactivating or SIN feature, as it is copied to both LTRs in the human target 
cell. A standard U3 deletion can also be made to produce a conventional SIN vector 
as described below. In the initial studies, FIV vectors incorporating the hybrid 5’ 
promoter were shown to transduce dividing, growth-arrested, and postmitotic human 
targets.^ These results have been reproduced by others,^^^’ and envelope 
glycoprotein-pseudotyped lentiviral vectors have now been derived from all three 
subgroups of primate lentiviruses, HFV-l, HFV type 2 (HIV-2), and simian 
immunodeficiency virus (SFV), '^^ '^ and from the ungulate group of
lentiviruses.^^^’^^ ’^^^  ^ HFV-l vector systems have so far received more extensive 
validation and molecular engineering for vector optimization,^^"^ but there is growing 
interest in exploring the potential of nonprimate lentiviral systems. It should be 
emphasized that no direct, methodologically rigorous comparisons of transducing 
efficiencies per particle in vivo are available for different lentiviral vector systems, or 
for that matter in human tissues, although equivalent efficacy per transducing units o f 
FFV and HFV vectors has been demonstrated in one human organ.^^"^
The following landmark studies elegantly demonstrate the most important feature of 
lentiviral vectors: permanent transduction of post-mitotic or terminally differentiated 
cells. Pawliuk et al. showed that sickle cell disease can be corrected in a transgenic 
mouse model using lentiviral gene therapy.^ Sickle cell disease is caused by a single 
point mutation in the human betaA globin gene that results in the formation of the 
abnormal hemoglobin HbS (alpha2betaS2). In homozygotes, the abnormal 
hemoglobin polymerizes in long fibers upon deoxygenation within red blood cells, 
which become deformed, rigid and adhesive resulting microinfarction, anemia and
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organ damage. Using a betaA globin gene variant that prevents HbS polymerization, a 
third generation HIV vector achieved expression for 10 months at the study endpoint 
and presence of the anti-sickling protein in up to 52% of total hemoglobin or 99% of 
circulating red blood cells. Red blood cell sickling could be successfully prevented in 
two mouse models and hematological parameters, splenomegaly and urine 
concentration defects could be prevented.
In a study involving a nonhuman primate model of Parkinson’s disease, HIV vectors 
were engineered to express the glial cell line-derived neurotophic factor.'^^^ 
Nonlesioned aged rhesus monkeys and young adult monkeys treated with MPTP 
received injections into the striatum and substantia nigra. Dopaminergic function was 
augmented in aged monkeys while in lesioned monkeys functional deficits o f hand- 
reach tasks hand-reach task, in which the time to pick up food treats out of recessed 
wells was measured, were reversed and nigrostriatal degeneration completely 
prevented. These functional improvements were also found using a modified 
parkinsonian clinical rating scale. Fluorodopa PET scans displayed solid uptake in the 
GDNF-treated animals. Expression was followed for 8 months in control animals. 
Sections from all monkeys were stained for CD45, CD3, and CDS markers to assess 
the immune response after lentiviral vector injection which are markers for activated 
microglia, T cells, and leukocytes including lymphocytes, monocytes, granulocytes, 
eosinophils, and thymocytes. Staining for these immune markers was weak, or absent. 
Mild staining for CD45 and CDS was seen in two animals and some CD45- 
immunoreactive cells displayed a microglial morphology. Most monkeys displayed 
virtually no immunoreactivity.
Lentiviral equine infectious anemia viral (EIAV) vectors expressing RNAi were 
designed to specifically target the human SODl gene, the dominant mutation of 
which (S0D1(G93A)) is responsible for a fatal neurodegenerative disease, 
amyotrophic lateral sclerosis.^R N A i is a post-transcriptional mechanism of gene 
silencing that is mediated by small interfering RNA molecules (siRNAs), 19- to 23- 
nucleotide double-stranded RNA duplexes that promote the cleavage of specific 
mRNAs. Long-lasting RNAi-mediated gene knockdown can be achieved using 
lentiviral vectors that express the siRNAs. SODl encodes superoxide dismutase, an 
enzyme that neutralizes superoxide radicals, which can damage cells if  their levels are 
not controlled. Superoxide radicals are byproducts of normal cell processes.
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particularly energy-producing reactions that occur in mitochondria. Motor neurons are 
particularly sensitive to SOD dysfunction when mitochondria cannot meet the high 
energy demands, additionally apoptosis may be induced and misfolded superoxide 
dismutase is toxic. In Ralph et al.’s study vectors were injected into various muscle 
groups in a SODl mouse model that is overexpressing S0D1(G93A). SODl levels 
were efficiently reduced resulting in prolonged survival of vulnerable motor neurons 
in the brainstem and spinal cord. This led to measurable motor performance in these 
animals and a considerable delay in the onset of ALS symptoms as well as extension 
of survival time by almost 80%. This study demonstrated how lentiviral vectors can 
be used efficiently to deliver RNAi to treat a presently incurable disease. Early 
concerns that retroviral viral vectors that require packaging of vector RNA containing 
RNAi target sequences would be destroyed by production of interfering RNA in the 
same cell could not be confirmed.
Another lethal disease, metachromatic leukodystorphy, was successfully addressed by 
HIV lentiviral gene therapy in a study by Consiglio et al. involving a mouse model.^*"  ^
Metachromatic leukodystrophy (MED) is an inborn lipidosis caused by lysosomal 
enzyme arylsulfatase A (ARSA). ARSA is required to catalyze the first step in the 
degradation pathway o f galactosyl-3-sulfate ceramide (sulfatide), a major 
sphingolipid of myelin. MED is characterized by myelin degeneration in both the 
central and peripheral nervous system, associated with the accumulation of sulfatide 
in glia cells and neurons. Children affected by the severe form of MED display 
progressive neurologic symptoms, including ataxia, seizures, quadriplegia, and die 
decerebrated early in infancy. Currently there is no effective treatment for MED or 
other storage diseases affecting the CNS (central nervous system). HIV vectors 
delivered the functional human ARSA gene into the brain of adult mice with germ- 
line inactivation of the mouse gene encoding ARSA, As2. Purified, concentrated 
vector stocks were slowly injected under stereotactic guidance into the right fimbria. 
Expression of the active enzyme was sustained throughout a large portion of the brain, 
with long-term protection from development of neuropathology and hippocampal- 
related learning impairments.
In another well publicized study, Dupre et al. compared HIV vectors to MEV vectors 
to restore function in T cells for Wiskott-Aldrich syndrome (WAS) p a tie n ts ,^ an  X- 
linked primary immunodeficiency with a median survival below the age o f 20 due to
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infections, hemorrhage and lymphomas. While transplantation o f hematopoietic stem 
cells from HLA-identical siblings can be a definite treatment, it is only available for a 
minority o f patients. Lentiviral vectors transduced T cells form WAS patients at 
higher rates compared to MLV vectors and efficiently transduced both activated and 
naïve WAS T cells. A selective growth advantage of HIV transduced T cells was 
found.
6.3.3.4. Non-Viral Gene Transfer
Although lentiviral and the adenovirus associated viral vectors are less immunogenic 
than for instance adenoviral and herpes viral vectors, those foreign proteins may still 
elicit some immune response and their capacity is limited. In addition large scale 
production is relatively difficult to achieve. Non-viral methods in contrast require 
only a small number o f proteins, the capacity is much larger, there is little risk of 
infectious agents and industrial production much more easily achievable. This 
explains the popularity and use of naked DNA in approximately 18 percent and 
lipofection in 8 percent of clinical gene therapy trials.
As a major disadvantage o f non-viral gene transfer methods, transgene expression 
tends to be transient with notable exception of complex strategies that mimic entire 
chromosomes.^’  ^Methods of non-viral DNA transfer include use of naked DNA, 
liposomes or molecular conjugates. Currently, approximately 8 percent of clinical 
trials use non-viral DNA transfer the majority of which (7.6 percent) are liposomes.
Naked plasmid DNA can be directly injected into the target cell^’^  or administered 
intravenously^'^ although this is not very effective. Alternatively, particles can be 
coated with DNA and literally shot into the target tissue with a gene gun.^'^ This has 
been used to vaccinate with DNA, an elegant way of circumventing pre-existing 
immunity that is also inexpensive, allows delivery of several antigens on one single 
plasmid and co-expression of immunogenic cytokines where needed.
Liposomes are a lipid belayed that entraps aqueous fluid. DNA typically associates to 
the external surface of cationic liposomes which interact with the cell membrane. 
Liposome transfection is effective in vitro but very cell type dependent and often 
disappointing when used on non-dividing cells or in vivo. In an attempt to target and 
facilitate uptake into cells as endosomes various proteins have been included, e.g.
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anti-MHC antibody, Senday vims F protein^ or transferring/^'' Use of Senday 
vims allows the plasmid DNA to avoid degradation in the endosome/^^
Molecular conjugates are protein or other synthetic ligands to which a DNA binding 
agent has been attached. Similar strategies as with liposomes have been exercised 
including transferrin^^^, polymeric IgA^^^ and complexes of nonmodified human 
adenovims particles and a protein conjugate consisting of N-acetyl-glucosamine- 
modified bovine semm albumin.
Kusano et al. showed that direct injection of plasmid DNA into myocardium can 
result in effective gene transfer with rather dramatic results.^^^ In an attempt to 
improve recovery from acute and chronic myocardial ischemia after ligation of the 
proximal left anterior descending artery branch of the left coronary artery, a plasmid 
encoding human sonic hedgehog (Shh) was injected subepicardially with a curved 27- 
gauge needle into 5 sites along the anterior and posterior left ventricular wall in rats in 
600pg/0.Iml and 100pg/0.02ml in mice. In pigs the ischemic area was mapped by 
nonfluoroscopic electroanatomical mapping to guide injections of 800 pg/3 ml into 6 
sites with an injection catheter. Shh is a cmcial regulator of organ development during 
embryogenesis. Gene transfer resulted in tissue preservation and repair by initiating a 
repertoire of signaling pathways in the local tissue and by recruiting circulating 
progenitor cells to engage in the repair process. Left ventricular function was 
preserved in both acute and chronic myocardial ischemia.
An example of highly engineered nanoparticles is the study of Hood et al. who used 
cationic nanoparticles coupled to an integrin alphavbeta3-targeting ligand to deliver 
genes selectively to angiogenic blood vessels in tumor-bearing mice.^^^ As a proof of 
principle nanoparticles were conjugated to a mutant Raf gene, ATPmu-Raf, which 
blocks endothelial signaling and angiogenesis in response to a variety of growth 
factors. During vascular remodeling and angiogenesis, endothelial cells show 
increased expression of several cell surface molecules that potentiate cell invasion and 
proliferation, integrin alphavbeta3 being one of them. This molecule plays a key role 
in endothelial cell survival during angiogenesis in vivo and potentiates the 
internalization of various viruses. The authors found pronounced M21-L cell tumor 
regressions in athymic WEHI mice.
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Oritz-Urda et al. reported an innovative non-viral method to achieve stable genetic 
correction for an inherited human skin disease by transfecting a construct that sues the 
phi C31 bacteriophage integrase to deliver C0L7A1 cDNA into genomes of primary 
epidermal progenitor c e l l s . P h i  C31 bacteriophage integrase stably integrates large 
DNA sequences containing a specific 285-base-pair attB sequence into genomic 
pseudo-attP sites. In this study epidermal progenitor cells were obtained from 
unrelated patients with a blistering skin disorder called recessive dystrophic 
epidermolysis bullosa (RUEB) that is caused by mutations in the COL&Al gene.
Skin regenerated on SCID mice including type VII collagen protein expression, 
anchoring fibril formation and dermal-epidermal cohesion. The authors argue that 
viral vectors, in particular type C retroviral and lentiviral vectors, suffer from 
biosafety concerns that currently prevent them fi*om being used more broadly. They 
fail to acknowledge that any form of integration is mutagenic by definition and that 
predictions that lentiviral vectors will be similarly oncogenic as retroviral vector do 
not hold true in practice as discussed above.''^^ It will remain to be seen whether use 
of a prokaryotic integration system will be advantageous for eukaryotic DNA 
especially in the presence of a mature immune system.
6.3.3.S. Adeno-associated virus
Adeno-associated viral (AAV) vectors are currently used in only 4% of clinical gene 
therapy trials but enjoy increasing popularity for several reasons: AAV is not 
associated with human disease and there is little immunogenicity. Long-term 
expression can be achieved in dividing and non-dividing cells even without genomic 
integration (formation of intracellular concatomers). Disadvantages are that many 
patients had prior exposure and likely have some immunity against AAV, only 
relatively small transgenes can be used and that cloning can be difficult due to the 
sequence of the flanking terminal repeats. Achieving high titers and large volumes is 
still technically challenging. Although the AAV wild-type integrates preferentially 
into AAVSl in chromosome 19q.^^' AAV vectors favored integration in active 
genes^^^ and in that regards are reason for the same concerns that exist with lentiviral 
vectors.
Adeno-associated viruses (AAV) are small, non-enveloped viruses that belong to the 
parvovirus family, genus dependovirus. As such, AAV requires a helper virus, for
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instance adenovirus or herpes simplex virus, in order to replicate. In the absence of 
such helper virus, AAV can establish a latent infection within the cell by either site- 
specific integration or as an episome. The AAV capsid contains a linear single­
stranded DNA genome o f 4.7 kb and is only 22 nm in diameter. The genome has 
either plus or minus polarity.^^^’ Inverted terminal repeats (ITRs) at the termini 
consist o f 145 nucleotides that form a hairpin structure due to the multipalindromic 
nature of its 125 bases. This structure is needed to initiate replication and packaging 
and flanks the two large open reading frames (ORF) of the viral genome.^^^ AAV 
does not encode its own polymerase. The replication ORF (Rep) encodes for four 
replication proteins through the use of alternative splicing. The right capsid ORF 
(Cap) encodes for three viral structural proteins. Rep and cap are replaced by the 
transgene in AAV vectors but have to be provided in trans along with helper gene 
products. In contrast to wild-type AAV, in the absence of rep vectors will integrate as 
a single provirus preferentially in active genes or at random s i t e s . R a t h e r  than 
integration, the most common state are head to tail concatomers one the terminal 
repeats have slightly degraded.^^^’
AAV2 vectors rapidly gained popularity following the pioneering work of Laughlin et 
a/^^ and Hermonat et al,^^  ^because of their long-term persistence without detrimental 
effects to the host and a wide range o f infectivity that include both dividing and non­
dividing cells. AAV is relatively resistant to heat, solvents and change o f pH.^'"' Other 
serotypes with different tissue tropism have recently been found that facilitate 
targeted transduction.
Disadvantages of AAV are the size limitation, slow onset of gene expression and a 
possible association between AAV2 vector gene transfer and tumorigenesis as 
described in an animal model of mucopolysaccharidosis.^'" Similar to lentiviral 
vectors, AAV preferentially integrates into active chromatin^^^ although the frequency 
of true integration is low and in contrast to retroviral and lentiviral vectors not a 
required part of the life cycle.
AAV2 vectors have entered preclinical studies for hemophilia, cystic fibrosis, a l-an ti­
trypsin deficiency, Duchenne muscular dystrophy and rheumatoid arthritis. Genetic 
disease are the leading group of indications (32%), but also tumor (19%), and at about 
equal percentage ocular, cardiovascular and neurological diseases. Present AAV- 
based gene therapy trials are mainly focused on monogenic diseases (53%), followed
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by cancer (23%)/^^ The first clinical trial was concerned with cystic fibrosis/''^ which 
is still the leading indication/''^ Other trials are focused on infantile neuronal ceroid 
lipofuscinosis/'''' Canavan disease/''^ a  1-anti-trypsin deficiency^''^ and Parkinson’s 
disease^''^ (all phase I) and cystic fibrosis^''^’ (phase II).
The completed studies and trials demonstrated that while AAV2 based gene therapy is 
generally safe, there are significant shortcoming in transduction efficiency and more 
organ-specific transduction. Attempts have been made to improve efficiency by 
manipulating the AAV2 capsid (reviewed in^^") through site-directed mutagenesis, 
chemical conjugation and peptide display libraries. Other strategies employed 
packaging of AAV genomes with two different ITR serotypes, use of capsid serotype 
mosaics, pseudopackaging rAAV genomes and self-complementary AAV2 vectors^^' 
to circumvent the rate-limiting second-strand DNA synthesis.^^"’
I will review important studies with AAV vectors in the following. AAV vectors 
haven been used extensively for ocular gene therapy. These will be reviewed in a 
separate chapter about ocular gene therapy.
Manno et al. transduced the liver of seven patients with severe hemophilia B using an 
AAV vector expressing human factor IX by infusing vector through the hepatic artery 
in a dose escalation study.''^^ The authors find that vector infusion up to 2 x lO'^ 
vector genomes per kg was not associated with acute or long-lasting toxicity and that 
therapeutic levels were achieved at the highest dose tested. However, different from 
highly successful pre-clinical studies with dogs^^^ and mice,^^'' therapeutic levels 
could only be achieved for about 8 weeks when a gradual decline o f factor IX was 
observed that was accompanied by asymptomatic elevation of liver transaminases that 
eventually resolved. Destruction of hepatocytes was caused by cell-mediated 
immunity targeting antigens of the AAV capsid. This is a remarkable finding because 
unlike factor IX, AAV capsid antigens, are not synthesized in transduced cells. MHC 
class I presentation pathways favor peptides derived from de novo produced proteins; 
nevertheless, alternative pathways exist that allow for appropriate presentation of 
proteins passively taken up by cells. These sufficed for recognition of AAV- 
transduced hepatocytes by CD8+ effector T cells. Unlike experimental animals, 
humans are naturally infected by AAV-2 during childhood. Because AAV is naturally 
replication defective, this initial infection invariably takes place together with a helper 
virus infection such as adenovirus. Although AAV-2 on its own may not induce
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inflammatory reactions needed for stimulation of a maximal adaptive immune 
response, in combination with the helper virus, which causes activation of the innate 
immune system, it is likely that CD 8+ T cells directed to the antigens of the helper 
virus and of AAV are formed. Upon controlling the infection, the frequency of AAV- 
specific CD8+ T cells would be expected to decline, leaving behind a small pool of 
memory T cells, which through homeostatic proliferation are maintained throughout 
the life of an individual. On re-exposure to AAV capsid, these memory CD8+ T cells 
are activated and eliminate the AAV capsid-harboring cells.
Chamberlain et a/^^ showed that AAV vectors can be used to rescue dystrophic 
muscle through U7 snRNA-mediated exon skipping. The majority o f the clinically 
severe Duchenne muscle dystrophy is caused by a frame shift or stop in the mRNA. 
The authors were able to achieve persistent exon skipping (exon skipping occurs at 
low frequency and sometimes eliminates the mutation). The mutated exon on the 
dystrophin mRNA of the mdx mouse was rescued by a single administration o f AAV 
vector expressing antisense sequences linked to a modified U7 small nuclear RNA. 
This resulted in the sustained production of functional dystrophin at physiological 
levels in entire groups of muscles and the correction of the dystrophy in those.
Strong neuroprotection of nigral dopamine neurons and rescue of the parkinsonian 
behavioral phenotype could be achieved in study by Luo et a/^^ who used AAV 
vectors to deliver glutamic acid decarboxylase, the enzyme that catalyzes synthesis of 
the neurotransmitter G ABA in excitatory glutamatergic neurons of the subthalamic 
nucleus in rats. The abnormalities of Parkinson’s disease are caused by alterations in 
basal ganglia network activity that includes the disinhibition of the subthalamic 
nucleus and excessive activity of the major output nuclei. After transduction, neurons 
were responding appropriately to electrical stimulation with G ABA release.
Another study with AAV vectors is remarkable in that it demonstrated successful 
targeting and correction of a genetic defect in stem cells ex vivo. Chamberlain et al. 
used a strategy of homologous sequence targeting to disrupt the dominant-negative 
mutant CO LlA l collagen gene to osteogenesis imperfecta.^^^ Similar to retroviral 
vectors described in this review chapter, the study authors harvested and transduced 
mesenchymal stem cells ex vivo. These cells can differentiate into a variety of tissues 
including bone, fat, cartilage and muscle. Transduced cells could be specifically re­
transfused into bone most severely affected. One shortcoming is that the gene
-90
Introduction: Gene Therapy
targeting strategy is not mutation specific. However, phenotypical correction is still 
possible because individual cells may synthesize entire collagen fibrils without 
mixing of peptide chains from different cells, genetic mosaics for lethal forms of 
osteogenesis imperfect have a mild clinical course and the cells expressing wild-type 
collagen may have a growth advantage.
An example of relatively non-specific gene therapy that is able to modify a complex 
dysfunction is the study by Haberman et al. who successfully treated a model of focal 
seizure genesis in the rat inferior collicular cortex. In this model, electrical stimulation 
of a specific region in the inferior collicular cortex causes brief poststimulus wild- 
running seizure activity, in which the seizure behaviors exactly coincide with 
localized after discharge. In addition, in the absence of any perturbation, the electrical 
stimulation threshold for seizure genesis remains stable for long periods o f time. The 
authors targeted the N-methyl-D-aspartic acid (NMDA) excitatory amino acid 
receptor with an AAV-delivered antisense oligonucleotide.
6.3.3.6. Herpes simplex virus
The size of complete genomic loci precludes their use in most viral systems with 
exception of herpes simplex virus type I (HSV-1) amplicon vectors. HSV-1 is an 
enveloped DNA virus that belongs to the herpesviridae family, subfamily 
alphaherpesvirinae. The virion is 120 to 200 nm in diameter and contains a double­
stranded DNA genome of 152 kb. The transgene capacity is sufficient to 
accommodate approximately 95 percent of human genomic loci. Due to their 
neurotropism HSV vectors are attractive vehicles for gene therapy of neurological 
diseases and make for approximately 3 percent of all clinical gene therapy trials.
Disadvantages are similar to adenoviral vectors and include common immunity to 
HSV in the population and remarkable toxicity. Depending on whether amplicons or 
recombinant viruses are used the production can be technically demanding.
Two unique regions, termed UL and US for unique long and unique short, are linked 
by long and short internal repeat sequences (IRL and 1RS) in both directions and are 
flanked at the non-linker end by terminal repeats (TRL and TRS). Depending on the 
strain, the HSV-1 genome consists up to 81 genes of which approximately 50 percent 
are not necessary for growth in cell culture.^^^ Up to 50 kb of transfer DNA can be
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accommodated after deletion of these genes. HSV genes are grouped into immediate- 
early (IE or alpha) genes, early (E or beta) and late (L or gamma) genes. During lytic 
infection, VMW65, a tegument structural protein, activates the immediate early genes 
IPO, ICP4, ICP22, ICP27 and ICP477 which transactivate production of early genes. 
Early genes in return are responsible for nucleotide metabolism and DNA replication. 
Late genes are activated by early genes and code for structural proteins. This entire 
cycle that end with the death of the infected cell takes approximately 10 hours to 
complete.
Because herpes simplex virus is a human neurotropic virus use of derived vectors has 
mainly focused on transfer to the nervous system. A key feature of HSV is the ability 
to either proceed into a lytic life cycle or to persist as an intranuclear episome during 
latency. Because of the prevalence of HSV in the population, antibodies exist in most 
individuals.
The latency associated transcripts (LAT) located in the IRL region drive gene 
expression during latency and are involved in establishing of and reactivation from 
latency.^ ^^
HSV-1 vectors can be produced using either amplicons or recombinant HSV-1 
viruses. Amplicons contain the E l ori of E. coli, OriS, the HSV-1 origin of 
replication, HSV-1 packaging sequence and the transgene under control o f an 
immediate-early promoter and selectable m a r k e r . T h e  amplicon is transfected into a 
cell line that contains a helper virus which provides the missing structural and 
regulatory genes in trans. More recent amplicons utilize an Epstein-Barr virus derived 
sequence for episomal maintenance.^^'' Replication deficient recombinant virus can be 
constructed by deleting one of the immediate-early genes and providing it in trans 
(often ICP4). While these attenuated viruses can direct transgene expression to 
neuronal tissue, they are still toxic to neurons in cu l tu re .Dele t i on  of several 
immediate-early genes reduces cytotoxicity further and use of promoters that would 
be silenced otherwise in the wild type virus when latent. Such promoters are under 
investigation for long-term expression. Another option is use of replication- 
conditional mutants that can only replicate in certain cell lines that supply missing 
factors or enzyme e.g. the neurovirulence factor g34.5,^^' UTPase, ribonuclease 
reductase^^^ or thymidine kinase.^^^
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The main concern remains the strong inflammatory response to HSV-1 vectors at the 
application site as well as sites supplied by neurons originating from the area of 
injection/^'' In some studies fatality rates as high as 20 percent were observed among 
experimental a n i m a l s Y o r k  et al. found that removal of ICP47 can attenuate vector 
toxicity.^^^ Because HSV is neurotrophic by nature, gene therapy strategies have 
focused on neurological diseases. Potential uses of herpes simplex virus (HSV) 
vectors for gene therapy of neurodegenerative disorders and CNS malignancies.
HSV vectors had fallen in disfavor after initial optimism about exploiting its 
neurotropism and ability of episomal survival. Early studies received great attention: 
During et all showed that it is possible to maintain efficient behavioral and 
biochemical recovery for 1 year after gene transfer of human tyrosine hydroxylase in 
a Parkinson rat model with partially denervated striatum from 6-hydroxydopamine. 
Persistence o f tyrosinase could be detected by RNA and immunoreactivity.^^^ One 
problem is the immunogenicity of HSV thymidine kinase that is utilized now in 
suicide gene therapy when high levels of toxic acyclovir conversion products allow 
reliable ablation of expressing cell. However, HSV-tk may otherwise cause prolonged 
inflammation that is not desirable.^^^
HSV vectors have regained interest recently as their biology has become better 
understood. Exploiting neurotropism, the ability of the virus to spread through the 
nervous system and to form latent infections in neurons that last for the lifetime of the 
infected individual is the main topic in experimental applications. Replication- 
deficient HSV-1 vectors encoding human prepro-enkephalin were efficacious in 
reducing nociceptive behaviors and this reduction of nociceptive behaviors was 
abrogated by pretreatment using intrathecal opiate antagonist naloxone. Lu et al. 
demonstrated now that treatment of inflamed pancreas with enkephalin encoding 
HSV-1 recombinant vector reduces inflammatory damage and behavioral sequelae.
A fascinating finding is the seemingly paradox use of a potentially highly 
inflammatory virus to achieve both pain control and suppressed inflammation that 
provides better understanding of how close these two are. The study assessed the 
efficacy of pancreatic surface delivered enkephalin (ENK)-encoding herpes simplex 
virus type 1 (HSV-1) on spontaneous behaviors and spinal cord and pancreatic 
enkephalin expression in an experimental pancreatitis model. Replication-defective 
HSV-1 with proenkephalin complementary DNA was applied to the pancreatic
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surface of rats with dibutyltin dichloride (DBTC)-induced pancreatitis. On day 6, the 
treated rats had significantly improved spontaneous exploratory activities, increased 
met-ENK staining in the pancreas and spinal cord, and normalized c-Fos staining in 
the dorsal horn.
In an attempt to take advantage of HSV neurotropism and the HSV latency-associated 
promoter (LAP2) to attenuate damage to peripheral nerves, Chattopadhyay et al. 
transduced rat dorsal root ganglia.^^^ Interestingly, this could be achieved by 
subcutaneous rather than direct inoculation of replication-incompetent HSV-based 
vectors containing nerve growth factor (NGF) or neurotropin-3 (NT-3). When a pure 
sensory neuropathy was induced by overdose of pyridoxine and animals assessed 6 
months later the nerve damage was diminished in animals treated with the LAP2-NGF 
vector. Sensory amplitude, H-wave amplitude and behavioral measures of 
proprioceptive function were 30% to 85% of normal rats. Neurotrophin-3 treated 
animals had an even greater effect in preserving the largest myelinated fibers from 
degeneration.
A nonreplicating HSV vector expressing erythropoietin that was inoculated into the 
striatum of a MPTP mouse model of Parkinson disease was able to preserve 
behavioral function and tyrosine hydroxylase levels in the substantia nigra and 
dopamine transporter-immunoreactive terminal sin the striatum.^^^ Intranasal 
administration of the growth-compromised HSV-2 vector DeltaRR was able to 
prevent kainate-induced seizures and neuronal loss in rats and mice.^^" The anti- 
apoptotic HSV gene ICPIOPK was able to halt for at least 42 days kainic acid-induced 
seizures, neuronal loss, and inflammation, in both rats and mice.
6.3.4. Current Gene Therapy Trials
At the time of this writing a total of 1347 clinical gene therapy trials are under way or 
are awaiting approval (Figure 9) which are the result of intense basic science research 
and preclinical studies.
Clinical trials involving new drugs are commonly classified into four phases, each 
phase of which is treated as a separate clinical trial. The drug-development process 
will normally proceed through all four phases over many years. If the drug 
successfully passes through Phases I, II, and III, it will usually be approved by the
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national regulatory authority for use in the general population. Phase IV are post­
approval studies. Extensive pre-clinical studies are conducted before clinical trials are 
started. It is difficult to count those in gene therapy but an estimate can be made with 
a Medline search for “gene therapy” as the Medical Subject Heading (MeSH is the 
U.S. National Library of Medicine's controlled vocabulary used for indexing articles 
for MEDLINE/PubMed that provides a consistent way to retrieve information that 
may use different terminology for the same concepts): an astonishing 17803 papers 
are concerned with this topic, 5580 of which are reviews.
Phase I trials are the first stage of testing in human subjects for which a small group 
of healthy volunteers of 20-80 is selected. This phase includes trials designed to 
assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug. In 
March 2008, 820 gene therapy trials were underway (Figure 9).
Once the initial safety of the study drug has been confirmed in Phase I trials. Phase II 
trials are performed on larger groups (20-300) and are designed to assess how well the 
drug works, as well as to continue Phase I safety assessments in a larger group of 
volunteers and patients. In March 2008, 262 gene therapy trials were pending Phase II 
approval while 216 were already ongoing. When the development process for a new 
drug fails, this usually occurs during Phase II trials when the drug is discovered not to 
work as planned, or to have toxic effects. While some Phase II trials are designed as 
case series, other Phase II trials are designed as randomized clinical trials, where 
some patients receive the drug/device and others receive placebo/standard treatment.
Phase III studies are randomized controlled multicenter trials on large patient groups 
(300-3,000 or more depending upon the disease/medical condition studied) and are 
aimed at being the definitive assessment of how effective the drug is, in comparison 
with current gold standard treatment. Because of their size and comparatively long 
duration. Phase III trials are the most expensive, time-consuming and difficult trials to 
design and run, especially in therapies for chronic medical conditions. Thirteen gene 
therapy trials were pending Phase III approval and a total o f 36 were already in 
progress.
Phase IV trial is also known as Post Marketing Surveillance Trial. Phase IV trials 
involve the safety surveillance and ongoing technical support of a drug after it 
receives permission to be sold. The safety surveillance is designed to detect any rare
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or long-term adverse effects over a much larger patient population and longer time 
period than was possible during the Phase I-III clinical trials. Because of the newness 
of gene therapy, no gene therapy trial has reached this phase yet.
TRIAL PHASES
Phase I/ll 262
216
Phase li/ill I 13 
Phase III g  36
Figure 9: Gene therapy trials by phases.
Adenoviral and retroviral vectors account for 25% and 23% of vectors used or 337 
and 304 trials, respectively (Figure 10). Naked DNA follows closely with surprising 
18% (n= 244) of trials and lipofection (8%, n=102). In contrast, adeno-associated 
(AAV) and lentiviral vectors, the two most promising vector types for long-term 
therapy of noncycling cells, contribute to only 4% (n = 54) and 0.8% (n =  11) of 
trials, respectively. Indications of the AAV studies range from cystic fibrosis to 
bleeding disorders and Parkinson disease, while most lentiviral vector studies are 
concerned with treatment of already HIV positive subjects. The asymmetry of only a 
few studies with AAV and lentiviral vectors in contrast to numerous retro- and 
adenoviral studies reflects how much less preclinical experience with these vectors 
exists as well as how challenging large-scale production and safety concerns are.
Given that with 1 lethality per 1,000,000 vaccinia virus -  a poxvirus - is potentially 
more dangerous than AAV it is equally surprising that it is used more often (4.9%, 
n=66) than AAV (Figure 10). Poxvirus itself is used in 61 or 4.5% of gene therapy 
trials, respectively. Herpes virus has become more popular in recent years and there 
are currently 43 trials (3%).
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Vibrio cholerae 
Venezuelan equine encephalitis (VEE) virus...
Streptococcus mutans 
Simian virus 40 
Sendai virus 
Semliki forest virus 
Poliovirus 
Newcastle disease virus 
E. coli
Salmonella typhimurium 
Naked/Plasmid DNA + Adenovirus 
Listeria m onocytogenes 
Measles virus 
Adenovirus + Retrovirus 
Saccharomyces cerevisiae 
Gene gun 
Flavivirus 
Lentivirus 
RNA transfer 
Poxvirus + Vaccinia virus 
Unknown 
Herpes simplex virus 
Adeno-associated virus 
Poxvirus 
Vaccinia virus 
Lipofection 
Naked/Plasmid DNA 
Retrovirus 
Adenovirus
VECTOR TYPES
102
244
304
337
Figure 10: Vector types used in gene therapy clinical trials (data from free online 
database provided by The Journal of Gene Therapy).
By far the most common indication for short-term gene therapy is cancer (n=896), 
often fatal and with few therapy options, followed by 121 cardiovascular disease 
trials, 110 monogeneic and 89 infections disease gene therapy trials (Figure 11). A 
closer look at specific diseases reveals that most monogenic disorders are severe, 
often lethal disorders for which no good treatment options exist in most cases. Table 1 
provides a list of specific disease in the above categories.
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Ocular diseases 1 12
Neurological diseases 1 17
Others ■  26 1
Healthy volunteers ■  26
Gene marking
Infectious diseases ■ ■  89
Monogenic diseases 110
Cardiovascular diseases 121
Cancer diseases
DISEASE TYPES
896
Figure 11: Disease types addressed by gene therapy clinical trials (data from free 
online database provided by The Journal of Gene Therapy).
Although the vast majority of all studies are Phase 1 studies to assess the safety, first 
therapeutic successes have been reported. The treatment of a fatal form of severe 
combined immunodeficiency-Xl (SCID-Xl), an X-linked hereditary disorder 
characterized by an early block in the development of T and natural killer (NK) cells 
due to mutations in the yc cytokine receptor subunit, is the most prominent one. 
Stimulated hematopoietic stem cells were transduced ex vivo with a murine leukemia 
viral vector expressing the receptor subunit and re-infused.^^^ T and NK cells counts 
and function was restored to comparable levels of age-matched controls in 9 of 10 
children. This protocol profited from the selection advantage that yc-expressing 
lymphocyte progenitor cells had over the present cell population affected by the 
mutation. No exogenous selection strategy had to be applied.
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Monogenic disorders Cancer
Cystic fibrosis Gynecological
Severe combined immunodeficiency 
(SCID)
breast, ovary, cervix
Alpha-1 antitrypsin deficiency Nervous system
Hemophilia A and B glioblastoma, leptomeningeal carcinomatosis, glioma, 
astrocytoma, neuroblastoma
Hurler syndrome Gastrointestinal
Hunter syndrome colon, colorectal, liver métastasés, post-hepatitis liver cancer, 
pancreas
Huntington’s chorea Genitourinary
Duchenne muscular dystrophy prostate, renal
Becker muscular dystrophy Skin
Canavan disease melanoma
Chronic granulomatous disease 
(CGD)
Head and neck
Familial hypercholesterolemia nasopharyngeal carcinoma
Gaucher disease Lung
Fanconi's anemia adenocarcinoma, small cell, non small cell
Purine nucleoside phosphorylase 
deficiency
Mesothelioma
Ornithine transcarbamylase 
deficiency
Hematological
Leukocyte adherence deficiency leukemia, lymphoma, multiple myeloma
Gyrate atrophy Sarcoma
Fabry disease Germ cell
Familial amyotrophic lateral sclerosis
Junctional epidermolysis bullosa Neurological diseases
Wiskott-Aldrich syndrome Alzheimer's disease
Lipoprotein lipase deficiency Carpal tunnel syndrome
Late infantile neuronal ceroid Cubital tunnel syndrome
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lipofuscinosis
RPE65 mutation (retinal disease) Diabetic neuropathy
Mucopolysaccharidosis Epilepsy
Multiple sclerosis
Cardiovascular disease Myasthenia gravis
Peripheral vascular disease Parkinson's disease
Intermittent claudication Peripheral neuropathy
Critical limb ischemia
Myocardial ischemia Ocular diseases
Coronary artery stenosis Age-related macular degeneration
Stable and unstable angina Diabetic macular edema
Venous ulcers Glaucoma
Vascular complications o f diabetes Retinitis pigmentosa
Pulmonary hypertension Superficial comeal opacity
Heart failure
Other diseases
Infectious disease Inflammatory bowel disease
HIV/AIDS Rheumatoid arthritis
Tetanus Chronic renal disease
Epstein-Barr virus Fractures
Cytomegalovirus infection Erectile dysfunction
Adenovirus infection Anemia of end stage renal disease
Japanese encephalitis Parotid salivary hypofunction
Hepatitis C Type I diabetes
Hepatitis B Detrusor overactivity
Influenza Graft versus host disease
Table 1: Specific diseases addressed in current gene therapy trials.
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The long-term outcome of this promising trial experienced a setback when two 
patients developed T cell leukemia. While the mechanism is still under investigation, 
it is thought that a combination of several factors led to this outcome in 2 of 8 
patients.^^* The clones of both patients showed retrovirus vector integration in 
proximity to the LM 02 proto-oncogene promoter, leading to aberrant transcription 
and expression of LM 02, a transcription factor considered a central regulator of 
hematopoiesis. It is possible that insertion of onco-retroviral vectors can trigger 
deregulated premalignant cell proliferation by retrovirus enhancer activity on the 
LM 02 gene promoter at a much higher rate than previously thought .Addi t iona l  
factors might have been a varicella-zoster virus infection five months before 
clinically detectable lymphoproliferation that increased the immune reactivity of the 
T-cell clone and the selective growth advantage of the transduced cells. As the sister 
and a first-degree relative of one proband developed medulloblastomas there might 
have been an additional genetic predisposition for childhood cancer.
Only low levels of transduced progenitor cells were observed in an earlier treatment 
of adenosine deaminase (ADA) deficiency in another study, where patients received 
ADA preparations in addition to the transduced cells. This probably prevented 
selective outgrowth of the transduced cells,^^ '^^^  ^as supported by the observation that 
the number of peripheral blood mononuclear cells expressing the transgene increased 
after external application of ADA was stopped. B and NK cells counts decreased in 
these patients, but the number of T cells and function remained within normal limits.
Use of MLV vectors, based on type C retroviruses, requires extensive manipulation of 
stem cells and stimulation with cytokines to induce cell cycling to achieve 
transduction.^"^^’ This is undesirable because it may result in differentiation. The 
development of lentiviral vectors, which are able to transduce non-dividing cells at 
high efficiencies, will facilitate the long-term genetic manipulation of such tissues.
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T r ia l  ID  T it le
US-488
A Phase I Open-Label Clinical Trial of the Safety and Tolerability of Single Escalating Doses of 
Autologous CD4 T Cells Transduced with VRX496 in HIV Positive Subject
US-646
A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Therapeutic 
Effect of Repeated Doses of Autologous T Cells Transduced with VRX496 in Antiretroviral 
Experienced HIV-Positive Patients
US-667
A Phase I/II, Open-Label, Single Center Study to Evaluate the Tolerability, Trafficking and 
Therapeutic Effects of Repeated Doses of Autologous T Cells Transduced with VRX496 in HIV- 
Infected Subjects
US-725
A Phase I Pilot Study of Safety and Feasibility of Stem Cell Therapy for AIDS Lymphoma using 
Stem Cells Treated with a Lentivirus Vector Encoding Multiple Anti-HIV RNAs
US-737
A Pilot Study of Safety and Feasibility of T Cell Immunotherapy Using Lentivirus Vector- 
Expressed RIMAi in Autologous T Cells of HIV-1 Infected Patients Who have Failed Anti-Retroviral 
Therapy
US-758 Lentiviral-Mediated, Hematopoietic-Directed Gene Therapy for MPS VII
US-791
Treatment and Biological Imaging of Patients with Locally Advanced or Metastatic Melanoma 
with Lentiviral Vector MART-1 TCR/HSVl-sr39k (FUW-Ml-TCR/sr39k) Engineered Lymphocytes, 
MART-1 26.35-Pulsed Dendritic Cells, and Interleukin-2 after a Nonmyeloablative Conditioning 
Regimen
US-793
Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz 
and 4-1 BB Signaling Domains in Patients with Chemotherapy Resistant or Refractory CD19+ 
Leukemia and Lymphoma
US-852
A Phase I Open-Label Clinical Trial for the Treatment of Beta-Thalassemia Major with Autologous 
CD34+ Hematopoietic Progenitor Cells Transduced with Thalagen, a Lentiviral Vector Encoding 
the Normal Human Beta-Globin Gene
US-871
A Phase I/II, Open-Label Study to Evaluate the Safety and Antiviral Activity of Autologous T- 
Cells Transduced with VRX496 in Treatment of Naive Subjects with Earl Stage HIV-1 Infection
US-875
A Rollover Study to Evaluate Safety and Therapeutic Effect of Re-infusing Subjects Who 
Completed Participation in the VRX-496-USA-05-002 Trial with Autologous T Cells with VRX496
Table 2: Lentiviral vector trials.
Noteworthy is also the clinical trial of Manno et al. o f hemophilia B patients who 
received intramuscular injections of adeno-associated viral (AAV) vectors expressing 
coagulation factor AAV vectors are a good choice for long-term therapy, 
because they are capable of genomic integration, albeit this is not a required step as in 
retroviral vectors.^^ '^^^^ These patients showed some clinical benefits, although only 
low levels of factor IX were detected.
The successes with retroviral and adeno-associated viral vectors contrast the problems 
encountered with the first vectors to enter human trials, adenoviral (Ad) vectors.
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Potent immune responses to vectors and transduced tissue^^^’ were encountered, the 
magnitude of which became apparent by the death of a participant of a phase I trial/^"^
A total of 11 gene therapy trials with lentiviral vectors are underway at this point. 
While most address HIV, four trials differ in that they employ HIV vectors in non- 
HIV positive subjects: US-758 for hematopoietic-directed gene therapy for 
mucopolysaccharidosis VII, US-791 for patients with locally advanced or metastatic 
melanoma treated with engineered lymphocytes, US-852 for the treatment of beta- 
thalassemia major with autologous progenitor cells and US-793 to redirect autologous 
T cells to refractory leukemia and lymphoma. Few details are published about these 
trials perhaps because of the commercial interests behind them.
More recently, the first ocular gene therapy trials have begun. US-589 is a Phase 1 
study in glaucoma subjects receiving SCH 412499 (rAd-p21) administered as a single 
injection into the subconjunctival space prior to primary trabeculectomy. The concept 
behind this trial is less innovative as at least two well established anti-frbrotic agents 
are in use, mitomycin C and 5-fluorouracil that work very well.
Bainbridge et al. report that early results of a phase I ocular gene therapy trial for 
Leber’s amaurosis, an early-onset, severe retinal dystrophy caused by mutations in the 
gene encoding retinal pigment epithelium-specific 65-kDa protein that is associated 
with poor vision at birth and complete loss o f vision in early adulthood. The authors 
administered AAV vectors 2/2 expressing RPE65 complementary DNA (cDNA) 
under the control of a human RPE65 promoter to three young adults and observed in 
one patient significant improvement in visual function on microperimetry and on 
dark-adapted perimetry. This patient also showed improvement in a subjective test of 
visual mobility. This study was mainly concerned with safety and used adults with 
advanced disease and poor vision (below 20/120). It will be interesting to see how 
pediatric patient will benefit from the transfer as planned in the near future. Two 
additional trials started at Scheie's Center for Hereditary Retinal Degenerations, 
University of Pennsylvania and the University of Florida College of Medicine in 
Gainesville and the other at the University of Pennsylvania and Children's Hospital of 
Philadelphia.
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6.3.5. Ocular Gene Transfer
The chronicity of the majority of eye diseases poses a distinct challenge to physician 
and patient, often demanding lifelong management and good compliance with 
complicated medication regimens. In addition, treatment o f ocular tissue by current 
conservative means is most the time only indirect and non-specific. Most ocular cell 
types are terminally differentiated and non-dividing, which has further implications 
for disease outcomes in that degenerative diseases often are characterized by a 
permanent, cumulative loss of function and no therapy is available. Chronic, 
progressive ailments of the optic nerve and the outflow tract, o f the retina and of the 
cornea constitute leading causes of blindness. The impact on quality of life for the 
individual is dramatic and the burden of health care expenses and loss of labor is very 
high.^^^ Gene therapy of chronic eye diseases with a long-term expressing vector may 
offer a focused and cost-effective therapy option, but choice of vector is limited to 
ones that allow stable long-term expression for the therapeutic goal of cell 
preservation.
Other ocular diseases are characterized by proliferation, such as neovascularization of 
retina, choroid, or cornea and require an entirely different choice o f therapeutic gene 
and vector system. Transient expression to induce controlled cell death or stasis is a 
common goal in these cases.
Gene transfer has the advantage over drug application that sustained expression can 
be achieved locally, while minimizing any risk of systemic adverse effects. Ocular 
gene transfer usually requires a surgical approach because systemic vector application 
does not result in targeting to ocular structures. This can be accomplished by standard 
procedures through subretinal, intravitreal or intracameral injection. Since ocular 
tissues are highly compartmentalized, the transduction pattern by a given vector is 
dependent on the site of its intraocular administration. While subretinal injection of 
vectors largely results in gene transfer to cells lining this space (retinal pigment 
epithelium and photoreceptors),^^’ intravitreally or intracamerally injected vectors 
follow the flow of aqueous humor along retinal ganglion cells, lens, ciliary and iris 
epithelium, the trabecular meshwork and the comeal endothelium.
Host immune responses during ocular gene therapy are often limited because 
intraocular vectors are sequestered from the systemic circulation and additionally 
suppressed by anterior chamber-associated immune deviation (ACAID) or inhibition
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of delayed-type hypersensitivity (DTH) in the subretinal s p a c e . T h i s  
phenomenon can prevent development not only of cytotoxic T cells, but also of 
complement fixing antibodies. Other factors have been identified in the eye that 
ameliorate immune responses, such as transforming growth factor-p. Fas ligand, 
melanocyte-stimulating hormone, vasoactive intestinal peptide, and calcitonin gene- 
related peptide.^^ '^^^^
6.3.5.1. Anterior Segment
6.3.5.1.1. Corneal Disease
Few vectors are able to achieve efficient and long-term transduction of structures of 
the anterior segment. Adenoviral vectors have been used extensively, but resulted 
only in short-term expression most the time,^^^’ as did and
lipopolysaccharide (LPS).^^^ Transduction of cornea was limited to the endothelial 
layer^^ "^^^  ^in most cases. Longer expression can be achieved with AAV^^^ or 
lentiviral vectors.^^^ Gene therapy of for comeal disease will be reviewed in the 
following in a more limited fashion as the main focus of this thesis is gene transfer to 
the outflow tract for future glaucoma therapy and the retinal pigment epithelium.
The major topics of comeal gene therapy are comeal transplantation and graft 
rejection, herpetic stromal keratitis, comeal neovascularization, comeal haze and 
mucopolysaccharidosis VII. These diseases do not share many common features: 
while some are chronic or inherited, some are more acute. Most are leading causes of 
vision loss from comeal disease with exception of mucopolysacharidosis which is an 
attractive target because the genetics and molecular pathway is well understood and 
there are little therapeutic altematives. Advantages of the comea as a target tissue are 
that it many features of a live tissue culture: it is easily observable, spread out in a 
plane more than three dimensionally and transparent allowing for immediate 
inspection of the few layers present and non-invasive treatment. Because it is 
generally not vascularized comeal transgenes are less accessible by the immune 
system than in perfused organs. Sophisticated morphometric technology is available 
as a result o f recent developments in comea and refractive surgery. Potentially 
facilitating gene therapy is the ocular immune privilege that is the result o f the 
mentioned blood-ocular barrier that physically prevents cellular infiltration, the low 
expression of major histocompatibility complex class I and II molecules and the lack
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of lymphatic drainage. Active aspects of ocular immune privilege include the 
constitutive expression of inhibitors of complement activation by comeal endothelial 
cells and of Fas ligand (which induces apoptosis of activated T cells) by comeal cells. 
The aqueous humor further contributes to immune privilege as it contains 
immunosuppressive factors. The anterior chamber-associated immune deviation is a 
descriptive term applied to an immune response that is deficient of B cells that secrete 
complement-fixing antibodies and T cells that mediate delayed hypersensitivity. The 
result of ocular immune privilege is that immune defense takes place with no 
inflammation to preserve comeal clarity, a vitally important condition. Finally, the 
comea itself takes an active role in immune protection of the stmcture and function of 
the eye surface in that comeal epithelial cells and keratocytes secrete cytokines.
First gene transfer studies to the comea appeared in 1994.^^^ Aheady in 1996 attempts 
were made to prevent graft rejection by ex vivo manipulation of the comea prior to 
transplantation,^^^followed by Rouse et al. to treat and Rakoczy et al.^ ®^  to
address comeal neovascularization.
Graft rejection is the major reason for transplant f a i l u r e . G r a f t  rejection is mediated 
by elevated levels o f Thl cytokines, while Thl and Th2 cells are inhibitory. Many 
gene therapy approaches therefore attempt to support Th2 or inhibit Thl pathway. 
Several studies have investigated comeal gene transfer of IL-4^ "^^  and IL-10,^^^ both of 
which are Th2 cytokines, and CTLA4-Ig^^^ and P40 IL-12^ "^  ^which are antagonists of 
Thl response. Other interesting immunomodulary molecules are viral IL-10, a 
homolog to the human IL-10 that exhibits the immunosuppressive properties but lacks 
the immunostimulatory effects of human IL-10^^^ and indoleamine 2,3-dioxygenase, 
an intracellular enzyme that arrests activated T cells in the G1 phase.^^^ Stout et al. 
used a different approach by suppressing activation of endothelial cells and 
neovascularization that are related to graft rejection.^®^ Gene delivery of 
endostatimkringle 5 of plasminogen, a fusion protein that prevents endothelial cell 
proliferation and migration and also has anti-angiogenic properties was transduced 
into rabbit comea using HIV vectors. Graft survival from 14 and 18 days in the 
control group was extended to at least 39 days.
Different strategies that have been proposed to address herpes simplex virus keratitis 
include vaccination against a primary ocular HSV-1 'mÎQcXxon, prevention o f recurrent 
HSV reactivation and treatment of existing HSV keratitis symptoms as well as anti-
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neovascular approaches. Nebum et al. used recombinant vaccinia virus as a means to 
vaccinate against viral envelope glycoproteins as early as 1990 but provided only a 
small amount of protection.^^^ Recombinant HSV-1 virus encoding for cytokine 
adjuvants were used by Osorio et al.^*^  Mice immunized with IL-4-expressing virus 
cleared the virus from their eyes more rapidly than mice immunized with IL-2- or 
IFN-gamma-expressing virus. The same author constructed and compared then 
recombinant HSV-1 viruses expressing IL-12p35 or IL-12p40 (subunits of IL12 with 
different biological activity) with the previous IL-4 expressing virus by 
intraperitoneally immunized BALB/c mice.^^^ IL-12 had been shown to act as a 
molecular adjuvant by bridging both innate and adaptive immunity but toxicity was 
observed after systemic application in the past. IL-12 is a regulatory protein produced 
by activated hematopoietic phagocytic cells and dendritic cells. Biological activities of 
IL-12 include growth stimulation of activated CD4^ and CD8^ T cells and natural 
killer cells. HSV-I expressing IL12-p35 exhibited the lowest virus replication, more 
rapid virus clearance and the lowest level of reactivation in the eyes after virus 
challenge without the toxicity seen with IL-12.
Dahesia et al^ ^^  and Wasmuth et al^ "^^  attempted to attenuate or prevent recurrence o f  
HSV keratitis and comeal symptoms in relative early stages by topical ocular 
administration of plasmid DNA encoding antigens and cytokines and application of 
TNF-alpha-antisense oligonucleotides. DNA encoding the cytokines IL-4 or IL-10, 
but not IL-2 or interferon-gamma, modulated the severity o f the immunoinflammatory 
response to subsequent comeal infection with HSV. The antisense strategy diminished 
the release of TNF-alpha from lymphocytes in HSV-1-infected comeas, mitigating the 
course of HSV keratitis to some extent. Anti-neovascular therapy for HSV keratitis 
tries to prevent infiltration of CD4+ T cells into the stroma and derived from the 
observation that IL-12 can suppress comeal lesions via anti-angiogenesis. Various 
investigators have administered naked DNA encoding IL-18,^^^ RNAi knockdown of 
VEGF^^^ or MMP-9^'^ to prevent neovascularization. All o f these strategies worked in 
the short term decreasing neovascularization and reducing keratitis.
Corneal neovascularization can be caused by infection (such as the previously 
mentioned HSV keratitis), inflammation of various cause and trauma. Common 
animal models try to mimic these conditions by chemical, mechanical injury or
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implantation of angiogenic pellets. Anti-VEGF strategies are prevailing among anti- 
neovascular gene therapy as VEGF is the most potent neovascular molecule known: 
Lai et al. used adenoviral vectors to express FLtl, a VEGF receptor that can function 
as a sink^^^ resulting in protection of 92% of animals compared to control, while 
Stechschulte et al. found that naked plasmid cDNA alone injected under pressure in 
mouse comea effectively prevented neovascularization.^'^ Other authors have fused 
FLt23K, Flt24K, VEGF-binding domains of Fit 1 with KDEL, an endoplasmic 
reticulum retention peptide or albumin polyplexes as vehicles for Flt23K DNA to 
inhibit VEGF intracellularly.^'^’ RNAi^'^ and adenovirally encoded antisense 
VEGF^^' successfully knocked down VEGF. IE-18 similarly suppressed 
neovascularization as previously ment ioned.^Naked DNA administration of IL-1 
receptor antagonist that was shown in a model o f penetrating keratoplasty to reduce 
VEGF expression was unable to affect VEGF expression in a model of comeal 
neovascularization.^^^ Another interesting recent study that has potential to work 
longer term is that of Cheng et al. who used an AAV vector expressing angiostatin for 
subconjunctival injection in a model of alkaline induced comeal 
neovascularization.^^^ Surprisingly, angiostatin was found by PGR neither in the 
conjunctiva nor comea but limited to the extraocular muscle insertion sites suggesting 
serotype specific transduction as seen at other vector injection sites. The authors 
nevertheless found significant reduction of comeal neovascularization in the area of 
injection. As the main criticism the authors label regression of neovascularization 
what in fact is prevention of neovascularization as transduction is performed 3 weeks 
ahead of the alkali bum rather than in the clinically realistic, reverse order.
Several gene therapy studies have been conducted to address comeal haze, clouding 
or deposits some of which have similar approaches. Comeal haze can be a 
complication of excimer laser procedures used in refractive surgery and are a result of 
fibroblast proliferation. Therapeutic transgenes used were the dominant negative 
mutant cyclin G l, a survival factor that triggers apoptosis in various proliferative 
cells,^^"' or a suicide gene/prodmg combination of a retrovims encoding the HSV 
thymidine kinase gene with gan c i c lo v i r . HS V  thymidine kinase transforms 
ganciclovir to a toxic metabolite in proliferating keratocytes killing them.
A different condition that is associated with comeal deposits is 
mucopolysaccharidosis VII, a lysosomal storage disease caused by deficiency o f the
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enzyme beta-glucuronidase and the least common one. Treatment of comeal opacities 
is more of academic interest because of the rarity of this disease and because 
potentially life threatening issues need to be addressed first. A study by Kamata et al. 
showed widespread transgene expression of adenoviral vector mediated beta- 
glucuronidase transfer either intracameral injection or intracomeal administration 
(lamellar keratotomy), and rapid elimination of the lysosomal storage in comeal 
keratocytes occurred. This study is striking in how efficiently such a severe metabolic 
disease can be cured in local tissue and that the pathology of adjacent tissue resolves 
as well.^^^
6.3.5.1.2. Glaucoma
Although glaucoma is a leading cause of blindness at an age that has a maximum 
impact on the most productive years and is generating more costs than other leading 
causes of blindness not to mention the personal tragedies, gene therapy o f glaucoma is 
in its infancy. This is because the molecular pathophysiology is still not understood 
and in contrast to many degenerative retinal diseases, single genetic defects are the 
rare exception. Congenital glaucoma with single gene defects present with a 
developmental dysgenesis of the outflow tract that is already completed by the time or 
birth. This cannot be addressed by gene therapy anymore. Goals in gene therapy for 
the most common form of glaucoma, primary open angle glaucoma, are therefore to 
increase survival of retinal ganglion cells in the back of the eye or to facilitate outflow 
of aqueous humor in the fi*ont of the eye as well as to address issues of glaucoma 
surgery by adjunctive therapy (e.g. suppression of fibrosis in filtering blebs). The 
principle is to get an exogenous gene with a product that is therapeutically useful 
albeit not necessarily directly related to pathogenesis.
6.3.5.1.2.1. Outflow Tract Gene Transfer
Genetic modification of the aqueous humor outflow site o f mice, rabbits, rats, 
monkeys and human donor eyes^"'"'’ has been attempted before with a
variety of vectors, but was mostly unspecific and short-lived, with exception of 
lentiviral v e c t o r s . N o n - v i r a l  methods are generally impeded by low transfection 
efficiency and only transient expression. Hangai et al. used fusogenic liposomes from
-109
Introduction: Gene Therapy
hemagglutinating virus of Japan to transfer LacZ as well as fluorescein isothiocyanate 
(FITC)-labeled phosphorothioate oligonucleotides into the outflow tract of rats and 
rhesus monkeys. Interestingly, beta-galacosidase expression could be visualized 
longer than in adenoviral vector mediated similar transduction protocols perhaps due 
to lower immunogenicity. The authors report that expression could be followed for 
60 days in rats and 30 days in monkeys. FITC fluorescence could be seen for as long 
at 14 days in rat and 7 days in monkeys. While this transfer system makes for a safe 
way of gene transfer, transfer efficiency is disappointing both in numbers of cells 
transduced and expression levels per single cell.^^^
Comes and Borras investigated whether naked siRNA could be delivered to human 
TM in anterior chamber cultures by direct perfusion.^^'' SiRNAs were directed against 
the matrix Gla protein and the glucocorticoid receptor. With this simple and 
straightforward approach using readily available, unmodified siRNA, matrix Gla 
protein expression was silenced in the trabecular meshwork perfused with naked 
MGP siRNA by 95% and the glucocorticoid receptor by 93%, respectively. 
Pretreatment of glucocorticoid receptor siRNA followed by dexamethasone treatment 
caused a reduction of myocilin expression, a glaucoma associated gene, by 99%.
A follow up study to prior work in which accidental transduction of the anterior 
segment was seen,^^' Budenz et al. injected purified replication-deficient adenoviral 
vectors with a CMV-promoter driven beta-galactosidase expression cassette into the 
anterior chamber o f adult CD-I mice.^^^ Mice were sacrificed and processed for beta- 
galactosidase expression histochemically from 2 to 21 days. Expression was seen in 
comeal endothelium and trabecular meshwork for only 14 days after injection. The 
authors noted that despite early loss of expression there was no toxicity observed in 
transduced tissue. The expression levels and extent of expression appear to be rather 
marginal in the data published.
Borras et al. came to similar conclusions with adenoviral gene transfer to the anterior 
segment but in contrast to Budenz et al. the authors did observe a severe inflammatory 
response. In this study, anterior segment adenoviral gene transfer was performed in 
rabbits. Rabbits were injected once with 20 pi containing 8x10^ TU and evaluated 
48 hours after injection. Beta-galactosidase expression was seen in comeal 
endothelium, the anterior endothelium of the iris and the trabecular meshwork. 
Transduction of lens endothelium led to endothelial decompensation with cell
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detachment and comeal opacification highlighting the toxicity in some species of 
these first generation adenoviral vectors with E l deletion and E3 inactivation. 
Inflammatory responses included a severe anterior uveitis in some animals requiring 
sacrifice. Borras later studied transduction of perfused anterior human segments and 
porcine anterior segments with the same adenoviral v e c t o r . I n  contrast to the 
previously in vivo transduced rabbit eyes, transduction of these eyes ex vivo was 
tolerated much better at lower doses o f 10 ,^ 10  ^and 10  ^TU and did not affect outflow 
facility. At 10  ^TU the outflow facility was reduced suggesting toxicity. Transduction 
of along the outflow pathway was observed that included the trabecular, 
juxtacanalicular trabecular meshwork, and the inner wall of Schlemm's canal. 
Expression of the reporter enzyme was seen at 7 days. Later studies by the same lead 
author in monkeys with an eGFP expressing vector led to gonioscopically observable 
fluorescence in the trabecular meshwork.^^"' Ten to 100 fold more transducing units 
were used despite the previously determined toxicity threshold of below 10  ^TU in 
other species but similar eye size. Two monkeys were injected with 10  ^TU and two 
more with 10  ^TU due to anticipated difficulties visualizing fluorescence with a direct 
and insensitive detection system (personal communication). eGFP fluorescence was 
seen at both titers tested. One monkey received four consecutive injections into the 
same eye of 10  ^TU over a 7 month period. Expression lasted 3-4 weeks with little 
clinical signs of inflammation. In the monkey injected repeatedly, expression was 
again seen for 3-4 weeks but induced severe iritis and comeal decompensation on the 
fourth occasion. These results demonstrated the shortcomings of adenoviral gene 
transfer that is limited to a short amount of time likely due to the episomal state of the 
DNA and immunogenicity resulting in almost immediate failure with repeat 
injections. The study did not distinguish between potential immunogenic substances 
(adenoviral proteins versus eGFP) but eGFP expression has been observed long-term 
in various animals including monkeys^^^ and was tolerated well in the past.
Kee et al. tried to take adenoviral gene transfer to the ocular outflow tract a step 
further by using a therapeutic gene, stromelysin.^^^ MMP-3 (Stromelysin-1) can break 
down the extracellular matrix but has to be activated before that as other matrix 
metalloproteinases. Matrix metalloproteinases break down extracellular matrix during 
physiological processes such as embryogenesis, reproduction and tissue remodeling 
but also in disease processes such as arthritis and metastasis. Almost all MMPs are
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secreted in an inactive zymogene form (proprotein) that requires activation by 
extracellular proteinases. MMP-3 degrades fibronectin, laminin, collagen III, IV, IX 
and X as well as cartilage proteoglycans.
Stromelysin perfusion has been demonstrated to increase outflow f a c i l i t y , T h e  
authors injected vectors intracamerally in rat eyes and found stromelysin expression 
in trabecular meshwork, iris and the uveoscleral outflow pathway. This study was 
hampered by the lack of stromelysin activation and a resulting lack of outflow change. 
Outflow therapy with matrix metalloproteinase gene transfer remains an attractive 
option but attention must be paid to the complex biochemistry and interaction of these 
enzymes. Constitutively active matrix metalloproteinases have been described which 
may be more useful for this purpose.
In perfused human anterior segments. Ads carrying the dominant-negative RhoA 
effectively transduced the TM and increased outflow facility s l i g h t l y . I n  this study 
a CMV promoter driven dominant-negative form of RhoA with a single amino acid 
substitution of Thrl9 to Asn was expressed by a replication-deficient adenoviral 
vector in perfused human anterior segment cultures. At 66 hours post transduction, 
anterior segments experienced an increase in outflow facility of 32.5%. TM cells 
showed a reduction in actin stress fibers and of the focal adhesion-containing protein, 
paxilin. The authors interpreted the increased outflow as a loosening of the cell- 
substrate and cell-cell attachments along the outflow pathway. The Rho family of 
proteins belongs to the larger Ras superfamily of GTP-binding proteins and has been 
shown to regulate a complex network of cytoskeleton-dependent cell functions. 
Manipulation of any content of this pathway harbors the risk of triggering cell 
migration and cell division ultimately resulting in cancer. Any vector with this 
potential should have a suicide gene cassette as well to allow ablation e.g. by HSV-tk 
conversion of acyclovir. This is still not a sufficient solution for non-integrating 
vectors as the cancer cells cannot be ablated anymore once the transient expression is 
extinguished.
In human TM cells. Ad carrying aquaporin I induced an 8.7% increase in resting cell 
volume that paralleled an 8% decrease in paracellular permeability of infected 
monolayers.^^^ Conversely, aquaporin antisense adenoviral vector transduced cells 
had a reduced cell volume by 7.8%. It is possible that one way how prostaglandin 
analogues might increase conventional outflow is via an observed aquaporin
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downregulation.^^^ Because cell size is able to regulate outflow through the trabecular 
meshwork, gene therapeutic knockdown of aquaporin might increase outflow facility. 
Results of transduction of perfused anterior chambers have not been published yet.
The original idea of this author that aquaporin is responsible for water passage from 
the anterior chamber directly through trabecular meshwork cells into Schlemm’s 
canal^^^ appears to be too simplistic and not applicable to glaucoma gene therapy.
Caldesmon is another protein that participates in the regulation of actin stress fibers 
and their manipulation is able to change outflow. Gabelt et al. over-expressed rat non­
muscle caldesmon in human trabecular meshwork cells of cultured human and 
monkey anterior segments and found an increase of outflow facility by 43% at 66 
hours (human) and 35% (monkey), respectively .H isto logical studies showed that 
stress fibers gradually disappeared and novel actin structures were formed.
Caldesmon is a calmodulin- and actin-binding protein that regulates smooth muscle 
and nonmuscle contraction. The conserved domain of this protein possesses the 
binding activities to Ca^^-calmodulin, actin, tropomyosin, myosin, and phospholipids. 
This protein is a potent tonical inhibitor of the actin-tropomyosin activated myosin 
Mg-ATPase, and serves as a mediating factor for Ca^^-dependent inhibition of smooth 
muscle contraction. Caldesmon over-expression prevents focal adhesion and stress 
fiber formation even if the cells constitutively active Rho suggesting that caldesmon is 
operating downstream of the Rho signaling pathway.
The same group also studied C3 transgene expression and its effect on actin and 
cellular adhesions in cultured human trabecular meshwork cells and on outflow 
facility of cultured anterior monkey s e g m e n t s . C 3  transferase is an exoenzyme from 
Clostridium botulinum that targets Rho GTPases by specifically inactivating Rho 
through ADP-ribosylation. Similar to transduction with caldesmon, transduction with 
1.2x10^ TU adenoviral vector expressing C3 resulted in a dose-dependent 
morphological change about 3 to 4 days later with partial retraction, rounding and 
elongation. The authors observed disruption of the actin cytoskeleton, reduced 
vinculin-positive focal adhesions and loss of beta-catenin as assessed by 
immunofluorescence. Outflow facility increased rather dramatically by 90% as 
corrected for GFP transduced control eyes.
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As described in this thesis and discussed in detail below, use of lentiviral vectors for 
genetic modification of the ocular outflow tract is the only tool that has achieved 
stable long-term transduction.^^"'’ Similar to the HIV and FIV vectors
used in this thesis, Challa et al. used HIV vectors with an internal elongation factor 1 
alpha (EF-1 alpha) promoter driving eGFP expression.^""' In the later study authors 
found expression for three weeks at the study endpoint not only in the trabecular 
meshwork and the downstream outflow tract but also in the comeal endothelium. The 
authors speculate that frequent comeal neovascularization might be attributable to 
endothelial transduction and the fashion in which the needle is inserted (bevel up 
versus bevel down) but the lack of comeal infiltration or edema is inconsistent with 
this idea. More likely, this could be caused by the high titer used that were identical to 
the upper amount of TU used in the much larger feline eyes in our studies resulting in 
over-transduction with toxicity. Species differences may further result in different 
vector convection and exposure time. Balaggan et al. found the same using an equine 
infectious anemia vims (EIAV) in mice. In these even smaller eyes, high level 
transduction of TM and moderate transduction of comeal endothelium was observed 
after intracameral injection of approximately 2.8 x 10  ^TU.^"'  ^When pseudotyped with 
the rabies-G rather than VSV-G transduction was poor. In some cases eGFP 
fluorescence was observed in the comea in linear radial initial mid-stroma and central 
anterior stroma configuration that may be consistent with the pattem of neuronal 
innervations. Similarly, linear fluorescence was seen along the anterior border o f the 
iris and within the ciliary body that may be following ciliary body nerves and the 
ciliary neuronal plexus. Prior studies found neuronal tropism of rabies-G pseudotyped 
vectors (VSV-G recognizes the ubiquitous phosphatidylserine, whereas rabies-G uses 
the neuronal cell adhesion molecule, nicotinic acetylcholine receptor and p75
preferentially).^"'^
While most investigators have injected vectors and vehicles directly into the anterior 
chamber, Hudde et al. have described a way of achieving high multiplicities of 
infection and site specific targeting by direct injection into Schlemm’s canal.^"'"' The 
authors performed surgical sclera unroofing of Schlemm’s canal followed by direct 
injection of adenoviral vectors encoding MMP-3 (stromelysin). The authors found 
high transgene expression in the inner Schlemm’s wall and trabecular meshwork but
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failed to detect breakdown of the extracellular matrix. The same criticism of Kee et 
al.’s study discussed above applies here: although in cell culture MMP-3 appears to be 
active by zymographic assay, it is not clear whether MMP-3 is active in the ex vivo 
and in vivo experiments. A constitutively active form of MMP-3 should have been 
used. The authors confirm the intense immunogenicity of adenoviral vectors and find 
not only invasion of Schlemm’s canal and trabecular meshwork by inflammatory cells 
but also keratic precipitates although the vector was not applied intracamerally.
Another way of limiting transgene expression is the use of trabecular meshwork 
specific promoters. Liton et al. used the chitinase 3-like 1 (Ch3Ll) gene promoter 
after a comparative expression analysis of trabecular meshwork and Schlemm’s canal 
cells to restrict adenoviral vector expression to the TM.^"'  ^The authors transduced 
cultured cells and anterior human segments with 10  ^TU of adenoviral vectors that 
contained a Ch3Ll promoter driven lacZ cassette. Ch3Ll is a mammalian 
glycoprotein member of family 18 glycosyl hydrolases that is involved in tissue 
remodeling and inflammation and acts as a growth factor for connective tissue cells 
and as a potent migration factor for endothelial cells which could also play a role in 
both the normal physiology of the TM and the abnormalities that occur in glaucoma. 
Gonzales et al. found in a similar experiment by the same group that promoter 
fragments from the matrix Gla protein can specifically direct expression to the 
trabecular meshwork, while use of the vascular endothelin-cadherin gene promoter 
may allow differentiating between vascular and Schlemm’s canal endothelial cells.
A peculiar reverse observation is the complete inability of AAV vectors to achieve 
notable expression in the TM including primary cells cultures, organ cultures and 
living animals. AAV vectors have all the features that would make them highly 
desirable for long-term transduction of TM that apply to lentiviral vectors. Borras et 
al. studied the reasons for this restriction and found evidence for host downregulation 
of genes involved in cell cycle and DNA replication that require adenovirus 
coinfection for productive transduction.^"'^ This block can be overcome for the 
purpose of transduction with self-complementary AAV vectors which bypasses the 
required second-strand DNA synthesis to achieve a transcriptionally active AAV 
genome for gene expression.
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Many variations of the idea of wound healing modulation after glaucoma filtration 
surgery have been described. Perkins et al. developed a gene therapy approach 
adjuvant to glaucoma filtering surgery, where an outflow shunts is created from the 
anterior chamber to a fluid reservoir under the conjunctiva.^"'^ While this procedure 
can lower intraocular pressure very effectively when the fluid reservoir functions 
properly, scar tissue formation and closure of the draining shunt and reservoir often 
result in failure. Ad encoding the cell cycle inhibitor protein p21 prevented scar 
formation to an extent comparable to the commonly used mitomycin C. p21 is the 
major transcriptional target of the tumor suppressor gene, p53; despite this, loss-of- 
function mutations in p21 - unlike p53 - do not accumulate in cancer nor do they 
predispose to cancer incidence. This gene encodes a potent cyclin-dependent kinase 
inhibitor that binds to cyclin-CDK2 or -CDK4 complexes, and thus functions as a 
regulator of cell cycle progression at G l. The protein can interact with proliferating 
cell nuclear antigen, a DNA polymerase accessory factor, and plays a regulatory role 
in S phase DNA replication and DNA damage repair. This protein is cleaved by 
CASP3-like caspases, which leads to activation of CDK2, and may participate in 
execution of apoptosis following caspase activation. Other groups have used very 
similar strategies with the same gene producing similar results (reviewed here^"'^). 
Another approach to adjuvantive antifibrotic gene therapy is the use of RAD50, which 
is involved in the repair of mammalian DNA damage and antiproliferative activity 
that is p53-independent and p21-dependent.^^"
6.3.5.1.2.2. Retinal Ganglion Cells
Retinal ganglion cells (RGCs) represent the inner most cell layer of the neurosensory 
retina and their axons constitute the optic nerve. RGC death results irrevocably in 
optic nerve degeneration and loss of vision. Although technically easier to administer, 
gene transfer to retinal ganglion cells faces more significant barriers than subretinal 
injections targeting the RPE and outer neuroretina. Different from the liquefied, 
degenerated vitreous that is seen in patients with age related macular degeneration 
that allows easy diffusion and circulation of injected therapeutics, vitreous in 
experimental animals is without exception thick and gel like due to the relatively 
young age and perhaps species-difference. In contrast to the homogenous colloid 
structure of a gel, vitreous contains collagen strands that immobilize it and impede
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circulation. The vitreous is surrounded by a membrane, the hyaloid face while the 
internal limiting membrane presents another barrier that vectors must overcome 
before making physical contact with retinal ganglion cells. As discussed below, these 
barriers proved to be insurmountable to pseudotyped FIV vector in our own 
experiments.^^ It is possible that surface charge and vector particle size are more 
favorable for parvoviral AAV vectors to overcome these barriers than the larger 
pseudotyped lentiviral vectors. As the focus of my studies was anterior gene transfer 
to the outflow tract rather than posterior neuroprotection, the cause of impaired gene 
transfer to retinal ganglion cells has not been examined in a scholarly fashion.
After noticeable absence of studies demonstrating efficient gene transfer to retina 
ganglion cells for many years, there are now several interesting ones that use AAV as 
the vector. Neurotrophic factors are now known to be problematic in many cases. For 
instance while BNDF is neutrotrophic on neurons, it causes up-regulation of nitric 
oxide synthase^^' or by suppressing the heat shock protein 27.^^  ^CNTF can produce 
rapid weight loss and death in mice.^^^ BNDF is thought to be the most potent 
neuroprotective factor^^"' but it also influences other neuronal cells o f the retina such 
as amacrine cells, Müller glia, and cone pho torecep tors .Use  of the extracellular 
signal-regulated kinase 1/2 (Erkl/2) and the phosphatidylinositol-3 kinase pathway 
represents an alternative strategy to target the intracellular events that lead to RGC 
survival thus bypassing the use of exogenous peptide factors.^^^ This is what Zhou et 
al. chose to do: 8.5 x 10  ^TU of intravitreally injected AAV vectors were used to 
transduce retinal ganglion cells with the constitutively active or wild-type MAP2KI, 
the upstream activator of Erkl/2. After 5 weeks of ocular hypertension the dorsal 
retina RGC counts were almost twice as high as the control eyes. A major advantage 
of this approach over other strategies is that AAV serotype 2 mediates gene transfer to 
>70% of RGCs and a few displaced amacrine cells,^^^ but not other retinal cell types, 
hence Erkl/2 activation is largely restricted to a target neuronal population. Although 
a difference of 50% compared to controls might not deem much, this is the threshold 
below which only subtle visual field impairment occurs while above 50% RGC loss 
results in noticeable, severe visual impairment in primates.^^^
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The same senior investigator had previously used AAV vectors to transduce BDNF 
into RGCs by intravitreal injection. The protection against RGC loss was 
approximately 20% compared to control rats.^^^ In an earlier study this senior author 
used AAV to transduce the chicken beta-actin driven human baculoviral lAP repeat- 
containing protein-4 (BIRC4), a potent caspase inhibitor, into RGCs of an ocular 
hypertensive rat. BIRC4 is an intriguing molecule the discovery of which began when 
it was found that the baculovirus caspase inhibitory gene p35 was able to rescue 
photoreceptors in retinal degeneration-mutant fruit flies.^^'' Searches for homologs of 
p35 led to the discovery o f inhibitors of apoptosis protein (LAP) genes, also found to 
be evolutionarily conserved in viruses, insects, and m a m m a l s . l A P s  are defined by 
baculovirus LAP repeat domains critical to apoptosis inhibition.^^' One member of the 
mammalian lAP family, BIRC4 (also known as XLAP or hILP), is a direct inhibitor of 
downstream cell death proteases.
Another study that used AAV mediated gene transfer or the basic fibroblast growth 
factor (bFGF) and BDNF found that intravitreally injected rats were protected against 
NMD A challenge compared to controls at 1 month post challenge. The difference 
was relatively disappointing as BFGF achieved 18% protection and BDNF 12% in 
comparison to controls. Protection in the optic nerve crush model was only seen with 
bFGF and amounted 18%. Similarly, Ad mediated basic fibroblast growth factor 
(bFGF) expression rescued RGCs t r a n s ie n t ly . In  the later study only 
semiquantitation was performed by measuring optic nerve layer thickness making it 
difficult to judge outcome.
Leaver et al. used AAV-mediated gene transfer of CNTF to promote survival of 
axotomized retinal ganglion cells.^^"' This effect was bigger in bcl-2 over-expressing 
mice after optic nerve crush. The authors injected 1.5x10^ TU of AAV vectors and 
observed an increase of viability of RGCs by about 50% in bcl-2 overexpressing mice 
while there was only a disappointing 7% increase in wild type mice. Leaver et al. used 
AAV-2 vectors to transduce either BNDF or CNTF into eyes with optic nerve crush 
or transection with an attachment of a peripheral nerve.^^^ The authors found that 
only eyes with autologous peripheral nerve to optic nerve transplantation in 
combination with CNTF gene transfer would allow survival of about 25% at 7 weeks. 
Although these numbers are small overall, in a crush or transection model (as opposed
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to the less drastic insult of ocular hypertension) it is remarkable that about 1/4'" of 
retinal ganglion cells can survive the definite fate of apoptosis. In early gene transfer 
studies to retinal ganglion cells, Ad vectors were able to temporarily extend survival 
o f Muller cells of rats with axotomized RGCs^^" by about 4.5 fold by transducing 
brain-derived neurotrophic factor (BDNF).
Again using an AAV vector, Wu et al. achieved long-term expression of glial cell 
line-derived neurotrophic factor to retinal ganglion cells after injecting 1.1 x 10  ^TU 
of AAV expressing GDNF intravitreally. The authors note the absence of 
inflammation, cell loss or change of electroretinogram latency and observed 
expression at the 1 year study endpoint.""^ As the main shortcoming, this study did not 
examine whether ganglion cell survival is improved in a glaucoma model. Ishikawa et 
al. also used GDNF but directly electroporated plasmids into RGCs after intravitreal 
injection. The authors find an improved survival o f 50% of RGCs versus 15% in 
untreated controls at 2 weeks after optic nerve crush. The extent of survival is 
surprising given the relative inefficiency of gene transfer to only 24% of retinal 
ganglion cells.
Malik et al. demonstrated that AAV2 mediated gene transfer o f Bcl-XL is very 
effective in preventing cell death in 94% compared to 15% of RGCs compared to 
control eyes at 2 weeks and 46% at 8 weeks compared to 6% in controls after optic 
nerve crush.^"^ Risks versus benefits must be carefully considered in gene transfer of 
members of the Bcl-2 family and other anti-apoptotic molecules. BCL-xl stands for 
“basal cell lymphoma-extra large” and has been isolated from cancer cells. Apoptosis 
serves a physiological purpose and manipulation o f this mechanism could easily have 
the opposite effect. Bcl-xl is a transmembrane molecule in mitochondria that is 
involved in the signal transduction pathway of Fas ligand (FasL), itself a 
transmembrane protein that belongs to the tumor necrosis factor (TNF) family, the 
binding of which induces apoptosis.
Another approach to ganglion cell protection that is not directly related to glaucoma 
was demonstrated for experimental autoimmune encephalomyelitis, an autoimmune 
inflammatory disorder of primary central nervous system demyelination that has been 
frequently used as an animal model for testing treatments against multiple sclerosis.
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The optic nerve is a frequent site of involvement in both experimental autoimmune 
encephalomyelitis and multiple sclerosis. Reactive oxygen species such as superoxide, 
hydrogen peroxide, nitric oxide, and peroxynitrite are mediators of demyelination and 
disruption of the blood-brain barrier in experimental autoimmune encephalomyelitis. 
Cellular defenses against reactive oxygen species include catalase and superoxide 
dismutase. Superoxide dismutase dismutes superoxide to hydrogen peroxide (H2O2), 
and catalase detoxifies the H2O2 to H2O and O2. Qi et al. cloned the human 
extracellular superoxide dismutase or catalase gene into AAV vectors and transduced 
mice by intravitreal injection."^" Animals were then sensitized for EAE, followed by 
serial contrast-enhanced MRI for 6 months, and sacrifice. Western blot analysis of 
infected RGC-5 cells revealed that expression of dismutase increased 15-fold and that 
of catalase 3.5-fold. One month after intraocular injections, transgene expression 
increased 4-fold for dismutase and 3.3-fold for catalase. Six months after intraocular 
injections and EAE sensitization, combination therapy with dismutase and catalase 
decreased retinal ganglion cell loss by 29%, optic nerve demyelination by 36%, 
axonal loss by 44%, and cellular infiltration by 34% compared with the contralateral 
control eyes transduced with an eGFP expressing AAV vector.
6 3.5.2. Posterior Segment
6.3.5.2.1. Retinal Degeneration
The most experience in ocular gene therapy exists for retinal diseases, in particular for 
inherited retinal degeneration. The decoding of molecular mechanisms, identification 
of genetic defects and cloning of genes involved has dramatically advanced gene 
therapy in this area. Retinitis pigmentosa is a group of inherited photoreceptor defects 
that lead to incurable, progressive degeneration in about 1 in 3000 people."^' There is 
a large number of natural or genetically engineered animal models with retinal 
degeneration analogous to human retinitis pigmentosa that can be used for 
development of preclinical therapy.
Retinal degeneration can involve lack-of-function mutations as well as gain of 
function mutations. Gene therapeutic replacement for a lack-of-flinction mutation is 
e.g. the premature stop codon of the beta subunit o f the rod photoreceptor-specific 
cGMP phosphodiesterase (PDE-p). The defect is caused by a premature stop codon 
that affects only the homozygous, but not the heterozygous, which suggests that even
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partial replacement of the defect might be sufficient. Rescue has been achieved in a 
mouse model (the rd mouse) with adenoviral ,AAV,"^^ gutted adenoviral"^"'and 
lentiviral vectors^^' carrying the same gene (PDEb).
Autosomal dominant retinitis pigmentosa is an example for gain-of-function 
mutations, which are more complex to treat. Defects may cause abnormal localization 
of proteins or altered function."^^’ AAV vectors have been used to deliver RNA- 
cleaving RNA molecules, ribozymes that leave the wild-type mRNA intact, while 
degrading the mutant RNA^^^and photoreceptor degeneration was slowed down for 
more than 3 months.
As described above in the therapeutic approaches for retinal ganglion cells in 
glaucoma, secondary strategies may consist of antiapoptotic"^^’ or neurotrophic 
therapy of p h o t o r e c e p t o r s . A d  vector with rhodopsin promoter driven expression 
of bcl-2, an anti-apoptotic molecule, temporarily rescued photoreceptors in the rd 
mouse was able to rescue photoreceptors.Rescue with AAV vectors expressing 
neurotrophic factors CNTF^^^'or GDNF"^' resulted in improvement of retinal 
morphology in rats, but there was no functional ERG improvement with CNTF.^'^
Efficiency of non-viral transduction into the retina can be enhanced by simultaneous 
electroporation. Electroporated plasmids injected into the subretinal space can 
produce reporter gene expression for up to 50 days"^^ but this can be extended to more 
than 4 months with cotransfection of phiC31 integrase to allow integrase-mediated 
recombination with attB sequences.^^^ It is important that electroporation be 
optimized for each species as severe disruption of ocular structures can occur with 
inflammation, cataract formation, retinal degeneration and phthisis bulbi because of 
its physically violent nature.
Lentiviral vectors are an excellent choice for disorders that originate in the retinal 
pigment epithelium and can be applied to treat both degenerative as well as vaso- 
proliferative conditions. However, transduction of neuroretina is inefficient or 
impossible depending on the age and species. In our own experience as detailed 
below, FIV vectors only transduced retinal pigment epithelial cells even when 
injected into 5 day old rats. This contrasts to results with HIV vectors in mice that 
were injected at day 2 resulting in efficient transduction of neuroretina.^^' In all other 
studies lentiviral gene transfer to neuroretina was disappointing no matter what
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promoter or pseudotype.^^"' It is likely that this is the result o f barriers and physical 
vector properties (charge, size) that may depend on species and animal maturity. 
Neuroretinal transduction can be improved by local trauma and enzymatic disruption 
of the inter-photoreceptor maxtrix.^^^’ Lentiviral vector mediated expression in 
the RPE has been reported for up to 2 years.^^’ SIV and HIV vectors have been 
used successfully to treat retinal degeneration caused by a genetic defect o f the 
RPE 344,688 findings suggest that lentiviral vectors that are integrase defective
can be used to achieve high enough expression levels to be therapeutic in RPE 
disease.^^^’ Yanez-Munoz et al. show that Rpe65^ '^^^^ '^  ^mutant mice with a 
phenotype similar to that of individuals with Leber congenital amaurosis, a severe 
form of early-onset autosomal recessive retinitis pigmentosa that results from 
mutations in RPE65 can be rescued with HIV vectors that have a D64V mutation. 
Vectors can persist as episomal double-stranded DNA circles.
AAV vectors are the common vectors used for gene transfer to the retinal pigment 
epithelium and the neuroretina. Although the majority of AAV vectors does not 
integrase but remains in the cell in the form of concatomers, transgene expression 
from AAV vectors has been followed for several years. ^Tissue specificity as well 
as expression kinetics are surprisingly dependent on the vector serotype and ocular 
structure into which vectors are injected. Recent hybrid vectors in which AAV an 
AAV genome is packaged in a capsid from a different serotype have expanded the 
applicability. For instance, while AAV-2 vectors typically show a delayed onset of 
expression, slowly increasing expression after 2-4 months (which may be an 
advantage that allows gentle accumulation of a foreign transgene with less disruption 
of intracellular metabolism and immunogenicity), AAV-2/1, AAV-2/5 and AAV-5/5 
vectors cause rather rapid expression as early 3 days after transduction. AAV-2/2 and 
AAV-2/5 transduce the RPE and photoreceptors, while AAV-4/4 and AAV-2/4 are 
restricted to the RPE."^' Successful gene replacement has been achieved in both 
rodent and large animal models of inherited retinal degenerations with AAV-5 
vectors."^'’ A novel serotype, AAV-2/8 can transduce photoreceptors and RPE 
even more efficiently than AAV-2/2 and AAV2/5. The self-complementary version of 
AAV-2/8, a strategy in which sense and antisense genomes are mixed in the final 
vector preparation, shows even faster and higher transgene expression than AAV- 
2/8.®^
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For both experimental and therapeutic purposes, gene regulation is a desirable feature. 
This has been accomplished in the retina with dual vector as well as single vector 
systems with both rapamycin and tetracycline-inducible systems."^"' Lebherz et al. 
achieved regulated long-term expression with a dimerizer-inducible expression 
system (rapamycin) in non-human primates for 2.5 years.^^^ In an experimental model 
of uveitis tetracycline-inducible expression of IL-10 using a single AAV vector 
worked well."^" Other researchers have used promoters that respond to environmental 
changes such as ischemia with mixed success.^^^ The authors do not quantify the 
change of expression. The use of native promoters is o f advantage as other inducible 
systems have been noted to be immunogenic (reviewed in"^^).
Proof-of-principle for gene replacement therapy has been demonstrated in several 
experimental models of inherited retinal degeneration resulting from loss-of-function 
mutations and is the most classical example of gene therapy. AAV vectors are the 
foremost vectors but not the only ones. In the rds mouse model peripherin, a 
membrane glycoprotein that is responsible for the formation and stability of 
photoreceptor outer segments can be replaced and restore function if  done within 14 
weeks. However, gene replacement is not maintained in the long term most likely 
because of the timing of intervention.^^^ A protein anchored in the photoreceptor 
connecting cilia, the retinitis pigmentosa GTPase regulator interacting protein 
(RPGRIP), can be replaced as well and is able to preserve photoreceptors and function 
in a mouse model of Leber’s congenital amourosis.^'"'AAV-2 mediated expression of 
retinoschisin in a model of X-lined recessive juvenile retinoschisis allowed the 
electroretinographic improvement however, the retinal structure did not recover.^'" 
When younger animals were used in the same model functional and structural 
improvements were found for up to one year using AAV-5 vectors.^''^ Another 
common murine model is the Royal College of Surgeons rat that is lacking Mertk, an 
RPE receptor tyrosine kinase involved in the phagocytosis of shed photoreceptor 
outer segments. Rescue of this model was achieved with both AAV2 and lentiviral 
vectors."^^’ HIV-vector mediated gene transfer was more efficient in this model, 
likely an effect of the RPE-specific tropism as well as the more rapid onset compared 
with AAV-2 vectors. Another interesting model is the murine model of ocular 
albinism in which gene replacement of OAl has been performed, restoring the 
number of melanosomes and improving the electroretinographic abnormalities.^''"'
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RPE65 is another model of Leber’s congenital amaurosis. RPE 65 is an RPE-specific 
visual cycle isomerase which is essential for the synthesis of 11-cis-retinal. Dejenka et 
al. performed in utero delivery o f RPE65 in RPE65-/- knockout mice with resulting 
rescue.^^^ By now several groups have treated Swedish Briard dogs which are 
homozygous for an RPE65 null mutation.^^^’ The phenotype in these dogs is
similar to humans with very poor vision from early life and almost absent dark- and 
light adapted electroretinography.
The study of Acland et al.^^  ^was regarded a breakthrough because it was the first case 
in which actual visual function was restored through gene therapy: dogs with a 
genetic defect equivalent to Leber's amaurosis in humans (RPE65-deficiency with 4 
bp deletion resulting in a premature stop codon) recovered already altered vision and 
retinal function in electroretinography (ERG) after a single subretinal injection of 
AAV expressing RPE65 wild type. Four months after injection, electroretinography 
(ERG) of the treated eyes as well as behavioral and visual assessment tests, 
demonstrated that the dog had recovered the ability to avoid objects only on the side 
of the treated eye. This represents the first case of restoring visual function by gene 
therapy. Gene transfer corrected this phenotype and noticeably changed the dogs’ 
behavior for the 3 years these animals were followed.^^^
The first cone-target gene therapy was recently presented in which the authors 
corrected cone-mediated ERG function and restored visual acuity in an animal model 
of achromatopsia with AAV vectors that have an internal red/green cone rhodopsin 
promoter driving a-transducin expression.^®^ Using adeno-associated virus (AAV) 
gene therapy, Alexander et al. further showed that it is possible to rescue visual acuity 
in the Gnat2^ ^^  ^mouse modef^^ of achromatopsia. This study demonstrates the 
feasibility of targeting cones in order to treat many of the most prevalent disorders 
threatening vision in humans.
Henning et al. used a mouse model of mucopolysaccaridosis VII to study AAV- 
mediated gene replacement o f beta-glucuronidase by intravitreal injection.^'^ The 
authors found reduction of partially degraded gycosaminoglycans in RPE cells and 
improved retinographic responses.
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Cleaving of mutant mRNA using ribozymes is an attractive solution for heterozygous 
genetic defects with a pathogenic gene product rather than simple lack of function. 
One rationale that has driven ribozyme use for retinal degenerations is the fact that it 
will be impossible to develop individual gene therapies for the over 100 different 
mutations that have been described for the rhodopsin gene alone in retinitis 
pigmentosa. Gorbatyuk demonstrated that this can be accomplished in combination 
with gene replacement o f a ribozyme-resistant wild-type rhodopsin.^^^ Small 
interfering RNA (RNAi) has revolutionized the field and as a result ribozyme use has 
fallen into disfavor. Paskowitz et al. elegantly show that RNAi mediated knock-down 
can be accomplished with both AAV and HIV vectors in rat RPE and suppress basic 
fibroblast growth factor within a few days after vector injection which remained 
stable throughout the study which concluded at 60 days.^*^ Others have knocked 
down rhodopsin without yet providing wild-type substitution.^Because rhodopsin is 
produced in large amounts and rapidly, it is difficult to knock down entirely. This may 
be an insurmountable obstacle for aggressive dominant mutants such as the rhodopsin 
P23H mutation.^^^
6.3.S.2.2. Retinal and Choroidal Neovascularization
Choroidal and retinal neovascularization is a major cause for visual loss.^^ '^^^  ^In view 
of limited efficacy and significant adverse effects of current treatments^^^’ novel 
strategies are needed. Stable long-term expression of anti-angiogenic proteins from 
gene therapeutic vectors have already produced first promising results with vectors 
expressing vascular endothelial growth factor (VEGF) receptor as a VEGF sink,^^®’ 
angiostatin,^*^ endostatin,^'^^ and pigment epithelium-derived factor (PEDF).^*^’
347,356
Diabetic retinopathy and age-related macular degeneration are two major causes of 
blindness in developed countries and share ocular neovascularization as a central 
feature. Present novel therapy with small molecules requires repeated injection into 
the vitreous. Ocular gene transfer offers the opportunity of sustained and targeted 
delivery of angiostatic molecules preventing potential systemic complications such as 
thromboembolic events.
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Murin oxygen induced retinopathy is a common model of ischemia-induced, VEGF- 
dependent retinal neovascularization. Adenoviral and AAV vectors have been used to 
express soluble fms-like tyrosine kinase (sFlt-1), a VEGF receptor .^After  induction 
of proliferative retinopathy in mice by oxygen exposure, intravitreally injected 
adenoviral vectors resulted in a 56% reduction o f neovascular endothelial cells and a 
52% reduction in AAV injected eyes.
In lieu o f an animal model of AMD, choroidal neovascularization models of laser- 
induced rupture of Bruch’s membrane have been developed. Subretinal delivery of 
AAV vectors expressing sFlt-1 can successfully suppress such neovascularization.^^^ 
Expression of PEDF^"^  ^or angiostatin^^^ can equally successful prevent choroidal 
neovascularization.
Lamartina et al. used helper dependent adenoviral vectors that the authors have 
previously used to express eGFP for up to one year previously to transfer sFlt-1 into a 
rat model of oxygen induced retinopathy.^*^ Retinal neovascularization was inhibited 
by more than 60%. HD-Ad/GFP promoted long-lasting (up to 1 year) transgene 
expression in retinal Müller cells, in marked contrast with the short-term expression 
observed with FG-Ad/GFP.
Comparably fewer studies with lentiviral vectors delivering angiostatic proteins have 
been performed. Most noteworthy is Igarashi et al.’s use of HIV vectors expressing 
angiostatin to reduce neovascularization dramatically by 90%.^^^ EIAV vectors also 
achieved impressive reduction in a laser model of choroidal neovascularization: EIAV 
vectors expressing endostatin resulted in an approximately 60% reduction in 
neovascularization area and angiostatin expressing vectors a 50% reduction.^^** 
Hyperpermeability was also assessed and was reduced by 26% with endostatin versus 
24% with angiostatin.
6.3.S.3. Ocular Malignancies
Uveal melanomas (iris, ciliary body, and choroids) or retinoblastomas constitute 
potential targets for gene therapy that require an entirely different approach. The 
known problems of preferential tumor transduction, tumor penetration and avoidance 
of the delicate adjacent structures in the eye present difficult hurdles. The initial
- 126 -
Introduction: Gene Therapy
optimism that gene therapy for ocular tumors will allow better treatment modalities 
has not materialized. In the contrary, it has become more obvious that classical 
methods of cancer therapy are preferable. For instance, retinoblastomas respond well 
to adjuvantive chemotherapy to shrink a tumor e.g. prior to laser therapy. This allows 
confining damage with excellent manual control in the hand of the treating surgeon. 
Any cytotoxic therapy in the eye can easily be detrimental to neighboring structures. 
Uveal melanomas in contrast can be treated with sutured radioactive plaques that can 
be applied directly above the lesion on the sclera and removed after destruction of the 
tumor.
Kimura et al. was one of the first ones to propose and demonstrate cytotoxic gene 
therapy to proliferating cells in the eye.^^* Originally thought out for proliferative 
vitreoretinopathy, this approach has been adopted to ocular malignancies later on. The 
authors took advantage of the trademark of type C retroviral vectors, selective 
transduction of dividing cells that distinguishes this vector type from others. Because 
type C retroviral vectors require cellular division to obtain access to the genome for 
integration, only the diseased tissue is affected. Rabbit with experimental proliferative 
vitreoretinopathy were transduced with retroviral MLV vectors, expressing the herpes 
simplex virus thymidine kinase (HSV-tk) gene, allowing for the selective killing of 
these cells after ganciclovir exposure. Unfortunately, in vivo transduction efficiency 
was low after intravitreal injection in with a relative transduction efficiency of 
approximately 2%. Despite this, transduction of HSV-tk was associated with a 
powerful bystander effect both in vitro and in vivo with significant effects even when 
HSV-tk-positive cells represented only 1% of the population. In vivo transduction 
followed by GCV significantly inhibited the development of proliferative 
vitreoretinopathy.
Hurwitz et al. popularized the idea of treating retinoblastoma with herpes simplex 
virus thymidine k i n a s e . T h i s  approach can result in efficient tumor ablation and has 
been approved for a phase 1 human clinical trial.^^^ Because present treatment for 
large retinoblastoma are enucleation followed by radiation or chemotherapy (and 
secondary malignancies later in life), search for novel therapies is justified. The 
authors tested the hypothesis that gene therapy can reduce the tumor size sufficiently 
to allow local control by laser or cryo treatment in a murine model o f retinoblastoma. 
Intravitreal injections of retinoblastoma Y79Rb cells in immunodeficient mice create
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an aggressive, metastatic murine model of retinoblastoma. When these murine 
retinoblastomas were transduced in vivo with adenoviral vectors expressing HSV 
thymidine kinase followed by intraocular injection of ganciclovir, 70% showed a 
complete ablation of detectable tumor. Mice had a significantly longer progression- 
free survival compared with controls. A clinical trial was subsequently initiated to 
apply these results to patients with retinoblastoma that demonstrated the safety of 
vector application and remission in one patient.
The same group has now instigated a recently discovered picoma virus, Seneca 
Valley Virus, a conditionally replication competent virus that is not pathogenic to 
normal human cells but causes lysis in human retinoblastoma c e l l s . I n  the above 
mentioned xenograft murine model o f metastatic retinoblastoma was injected with 
10*^  viral particles. Only 1 out of 20 animals showed invasive disease versus 7 out of 
20 in the control group. CNS metastasis was prevented in all animals compared to 4 
metastatic events in the control group. No adverse events were observed.: 18006805
Plasminogen activators are facilitating tumor metastatic by promoting invasion of 
tissue barriers. Uveal melanoma is the most common intraocular malignancy in adults 
and has a mortality o f 50%. Ma et al.^^  ^explored the possibility of preventing the 
metastasis of intraocular melanomas by disrupting plasminogen activator function 
through gene transfer. A replication-deficient adenovirus vector was used for the in 
vivo transfer of plasminogen activator inhibitor type 1 by intraocular injection. The 
authors found transduction of more than 95% of human and murine uveal melanoma 
cells in the eyes of nude mice, a 50% reduction in the number of animals developing 
liver métastasés and a 78% reduction in the metastatic tumor burden in animals that 
eventually developed métastasés. Intravenous injections of this vector resulted in 
transduction of normal liver cells and culminated in a sharp reduction in the incidence 
of métastasés and a significant prolongation of host survival. The effect seen in this 
study is rather dramatic and encouraging. As a significant difference to human 
melanomas, the tumors in this study are very small and high transduction rates can 
more readily be achieved than in the solid tumors of humans.
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7. Materials and Methods
7.1.Materials
The following is a comprehensive list of materials and reagents used in the context of 
this thesis. The next chapter will provide details about their application and use.
7.1.1. Amplification of Plasmid DNA in Bacteria
Bacterial plasmid DNA
Competent E. coli One Shot Top 10 high efficiency kit (Invitrogen, Carlsbad, 
California)
Competent E. coli Subcloning Efficiency Dh5alpha (Invitrogen, Carlsbad, California) 
Waterbath
7.1.2. DNA Analysis
Restriction enzymes (New England Biolabs, Ipswich, MA)
7.1.3. Cloning using Plasmid Vectors
Restriction enzymes (New England Biolabs, Ipswich, MA): cutting of DNA
DNA ligase (New England Biolabs, Ipswich, MA): joining of DNA fragments
T4 Polynucleotide Kinase (New England Biolabs, Ipswich, MA): addition of 5 '- 
phosphates to oligonucleotides to allow subsequent ligation
DNA Polymerase I, Large (Klenow) Fragment (New England Biolabs, Ipswich, MA)
7.1.4. Polymerase Chain Reaction
Taq PCR kit (New England Biolabs, Ipswich, MA)
High Fidelity PCR (Roche Applied Science, Indianapolis, IN)
Primers, custom made by Mayo Clinic Sequencing Core
7.1.5. DNA Sequencing
Primers, custom made by Mayo Clinic Sequencing Core
7.1.6. Cloning of Viral Vectors
Generally, current retroviral vectors systems such as the one used in the context of 
this thesis are replication-defective and tripartite. They consist of: 1. transfer vector, 2. 
packaging plasmid and 3. envelope plasmid. Same molar ratios of 3:3:1 apply but
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might have to be optimized depending on the individual vector system. Components 
of the FIV vectors system are discussed in detail in the chapter “FIV Vectors”.
7.1.6.1. Feline Immunodeficiency Virus (FIV) vectors
1. pMD.G: plasmid encoding VSV-G: 84 pg for CFIO, 16.8 pg (CF2), or 1 pg (T75).
2. Transfer vector. pGiNWF: minimal bi-cistronic FIV transfer vector plasmid coding 
for EGFP and neomycin phosphotransferase neoR, containing WPRE and FIV central 
DNA flap; pCT26: lacZ-encoding second generation FIV plasmid or other FIV 
transfer vector: 252 pg for CFIO, 50.4 pg (CF2), or 3 pg (T75). This vector also has 
the central DNA flap inserted between the end of the gag segment and RRE.
3. pFP93: minimal FIV packaging plasmid coding for structural and enzymatic 
proteins derived from the Gag/Pol precursor (matrix, capsid, nucleocapsid, protease, 
reverse transcriptase, RNase H, integrase, dUTPase) and Rev (regulator o f expression 
of virion proteins): 252 pg for CFIO, 50.4 pg (CF2), or 3 pg (T75).
Ratio of pMD.G/pGiNWF/pFP93 is 1/3/3. DNA used for vector preparation for in 
vivo applications must be sterile and endotoxin free to prevent toxic or inflammatory 
reactions in animals. There are several kits commercially available, EndoFree Plasmid 
Maxi Kit (Qiagen, cat. no. 2362).
7.1.6.2. Murine Leukemia Virus (MLV) beta-galactosidase 
expressing vector LZRNL"*®^
1. 293GP-LZRNL cells (retrovirus packaging cell line 293GP expressing the Moloney 
gag and pol genes"*^  ^and LZRNL provirus (LTR-lacZ-RSV-neoR-LTR)^^^
2. pCMV-G^^^
7.1.6.3. Human Immunodeficiency Virus (HIV) vectors^ "^ ®’
1. pHR9CMVlacZ^^**’^^**
2. pCMVDR8.9^ *^*’^^**
3. pCMV-G*^^
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7.1.6.4. Adenoviral Vector
Ad.CMVlacZ’ ”^ "^
7.1.7. Cell Cultures
7.1.7.1. Cell Cultures
The same culture materials as described in the following were used in all cell cultures 
that were part of this thesis unless otherwise mentioned. Materials and reagents are 
therefore not listed separately. All cell lines can be obtained from the American Type 
Culture Collection (ATCC) unless otherwise noted. Tissue culture techniques were 
performed in a tissue culture hood approved for biosafety level 2 + handling.
7.1.7.2. Cell Cultures for Retroviral Vector Production
1. 293T cells.
2. Adherent fibro-epithelial cell lines for titration: CrFK cells.
3. Dulbecco’s modified Eagle medium with 10% fetal calf serum (DMEM-10), 
penicillin G sodium 100 units/mL, streptomycin sulfate 100 pg/mL and L- 
glutamine 2 mM.
4. Trypsin, tissue culture grade
5. PBS (phosphate-buffered saline), tissue culture grade.
6. Distilled water, sterile.
7. 70% isopropanol or ethanol.
8. 37°C humidified incubators, 5% C02.
9. Nikon Coolpix 990 camera for digital image capture (Nikon, Melville, NY)
10. Nikon Eclipse TE300 microscope (Nikon, Melville, NY)
7.1.7.3. Cell Cultures for Production In Cell Factories
1. Cell Factory with desired number of layers (Nunc Cell Factory, available as 1-layer 
CFl, 2-layer CF2, 10-layer CFIO, and 40-layer CF40).
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2. Cell Factory start-up kit (cat. no. 170769) with the following components: HDPE 
connectors (cat. no. 171838), white Tyvek cover caps (cat. no. 171897), blue sealing 
caps (cat. no. 167652), Gelman 4210 bacterial air vent filter.
3. 2 L Kimax aspirator bottle (Kimble Glass, cat. no. 14607-2000) or similar bottle.
4. Funnels, sterile.
5. Cell strainers (BD Falcon, cat no. 352350)
7.1.7.4. Cell Cultures for Production in T75 Flasks
Appropriate number of T75 tissue culture flasks with gas-permeable cap.
7.1.7.5. Human Ocular Anterior Segment Cultures
Human donor eyes from the local eye bank
Custom made anterior chamber segment perfusion equipment as described by 
Douglas H. Johnson^^* consisting of:
1. Bottom chamber
2. Scleral sealing ring
3. Cover
4. Perfusion tubing
5. Pressure transducer
6. Pressure recording software
7. Microperfusion pump
7.1.8. Transfections
1.2.5MCaC12.
2. 0.01 MTris-HCl, pH 8.0.
3. 2X HBS (HEPES-buffered saline). Stock solution of dibasic Na2HP0 4 : 52.5g 
Na2HP0 4 , 5000 mL H2O. 2X HBS: 80 g NaCl, 65 g N-2-hydroxyethylpiperazine- N- 
2-ethanesulfonic acid (HEPES) (sodium salt), 100 mL Na2HP0 4  stock solution. Bring
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volume to 5000 mL and adjust pH o f 6.95, 7, and 7.05 with 1 N NaOH. Optimal pH 
needs to be determined (see Notes and recipes): pH 6.95, 7.00, or 7.05.
4. Fresh culture media.
7.1.8.1. Cell Factories
1. Sterile plastic bottle (CF2, 250 mL; CFIO, 500 mL).
2. Waste beaker with same volume as culture media in use.
3. Sterile Cell Factory loading bottle with silicon tube and connector.
7.1.8.2. T75 Flasks
1. Clear polystyrene 5-mL tubes (Falcon, cat. no. 352058).
7.1.9. Vector Harvest
7.1.9.1. Cell Factories
1. 500-mL filter units, 0.22-pm pore size
2. Cryo vials
3. -80 C freezer
7.1.9.2. T75 Flasks
1. Small filter unit (50 mL).
2. Cryovials
3. -80 C freezer
7.1.10. Vector Concentration
7.1.10.1. Cell Factories
1. 500-mL filter units, 0.22-pm pore size.
2. 250-mL polyallomer Oak Ridge ultracentrifuge bottles (Sorvall, cat. no. 54477) 
with fluorocarbon caps (Sorvall, cat. no. 54421) for A612 rotor (Sorvall, cat. no 
11997).
3. Scale.
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4. 36-mL disposable polyallomer ultracentrifuge tubes (Sorvall, cat. no. 03141) for 
SureSpin 630 rotor (Sorvall, cat. no. 79367).
5. 1.8-mL screw cap cryo vials, sterile.
6. 0.5- and 1.5-mL microcentrifuge tubes, sterile.
7. PBS, tissue culture grade/suitable for in vivo application.
8. 70% molecular grade ethanol in squeeze bottle.
7.1.10.2. T75 Flasks
1. Scale.
2. 36-mL disposable polyallomer ultracentrifuge tubes (Sorvall, cat. no. 03141) for 
SureSpin 630 rotor (Sorvall, cat. no. 79367).
3. 1.8-mL screw cap cryo vials, sterile.
4. 0.5- and 1.5-mL microcentrifuge tubes, sterile.
5. PBS, tissue culture grade/suitable for in vivo application.
5. 70% molecular grade ethanol in squeeze bottle.
7.1.11. In Vivo Applications
7.1.11.1. Animals
Specific pathogen-free domestic cats (Harlan, Indianapolis, IN)
Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN)
7.1.11.2. Imaging
1. Nikon digital microscopy camera DXM 1200 (Nikon, Melville, NY)
2. Nikon image capture software (Automatic Camera Tamer (ACT-1), Nikon, 
Melville, NY)
3. Custom made cat restrainer as detailed below
4. Zeiss gonioscope to visualize the trabecular meshwork
5. Tiletamine HCl/Zolazepam HCl (Telazol, Fort Dodge Laboratories Inc., Fort 
Dodge, lA)
6. Slit lamp (Haag-Streit, Mason, OH)
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7. Gonioscope (Posner, Ocular Instruments, Bellevue, WA)
8. Microscope (Nikon Eclipse E400)
9. GFP-optimized filter (Nikon, EF-4 B-2E/C FITC, cat. 96107)
7.1.11.3. Pressure recording
Handheld pneumatonometer (Model 30 Classic, Medtronic, Fridley, MN) to 
determine lOP
7.1.11.4. Subretinal Injection in Rats
1. Custom needle (32 ga, 12° bevel, 7 mm length, Hamilton Co., Reno, NV)
2. 5 pi Hamilton microsyringe (Hamilton Co., Reno, NV)
3. Inhalation anesthesia with Metofane® (Schering-Plough Animal Health Corp, 
Union, NJ)
7.2.Methods
7.2.1. Manipulation of Vector Components
7.2.1.1. Cloning using Plasmid Vectors
Molecular cloning is the procedure of isolating a specific DNA sequence and copying 
it with techniques of molecular biology. Cloning is used to amplify a DNA sequence 
in order to change its ends (e.g. by adding restriction enzyme sites) and to link it to 
other DNA. Most the time DNA is amplified in E. coli in circular form as a plasmid 
and therefore needs an origin of replication. For selection of bacteria that contain the 
desired plasmid, an antibiotic resistance gene (e.g. for ampicillin resistance) is needed 
as well.
Cloning of a DNA fragment requires fragmentation with restriction enzymes, ligation 
with ligases (DNA linking enzymes), transformation into bacteria, selection with 
antibiotic resistance for successful transformation and screening with restriction 
enzymes and electrophoresis.
7.2.1.1.1. Creating DNA Fragments
DNA fragments can be created with single or combination of restriction enzymes as 
described above for diagnostic purposes. The difference here is the careful choice o f
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location of the restricted location in order not to destroy an intact feature (e.g. gene, 
promoter, internal ribosomal entry site, etc). This is often followed by gel 
electrophoresis to confirm the digest, to isolate and purify the desired insert.
7.2.1.1.2. Manipulation of Restriction Sites
Restriction sites can be manipulated with several other enzymes that are capable of 
removing 5’ or 3’ single strand overhangs or filling in of single strand overhangs. The 
enzymes below were used for molecular cloning as described in the cloning history.
Exonuclease T (Exo T) (cat. No. M0265S), also known as RNase T, is a single­
stranded DNA or RNA specific nuclease that requires a free 3' terminus and removes 
nucleotides in the 3' ^  5’ direction. Exonuclease T can be used to generate blunt ends 
from a DNA molecule that has a 3' extension.
T7 Exonuclease (cat. No. M0263S) acts in the 5' to 3' direction, catalyzing the 
removal of 5' mononucleotides from duplex DNA. T7 Exonuclease is able to initiate 
nucleotide removal from the 5' termini or at gaps and nicks of double-stranded DNA. 
It will degrade both 5' phosphorylated or 5’ dephosphorylated DNA. It has also been 
reported to degrade RNA and DNA from RNA/DNA hybrids in the 5' to 3' direction 
but is unable to degrade either double-stranded or single-stranded RNA. The protein 
is the product of T7 gene 6.
DNA Polymerase I, Large (Klenow) Fragment (cat. No. M0210S) is a proteolytic 
product of E. coli DNA Polymerase I which retains polymerization and 3 '^  5' 
exonuclease activity, but has lost 5'—> 3' exonuclease activity. Klenow retains the 
polymerization fidelity of the holoenzyme without degrading 5' termini.
7.2.1.1.3. Isolation of DNA Fragments from Agarose Gel
DNA fragments were extracted from agarose gel using the QIAquick Gel Extraction 
Kit (cat. No. 28704) using a microcentrifuge.
DNA fragment were excised from the agarose gel with a clean, sharp scalpel and 
weighed in a microcentrifuge tube. 3 volumes of Buffer QG to 1 volume o f gel (100 
mg ~ 100 pi) were added and incubated at 50°C for 10 min interrupted by frequent 
shaking to facilitated mixing. The QIAquick spin column was placed in a provided 2
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ml collection tube, the sample was applied to the column and centrifuged for 1 
minute. The flow-through was discarded and placed back in the QIAquick column. 
0.75 ml of Buffer PE was added to the QIAquick column and centrifuge for 1 min for 
washing. The flow-through was discarded and the QIAquick column was centrifuged 
for an additional 1 min at 17,900 x g. The QIAquick column was placed into a clean 
1.5 ml microcentrifuge tube, 50 pi of Buffer EB (10 mM Tris Cl, pH 8.5) was added 
to the center of the QIAquick membrane and centrifuged for 1 min to elute DNA.
7.2.1.1.4. DNA ligation
A ligase catalyzes the formation of a phosphodiester bond between juxtaposed 5' 
phosphate and 3’ hydroxyl termini of both blunt ends and cohesive end termini. 
Ligations were performed at room temperature using 1 pi of T4 DNA Ligase (cat. No. 
M0202T) in a 20 pi reaction for 10 minutes for cohesive ends. For blunt ends, 1 pi 
high concentration T4 DNA Ligase was used for 10 minutes (cat. No. M2200S). 
Cloned plasmids were then transformed into bacteria, extracted and analyzed as 
described in the following.
7.2.1.2. Amplification of Plasmid DNA in Bacteria
7.2.1.2.1. Transformation of Competent Bacterial Cells
Bacterial transformation is the uptake of DNA resulting in a stable genetic change. 
This uptake is only able in so called competent cells that are able to uptake exogenous 
DNA. In the laboratory, this competence is referred to as “artificial” because cells are 
made passively permeable to DNA by mechanisms that would not normally occur in 
nature. For plasmid DNA, cells are chilled and incubated with DNA to make the cell 
wall more permeable followed by a brief heat shock that causes the DNA to enter the 
cell. Electroporation would be another way of transformation but this method was not 
applied in this thesis and will not be discussed further.
A plasmid must contain an origin of replication to persist and be stably maintained in 
the cell. A gene coding for antibiotic resistance is also contained to allow selection to 
transformed cells from the abundant non-transformed cells.
For all transformations Invitrogen One Shot Top 10 cells (cat no C4040-6) were used. 
Transformation was started immediately following the thawing of the cells on ice and
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mixed by swirling. Before starting the water bath was warmed to 42°C and both the 
vial of media and the plates were warmed to room temperature. One pi of each 
ligation reaction was added directly into the vial o f competent cells and mixed by 
tapping. The vials were incubated for 30 minutes on ice followed by heat shock at 
42°C in the water bath and placement on ice again. 250 pi of pre-warmed medium 
was added to each vial. The vials were placed on a shaker at 37°C for exactly 1 hour 
at 225 rpm. 20 pi o f bacteria were then spread on a pre-warmed plate and placed 
inverted into an incubator overnight at 37°C. Colonies were picked, grown in 
minipreps and analyzed with restriction digest.
7.2.1.2.2. Amplification and Recovery of Recombinant 
Plasmid DNA
Ten clones from each agar plate were picked with disposable pipette plastic tips and 
dropped into 10 ml disposable media tubes that were filled with 1 ml lysogeny broth 
(LB). The minipreps were incubated on shaking incubators at 37C overnight.
LB media is a nutritionally rich medium that is primarily used for the growth of 
bacteria. It is also known as Luria broth or Luria-Bertani broth. LB media 
formulations have been an industry standard for the cultivation of Escherichia coli as 
far back as the 1950s. These media have been widely used in molecular microbiology 
applications for the preparation of plasmid DNA and recombinant proteins. It 
continues to be one of the most common media used for maintaining and cultivating 
recombinant strains of Escherichia coli. There are several common formulations of 
LB. Although they are different, they generally share a somewhat similar composition 
of ingredients used to promote growth, including peptides and casein peptones, 
vitamins, trace elements (e.g. nitrogen, sulfur, magnesium) and minerals. Peptides and 
peptones are provided by tryptone. Vitamins and certain trace elements are provided 
by yeast extract. Sodium ions for transport and osmotic balance are provided by 
sodium chloride. Bacto-tryptone is used to provide essential amino acids to the 
growing bacteria, while the bacto-yeast extract is used to provide a plethora of organic 
compounds helpful for bacterial growth.
For 1 liter o f LB lOg tryptone, 5g yeast extract and lOg NaCl were mixed and 
suspended in 800 ml of distilled water. Further water was added to make for a total of
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1 liter. The mix was autoclaved at 121°C and stored at 4°C. Immediately prior to use 
ampicillin was added to 100 mg/ml to allow selection of plasmids.
For miniprep cultures, 1 ml of LB media with ampicillin was used to grow picked 
clones overnight while for maxiprep cultures 150 ml or more was grown once the 
proper clone was confirmed. Cultures were incubated at 37C overnight.
To extract plasmid DNA from miniprep picked clones, DNA was isolated using a 
Miniprep kit (QIAprep Spin Miniprep Kit, Cat. No. 27104; Qiagen, Hilden, Germany) 
and a microcentrifuge.
This protocol was designed for purification of up to 20 pg of high-copy plasmid DNA 
from 1 ml overnight cultures of E. coli in LB medium. The bacterial cells were 
harvested by centrifugation at 6800 x g in a conventional table-top microcentrifuge 
for 3 min at room temperature in microcentrifuge tubes. Bacterial pellets were 
resuspended in 250 pi Buffer PI and transferred to a microcentrifuge tube. RNase A 
had been added to Buffer PI. No cell clumps were visible after re-suspension of the 
pellet. Bacteria were resuspended completely by pipetting up and down until no cell 
clumps remained. 250 pi Buffer P2 was added and mixed thoroughly by inverting the 
tube 4-6 times. The lysis reaction was not allowed proceed for more than 5 min. 350 
pi Buffer N3 was added and mixed immediately and thoroughly by inverting the tube 
4-6 times. Tubes were centrifuged for 10 min at 17,900 x g in a table-top 
microcentrifuge and a white pellet formed. The supernatants from were applied to the 
QIAprep spin columns by pipetting and centrifuged for 30-60 s, the flow-through was 
discarded. QIAprep spin columns were washed by adding 0.75 ml Buffer PE and 
centrifuged for 30-60 s. The flow-through was discarded and centrifugation was 
continued for an additional 1 min to remove residual wash buffer. The QIAprep 
column was placed in a clean 1.5 ml microcentrifuge tube. To elute DNA, 50 pi 
Buffer EB (10 mM TrisCl, pH 8.5) was added, let stand for 1 min, and centrifuged for 
1 min.
7.2.1.2.3. Quantification of Nucleic Acid
Because DNA and RNA absorb ultraviolet light with an absorption peak at 260 nm, a 
UV spectrophotometer could be used to calculate DNA concentration using the Beer 
Lambert Law. DNA was diluted in water at a ratio of 1:10 or above till reliable
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readouts were obtained. DNA purity was estimated using the absorption ratio at 
260:280 nm and only samples with 90% purity or above were accepted.
7.2.1.3. DNA Analysis
7.2.1.3.1. Restriction Enzyme Digestion of Plasmid DNA
Restriction enzyme digests were used to analyze DNA. This technique uses restriction 
enzymes that are capable of cutting DNA into shorter fragments that can be visualized 
in gel electrophoresis. A restriction enzyme cuts DNA segments with a highly specific 
nucleotide recognition sequence that typically consists of six, to twelve nucleotides. 
Because of the limited number by which these sequences can occur along a DNA the 
distance at which a cut occurs is very characteristic for a DNA of interest. The same 
technique was used not only to identify correct orientation of inserts in vector 
plasmids used in this thesis but also for cloning as DNA fragments with 
corresponding cut sequences can be ligated back together. The enzymes used in this 
thesis are listed in the FIV cloning history. DNA was analyzed by digesting with 
commercially available restriction enzymes. All restriction enzyme digests used in 
this thesis were from New England Biolabs (New England Biolabs, Ipswich, MA) and 
followed the New England Biolabs protocols. A restriction digest was performed 
using 1 microliter of enzyme solution at 37C for 1-2 hours in a volume of 10 to 20 
microliter. Solutions that allow restriction to occur consist of the plasmid DNA, an 
enzyme optimized buffer that allows the reaction to occur, the restriction enzyme and 
water to bring the reaction volume to 10 microliter.
7.2.1.3.2. Gel Electrophoresis of DNA
Agarose gel electrophoresis is a method to separate DNA. Nucleic acid is negatively 
charged and migrates at different speed based on molecule size through the agarose 
gel grid following an electric field towards the (positively charged) cathode. Shorter 
molecules move faster and migrate farther than longer ones. Increasing the agarose 
concentration of a gel reduces the migration speed and enables separation of smaller 
DNA molecules. Migration speed increased with increasing voltage but resolution 
might suffer. In order to visualize the DNA gels are stained with ethidium bromide 
which fluoresces under UV light when intercalated with DNA. As ethidium bromide 
is a carcinogen it has to be handled carefully.
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7.2.1.4. Polymerase Chain Reaction
Polymerase chain reaction (PCR) is used to amplify a specific region of a DNA 
strand. The PCR applications in this thesis employed a heat-stable DNA polymerase 
from Thermus aquaticus, Taq polymerase. This DNA polymerase enzymatically 
assembles a new DNA strand from nucleotides, using single-stranded DNA as the 
template and DNA primers required for initiation of synthesis. This is achieved by 
thermal cycling to a defined series o f temperature steps. The selectivity of a PCR is 
primarily due to highly complementary primers to the DNA region targeted for 
amplification and to the thermal cycling conditions.
Any PCR requires a DNA template that contains the DNA region to be amplified, one 
or more primers, which are complementary to the 5’ and 3' ends of the DNA region, a 
polymerase with a temperature optimum around 70°C, deoxynucleoside triphosphates 
(dNTPs), a buffer solution, magnesium and monovalent cation potassium ions.
The PCR protocol typically 20 to 35 repeated temperature cycles with 2-3 discrete 
temperature steps each. The cycling is preceded by a single temperature step at a high 
temperature to meld DNA at above 90°C. Temperature and the length of time depend 
on the enzyme used and the melting temperature of the primers.
In the initialization step the reaction is heated to 94°C and held for about 5 minutes 
for a so called hot-start. The dénaturation step is the first regular cycling event that 
consists of heating to 94C for 20-30 seconds resulting in DNA template and primer 
melting by disrupting hydrogen bonds between complementary bases and yields 
single strands of DNA. During the subsequent annealing the temperature is lowered to 
50-65°C for 20-40 seconds allowing annealing of the primers to the single-stranded 
DNA template. Typically the annealing temperature is about 3-5 degrees Celsius 
below the Tm of the primers used. The polymerase binds to the primer-template 
hybrid and begins DNA synthesis. In the extension phase the temperature is increased 
to the optimum activity temperature of about 72C for Taq. At this step the DNA 
polymerase synthesizes a new DNA strand complementary to the DNA template 
strand by adding dNTPs that are complementary to the template in 5' to 3' direction, 
condensing the 5'-phosphate group of the dNTPs with the 3'-hydroxyl group at the end 
of the nascent (extending) DNA strand. The extension time depends both on the DNA
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polymerase used and on the length of the DNA fragment to be amplified (typically 
1000 bases/minute). Because the amount of DNA target is doubled each cycle the 
amplification is exponential. During final elongation at 70-74°C for 5-15 minutes, the 
remaining single-stranded DNA is ftilly extended. Usually a final hold at 4C is added 
after this for short-term storage.
7.2.1.5. DNA Sequencing
DNA sequencing is the process of determining the nucleotide order o f a given DNA 
fragment. The classical technique developed by Frederick Sanger uses sequence- 
specific termination of a DNA synthesis reaction using modified nucleotide 
substrates. Sequencing is initiated at a specific site on the template DNA by using a 
short oligonucleotide 'primer' complementary to the template at that region and 
extended using a DNA polymerase. The sequencing reaction contains the four 
deoxynucleoside bases in addition to the primer and DNA polymerase, along with a 
low concentration o f a chain terminating nucleotide. Limited incorporation of the 
chain terminating nucleotide by the DNA polymerase results in a series of related 
DNA fragments that are terminated only at positions where that particular nucleotide 
is used. The fi-agments are then size-separated by electrophoresis in a slab 
polyacrylamide gel or in a glass capillary filled with a viscous polymer. The primers 
used for sequencing of FIV vectors are described in the cloning history where 
appropriate.
7.2.1.6. FIV Vector Components
7.2.1.6.1. Glossary of Lentiviral Vector Components
The LTR (Long Terminal Repeat) comprises U3-R-U5 (5'to 3') and measures 300 to 
1800 base pairs composed. LTRs are located at both ends of the unintegrated and 
integrated proviral linear DNA. The LTRs are also found in closed circular forms of 
retroviral DNA that can contain one or two LTRs.
R (Repeat) is a nucleotide sequence at both ends genomic RNA that measures only 15 
to 250 nucleotides. The boundaries are defined by the RNA transcription initiation 
and polyadenylation (AAUAAA). R is present in both LTRs between U3 and US. In 
HIV, R is the binding site for the transactivator Tat.
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U5 (Unique 5') is located between R  and the primer binding site, PBS. In the viral 
RNA genome it is only present once but in the in integrated provirus also copied to 
the 3' end as part of the LTR.
PBS (Primer-binding Site) is a very short sequence that usually starts with 5'TGG 
and measures 18 nucleotides. PBS binds tRNA and initiates reverse transcription. It 
therefore has to be specific to the host tRNA.
gag is one of the retroviral genes that are found in all retroviruses. It encodes the 
group specific antigen. Gag that is subsequently cleaved into matrix (MA), capsid 
(CA) and nucleocapsid (NC) that form the virus core.
The polyprotein pro  is cleaved from Gag-Pro-Pol into a protease (PR) and dUTPase 
(DU).
pol codes for reverse transcriptase (RT) and integrase (IN).
env encodes for an envelope precursor protein that is further processed to surface 
(SU) and transmembrane (TM) structural proteins.
The SD (Splice Donor Site) is a site where an upstream 5’ RNA is joined to the splice 
acceptor (SA) 3' RNA.
RRE (Rev Response Element) is a binding site for the Rev protein to aid the export of 
unspliced RNA fi*om the nucleus.
The PPT (Polypurine Tract) is a purine-rich sequence of 7-18 nucleotides 
immediately upstream of U3 that is cleaved during reverse transcription to produce 
the RNA primer for synthesis o f the plus (+) strand of viral DNA. Lentiviruses use an 
additional central polypurine tract to form a three dimensional structure that 
participates in nuclear import and facilitates transduction of non-dividing cells.
U3 (Unique 3 )  is a sequence of -190 to 1200 nucleotides that are positioned between 
PPT and R near the 3 'end of viral RNA and is present once in viral genome RNA but 
twice in viral DNA as part of the LTR. U3 contains promoter-enhancer sequences that 
control viral RNA transcription from the 5'LTR.
Poly (A) Tract is consists of 50-200 adenylic acid residues following the R sequence 
at the 3 'end of the viral RNA. It is added posttranscriptionally and not encoded in the 
viral genome. A signal for polyadenylation (AAUAAA) is generally present about 
15-20 nucleotides upstream (5') o f the site of polyadenylation within R.
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The IR (Inverted Repeat or att site) are short sequences of 3 to 25 bp that form 
inverted repeats at the ends of the LTR providing recognition sites for the integrase.
CMV (cytomegalovirus) immediate early promoter is a strong promoter with a broad 
host range that functions in most eukaryotic cells.
1RES (internal ribosome entry site) allows for cap independent translation initiation 
in the middle o f an mRNA. In vectors this allows for expression of two proteins (cap- 
mediated and 1RES mediated) from the same transcript.
VSV-G (vesicular stomatitis virus G protein) is one of five major proteins of VSV, a 
member of the vesiculovirus genera of the rhabdovirus family. It enables viral entry 
by mediating attachment and fusion of the viral envelope with the endosomal 
membrane after endocytosis. It provides broad tropism and has sufficient stability to 
survive ultracentrifugation.
WPRE (woodchuck hepatitis virus posttranscription regulatory element) enhances 
transcription through an unknown mechanism
7.2.1.6.2. FIV Packaging Constructs
The first packaging construct, CFlAenv,* was cloned hy Eric M. Poeschla in whose 
laboratory I conducted my studies. It was made by blunting the AcI-BlpI fragment 
containing most of the viral genome into the polylinker of a human cytomegalovirus 
immediate early gene promoter expression plasmid and then deleting a 0.9 kb 
fragment of the env gene (Figure 12, Top and Middle). Roman Barraza further 
reduced significant overlap with cis-acting transfer vector sequences in CFlAenv, the 
5’ LTR (U3, R, and U5 elements) by additionally deleting 154 nt o f the FIV leader 
upstream of Sad, leaving 119 nt of leader upstream of gag including the interval 
between the major splice donor and gag. Viral sequences terminated 37 nt 
downstream of the second exon of Rev and most of U3 (all of R and U5 are missing) 
at the 3’ end, the dispensable vif gene is intact. During a series of modifications, 
Roman Barraza deleted cis-acting sequences and unneeded viral coding sequences 
while preserving Gag/Pol expression. In contrast to CFlAenv, the resulting construct, 
pFP93, lacks all viral leader sequences, as well as vif, and contains less residual env 
sequence (Figure 12, Bottom). At the 3’ end, viral sequences terminate with the stop 
codon of Rev.
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Figure 12: Genomic structure of FIV and derivative packaging constructs. Top: 
Genome of FIV34TF10. LTR is long terminal repeat; U3, 3'-unique region of LTR; 
U5, 5'-unique region of LTR; R, repeat element of LTR; SD, major splice donor; Gag, 
group antigen (encodes structural components of virion core particle); Pol encodes a 
polyprotein that is cleaved by the viral protease into the five enzymatic activities: 
reverse transcriptase, integrase, RNAse H, protease, and dUTPase; Vif, virion 
infectivity factor; SU, surface envelope glycoprotein; TM, transmembrane portion of 
the envelope glycoprotein; RRE, rev response element. Grf2 is open reading frame 2. 
The OrfZ gene product may have LTR transactivating activity similar to HIV-1 Tat. 
However, 0RF2 is not expressed by FIV 34TF10 because of the illustrated premature 
stop codon, and in any case, the vector system dispenses with the promoter activity of 
the FIV U3 element entirely by using a CMV promoter substitution and fusion at the 
TATA box (explained below). Middle: First generation packaging construct 
pCFldeltaewv. Bottom: Second generation packaging construct pFP93. Note deletions 
of vif, Orfl, additional env sequences, and removal of all viral sequences upstream of 
gag. Deletions of vif  and orf 2 are attenuating to FIV in vivo.
7.2.1.6.2.1. Deletion of Leader Sequence and 
Nonstructural Genes
Roman Barraza replaced all FIV sequences upstream of the gag gene with a 9 nt
canonical splice donor sequence. Vif, additional env, and U3 sequences were also
removed. Splice donor and acceptor sites were selectively inserted between pol and
rev to permit splicing.
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7.2.1.6.2.2. Packaging Signal Exclusion
Iris Rentier mapped encapsidation (packaging) determinants in FIV genomic mRNA 
using RNAse protection/^^ Her data demonstrated that the packaging constructs 
lacked the necessary encapsidation determinants.
7.2.1.6.2.3. Development of Class I Integrase Mutants 
for Control Vectors
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Figure 13: Class I FIV integrase mutations. The three universally conserved amino 
acids (D64, D116, and E l 52) that are required for fonction of the integrase catalytic 
center are illustrated. The aspartic acid (D) at position 64 was mutated to valine (V) 
by site-directed mutagenesis. Subsequently, addition of a second mutation (D116A) 
has been shown to preserve class I properties.
To establish that transgene expression in vivo oecurs from integrated vector DNA and 
to provide a control for pseudotransduction, I constructed a single amino acid mutant 
of FIV integrase (D64V, Figure 13). Pseudotransduction is false-positive transduction 
caused by carryover of preformed protein present in the vector preparation. This 
source of artifactual transduction needs to be considered in all lentiviral vector 
experiments. 293T cells cotransfected with VSV-G, a vesiculating protein, can release 
large amounts of preformed marker gene protein into the supernatant. Generally this 
results in a mottled, nonuniform appearance of the target cell, but this distinction is 
not always reliable, and in vivo in tissues it can be hard to distinguish from genuine 
de novo synthesis. Although enhanced green fluoreseent protein (EGFP) can 
occasionally produce this problem, P-galactosidase (laeZ) is more likely to confound. 
Two controls for pseudotransduction can be used. First, the packaging plasmid can be 
omitted during vector production (transfer vector and VSV-G are transfected). This 
“mock” vector should be processed in parallel with the real vector. The second, more 
elegant, control is a class I integrase mutant packaging plasmid.
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The aspartic acid residue at position 64 is required for integrase catalytic activity that 
consists of DNA cleaving and joining. It is a universally conserved participant in the 
catalytic center of retroviral integrases.^^^ I performed site-directed mutagenesis of 
FIV integrase in three steps to create a D64V-requivalent (amino acid D66V (aspartic 
acid to valine) in FIV), selectively integration deficient FIV vector as a control for 
experiments. This allowed generating control vectors that only became available at 
the end of the present thesis. Other controls were used in prior experiments. A 1.8 kbp 
integrase fragment of FIV pol was generated by PCR using FIV packaging plasmid 
CFlAenv,* as the template using sense primer 5’-
ATATACTAGTTCTAGAGAAGCCTGGGAATC-3’ and antisense primer 5’- 
ATATGAATTCTCCGGAGGTAGCCTAG-3 ’. The restriction sites EcoRI and Spel 
introduced by these primers were then used to subclone the integrase fragment into 
pCI (Promega, Madison, WI). The GAT encoding aspartic acid at position 66 of the 
integrase was changed to GTA (valine) by mutagenesis (QuikChange, Stratagene, La 
Jolla, CA) with sense primer 5’-
GCCTGGTATCTGGCAAATGGTATGCACACACTTTGATGGC-3’ and antisense 
primer 5 ’-GCCATCAAAGTGTGTGCATACCATTTGCCAGATACCAGGC-3 ’. The 
mutation, and lack of introduction of inadvertent second-site mutations in the insert, 
was confirmed by sequencing. Finally, the fragment was excised with internal BspEl 
and Bsu36I sites and ligated between BspEl and Bsu36I in CFlAenv to form 
packaging plasmid CFlAenv.D66V. RT activity was determined in triplicate for both 
CT25 and the integrase mutant CT25.D66V.^^ Experiments were conducted with 
equal RT units of each vector. The measurements or RT activity were carried out by 
Dyana T. Saenz and M ary Peretz.
7.2.1.6.3. FIV T ransfer Vectors
Eric Poeschla found in his first studies o f FIV vectors that fusion of the hCMV 
promoter to the R repeat permitted high-level expression of FIV proteins and 
production of infectious virus in human cells. *’^^ * This hybrid LTR is the basis of all 
other transfer vectors that I will describe in the following.
- 147 -
Materials and Methods
7.2.1.6.3.1. Minimal Packaging Signal Inclusion
Complementary to the packaging construct changes, only 311 nt of the 1353 bp of gag 
were included in the transfer vector to reduce potential recombination with the 
packaging plasmid. I minimized gag by following analogy to other lentiviral vectors 
and found them to be fully functional in preliminary transduction experiments. Iris 
Kemler subsequently investigated encapsidation requirements of FIV and established 
that a smaller gag fragment enhanced encapsidation compared to the original 
vector.^^^
7.2.1.6.3.2. Central DNA Flap
Todd Whitwam demonstrated that the FIV central polypurine tract (cPPT) and central 
termination sequence (C IS) act as cis-acting elements"*^  ^as seen in other lentiviruses 
to enhance transduction of non-dividing cells or progenitor c e l l s . T h i s  feature has 
only a relatively small impact on FIV vector performance however its presence 
suggests some evolutionary advantage and was maintained in FIV vectors since its 
discovery to match other current lentiviral vectors systems. Todd Whitwam has to be 
acknowledged for integrating the cPPT and CTS into FIV vectors that I later used in 
my studies.
Todd Whitwam inserted the central polypurine tract (cPPT) into pCT26 by PCR 
amplifying the cPPT-CTS from FIV 34 TflO with sense primer 5’- 
aaaaCCTTCAAGAGGctgcagaaacaacctccttggataatgcc- 3’ and antisense primer 5’- 
atataCCTTCAAGAGGtctagactctccttatgtgtctcctagg-3’. The cPPT-CTS combination is 
also referred to as the central DNA flap, because the strand initiations and 
terminations that occur at these loci result in a triple stranded DNA flap structure at 
the completion of FIV reverse transcription. The amplicon was blunted into the EcoNI 
site of pCT25 downstream of the RRE. CT26 therefore contains, from 5’ to 3’, the 
hybrid promoter, R repeat, U5, leader, 311 bp of gag, RRE, central DNA flap, human 
CMV immediate early promoter lacZ, and 3’ LTR.
7.2.1.6.3.3. Woodchuck Hepatitis Virus
Posttranscriptional Regulatory Element (WPRE)
The woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is an
RNA transport element that enhances transgene expression^^^’ I inserted it
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upstream of the polypurine tract at the 3’-LTR by sticky-end cloning into a single 
Clal site using the WPRE flanking Clal sites. WPRE was derived from plasmid 
pCLNTluc-W^^"^ which contained WPRE flanked by two Clal sites of plasmid 
pCLNCX after substituting a BamHl-Hin&Wl thymidine kinase (TK)-luciferase
cassette for the CMV promoter.^^^
7.2.1.6.3.4. Plasmid Construction of eGFP and p- 
gaiactosidase FIV Transfer Vectors
P-galactosidase expressing contains, in series from 59 to 39, the hybrid U3-
substituted promoter of pCT5;* the FIV R repeat, US element, and leader sequence;
the first 311 bp of the gag open reading frame (ORF); the Rev response element; an
internal cytomegalovirus (CMV)-lacZ cassette; and the 39 long terminal repeat
(LTR).
pCT25, a lacZ transfer vector, was parental to a sequentially constructed series of 
eGFP-containing plasmids eventuating inpGiNWF: pGiN (also called 
CT25.eGFP.ires.neo), pGiNW, pGiNWcPPT-CTS, and pGiNWF. To first construct 
pGiN, peGFP-1 (BDE Biosciences-Clontech, Palo Alto, CA) was cleaved with Notl, 
blunted with Klenow fragment, and then cleaved with BamHI. The resultant 0.74-kb 
fragment was inserted into an MLV retroviral vector between BamHI and Hpal, 
yielding the EcoRI-containing sequence GCGGCCAACGAATTC at the 3’- junction. 
This eGFP insert was then excised with BamHI and EcoRI and inserted into the 
BamHI-EcoRI-cleaved backbone of pCT25, thus replacing lacZ and generating 
pCT25.eGFP.
A 1.49-kb Sal-Nhe fragment containing the internal ribosome entry site and neoR 
gene from pJZ30814 was then inserted by blunt-end ligation into the EcoRI site of 
pCT25.eGFP, generatingpG iN  (pCT25.egfp. ires.neo).
pGinW  was constructed by inserting the WPRE by blunt insertion of an EcoRV-XhoI 
fragment of pBluescriptllSK’WPRE-Bl 112 into the BspEI site of pGiN (yielding a 
regenerated BspEI site that is blocked by dam méthylation). Finally, the central DNA 
flap was inserted in several steps as follows. A 279-nt amplicon containing the FIV 
cPPT-CTS was synthesized by PCR, by using a sense primer tailed with a BstBI site 
(5’-
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ATATTTCGAATCAAATCAAACTAATAAAGTATGTATTGTGAAACAACCTC 
CTTGGATAATGCC- 3’) and an antisense primer tailed with an Xba site (5’- 
ATATACCTCTTTTAGGTCTAGACTCTCATGTGTCTCCTAGG- 3’). The sense 
primer fuses the cPPT with the 3’ end of the FIV RRE and deletes an unneeded splice 
acceptor. This BstBI-Xba amplicon was inserted into the corresponding sites of 
pGiNW, generating pGiNWcPPT-CTS. The latter maneuver removed the internal 
CMV promoter from pGinW and inserted the cPPT-CTS. To restore this promoter, 
the BamHI-XhoI fragment of pGiNW was inserted into the XhoI-BamHI backbone of 
pCR2.1 (Invitrogen, San Diego, CA). An Xbal linker (GCTCTAGAGC) was inserted 
into the Klenow-treated Aflll site of this intermediate plasmid, and the 614-nt Xbal- 
Xbal fragment was then inserted into the Xba site of pGiNWcPPT-CTS, generating 
pGiNWF. GiNWF contains, from 5’ to 3’, a hybrid U3-substituted promoter derived 
from pCT5,^ the FIV R repeat, U5 element, leader sequence, the first 311-bp of the 
gag gene, the Rev response element (RRE, nucleotides 8537-8952 of the FIV 34TF10 
genome), a sequence (FIV nt 4904-5191) containing the FIV central polypurine tract 
(cPPT), and the central termination sequence (CTS), the CMVp, eGFP, an internal 
ribosomal entry site (1RES) neoR, the woodchuck hepatitis virus posttranscriptional 
regulatory element (WPRE), 12 and the 3’ long terminal repeat (LTR).
7.2.1.6.3.5. Bi-cistronic Vectors Utilizing an Internal 
Ribosomal Entry Site (1RES)
proximal gag fragment
HCMVp R u s  b zz f  iRRElrLAplhCMVpl gene 1 I 1RES I gene 2 IWRREI U3 R US
I f f  t
tRNA cPPT CTS PPT
PBS
Figure 14: Second-generation bicistronic transfer vector. The central DNA flap 
and WPRE^^^ have been inserted, and gag has been reduced to 311 nt.
492
I created a bi-cistronic expression cassette was created that contains an internal 
ribosomal entry site (1RES), a picomavirus element that mediates cap-independent 
translation (Figure 14). The choice of transgene position influences the expression 
level achievable and is typically between 10 to 20-fold lower from the second position 
than from the first position when a standard ECMV 1RES is used.^^^
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Self-Inactivating FiV Vector
P|= P ° - ,
HIV 1 genome
5 LTR
3’^LTR USF
US
N F-AT7 T C F -iO .
sin HIV-1 vector \  , ‘ > \  ,
I R   S i l - - - 1 I R  I - . . . H I
Figure 15: HIV vector with self-inactivating (SIN) LTR modification (after ref. ^^ )^.
In parallel to HIV v e c t o r s , I  constructed a new series of FIV SIN vectors by 
deleting 172 bp in the U3 region of the 3' LTR, including the TATA box and binding 
sites for transcription factors (NFkB, NF-ATc, SPl) (Figure 15). Self-inactivating 
(SIN) lentiviral vectors improve significantly the biosafety by reducing the likelihood 
that replication competent retroviruses will originate in the vector producer and target 
cells. Although FIV LTR promoter function is minimal in non-feline cells, any 
residual promoter activity from either 5'- or 3'-LTR should be avoided. While 3'-LTR 
promoter activity could lead to expression of open reading frames downstream of the 
insertion site, 5'-LTR promoter activity may generate antigenic peptides from Agag. 
The U3 deletion o f the 3'-LTR SIN design is copied to the 5'-LTR during reverse 
transcription and inactivates both LTRs of the integrated vector (Figure 7).
pFSIN-MCS, a minimal FIV SIN vector with a large multiple cloning site and only 
230 bp of gag was generated as follows: pGINWF served as the template to delete 
171 bp of the 3'-U3 by overlapping primer extension. A first PCRs amplified the 
WPRE and the most 5' part of the 3'-U3 (first PCR sense primer: 5'- 
tatatctagatccggatcaagcttatcg-3 ' and antisense primer 5'-
CACTGGTTAGCTAGCTTCAGGGTTCCAATACTCATCCC-3') and a second PCR 
amplified the most 3' part of the 3'-U3, R, and U5 (second PCR sense primer 5'- 
ccctgaagctagcgtgctttgtgaaacttcgaggagt-3' and antisense primer 5'- 
TATAAAGCTCTCGACGC-3'; bold = overlap). PCR products were then combined 
and amplified with the most 5’ and 3’ primer to complete the deletion by fusion in a 
third PCR. The final product was digested with Xbal and Notl and cloned into 
pGINWF-G230 (pGINWF with only 230bp gag) to form FSIN. A directly synthesized
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multiple cloning site (MCS) of 90 bp length with 19 unique restriction sites was then 
inserted into the Xbal and Bspel sites o f pFSIN generating pFSIN-MCS. The eGFP 
cassette of pGINWF was subsequently cloned into this vector and used for studies in 
cats.
7.2.1.6.4. Retroviral Transfer Vectors for Outflow Tract and 
Retinal Experiments
Two lentiviral vectors (FIV based and HIV-1 based), an MuLV vector (LZRNL),"^^^
and an adenoviral vector "^^  ^were evaluated. Vesicular stomatitis virus glycoprotein G
(VSV-G) pseudotypes for FIV, HIV, and MuLV lacZ vectors were prepared by
transient plasmid transfection as previously described.^’ Plasmids used to generate
FIV vectors were a minimal transfer vector (pCT25), packaging construct
pCFlAenv,* and a VSV-G expression construct, pCMV-G."^^^ pCT25 contains, in
series from 59 to 39, the hybrid U3-substituted promoter of pCT5^; the FIV R repeat,
U5 element, and leader sequence; the first 311 bp of the gag open reading frame
(ORF); the Rev response element; an internal cytomegalovirus (CMV)-lacZ cassette;
and the 39 long terminal repeat (LTR). HIV-1 vectors were generated with
pHR9CMVlacZ and pCMVDR8.9^'^^’ plus pCMV-G. Adenovirus lacZ vector
(Ad.CMVLacZ) was prepared as described.^"^*
All retroviral vectors were filtered through a 0.45-mm pore size filter, concentrated by 
ultracentrifugation, resuspended, centrifuged at low speed to remove particulates, and 
titered on CrFK cells. For transduction of cultured human eyes, high-titer stocks 
of each of the lacZ-encoding vectors were generated and adjusted to 1 x 10  ^CrFK- 
transducing units (TU)/ml. As a control for pseudotransduction, a mock FIV vector 
was prepared by transient transfection into 293T cells of the same amounts of pCT25 
DNA and pCMV-G DNA used for generation of transducing vector, while omitting 
the packaging plasmid. Plasmid transfection efficiency was evaluated by 5-bromo-4- 
chloro-3-indolyl-P-D-galactopyranoside (X-Gal) staining and was greater than 80% 
for the transfected 293T producer cells for both mock and packaged CT25 vectors. 
39-Azido-29,39-dideoxythymidine (AZT, 50 mM; Sigma, St. Louis, MO) was used as 
an additional control for pseudotransduction in both cultured cells and perfused eyes. 
Reverse transcriptase measurements with a ^^P based assay were performed as 
previously described.^ Before normalization to 10  ^TU/ml, vector titers were 4.6 x 10^
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TU/ml for FIV, 1.2 x 10* TU/ml for HIV, 2.4 x 10* TU/ml for MuLV, and 1.1 x lO"
TU/ml for Ad.CMVlacZ.
7.2.1.6.5. History of Beta-Galactosidase Expressing 
Murine Leukemia Viral Vector LZRNL
The murine leukemia viral (MLV) vector LZRNL was a vector plasmid stably
transfected into MLV packaging cell line 293GP forming the cell line 293GP-
LZRNL"^^  ^and was generously provided hy J. C. Burns. 293GP-LZRNL cells express
the Moloney gag and pal genes as well as the LZRNL MLV provirus and only need to
be transfected with an envelope plasmid. The vesicular stomatitis G protein was used
in my experiments for this purpose. The MLV pro virus contains from 5’ to 3’ the
MLV LTR driving lacZ (beta-galactosidase) and further RSV-neoR-LTR.^^^
7.2.1.6.6. Cloning of Human Immunodeficiency Viral 
Vectors
Human immunodeficiency viral vector plasmid pHR9CMVlacZ and HIV packaging 
plasmid PCMVDR8.9 was a generous gift by Luigi Naldini. PHR9CMVlacZ 
contains a beta-galactosidase expressing cassette driven by a CMV promoter. 
Packaging plasmid pCMVDR8.9 contains HIV gag and pol genes under control of a 
CMV promoter.^'"''
7.2.1.6.7. History of Adenoviral Vector
The adenoviral vector used in this thesis was a generous gift by Robert D. Simari at 
the Mayo Clinic. It expressed P-galactosidase directed by the same human 
cytomegalovirus immediate-early promoter/enhancer^"^^’ as the FIV vector used 
here. This adenoviral vector (Ad.CMVlacZ)^^^'^^^ was derived from adenovirus-5 
serotype and contains deletions in regions E l a spanning 1.0 to 9.2 map units and E3 
spanning 78.4 to 86 map units, rendering it replication-deficient. The CMV-lacZ 
cassette was inserted into the E l deletion of Ad.ElA that was parental to 
Ad.CMVlacZ.^^^ Ad.CMVlacZ was a kind gift of J. Wilson^^^’ to R. Simari and Z. 
Katusic.^ ^^
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7.2.2. Cell Cultures
7.2.2.1.1. Cell Lines
7.2.2.1.1.1. 293T Cells
293T cells were readily available in the laboratory where the studies were conducted. 
293T cells are a highly transfectable derivative o f the 293 cell line (also known as 
HEK or human embryonic kidney 293 cells) into which the temperature sensitive 
gene for SV40 T-antigen had been inserted. Because these cells are so easily 
transfectable, they are the standard cell line for retroviral vector production when 
transient transfection is used (as opposed to inducible producer cell lines).
Historically, HEK 293 cells were generated by transformation of cultures o f normal 
human embryonic kidney cells with sheared adenovirus 5 DNA in the laboratory of 
Alex Van der Eb in Leiden, Holland in the early 70s. The human embryonic kidney 
cells were obtained from a healthy aborted fetus and originally cultured by Van der 
Eb himself, and the transformation by adenovirus was performed by Frank Graham 
who published his findings in the late 1970s."^ ^  ^The number 293 indicates the 
investigator’s 293rd experiment. Subsequent analysis showed that the transformation 
was brought about by an insert consisting of 4.5 kb from the adenoviral genome, 
which became incorporated into human chromosome 19.^ "^ "^  For many years it was 
assumed that HEK 293 cells were generated by transformation of either a renal 
fibroblastic, endothelial or epithelial cell. Recently, Shaw et al. demonstrated that 
HEK 293 cells have properties of immature neurons rather than epithelial 
properties.^"^^
On Day -1 of a respective experiment 3x10^  293T cells per T75 flask, 5 x 10  ^o f the 
above 293T cells into a CF2s or 2.5 x 10  ^per CFIO. The detailed transfection 
protocol is discussed below.
7.2.2.1.1.2. CRFK Cells
The CRFK feline kidney cell line was established by Rees A. Crandell from the renal 
cortex of a 12-week-old female domestic cat.^ "^  ^These cells exhibit typical epithelial 
morphology and are often utilized in viral research and in the production of vaccines.
Crandell feline kidney (CrFK) cells are robust, rapidly dividing cells that experience 
moderate contact inhibition at high confluency resulting in slower division. These
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cells were used for titration of transducing units of vector preparations and to 
determine vector differences upon cell cycle arrest with aphidicolin. As with other 
cells, 2.5 X 10  ^cells were seeded into each well of a 6-well plate one day prior to 
titration. On day 0, 4 h before transduction, old media was replaced with 2 mL fresh 
media per well.
7.2.2.1.1.3. Primary Human Trabecular Meshwork Cells
Human trabecular meshwork (TM) cells were kindly provided by Terete Barras who 
obtained them from a normal human eye at autopsy within 24 hours and treated as 
follows: The TM had been isolated by microdissection and digested with collagenase. 
Isolated cells were grown in 24-well plates for 2 weeks to near confluence in 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal calf serum (PCS). 
Doubling time was approximately 4 days.
I received a frozen vial of human TM cells from Douglas H. Johnson at the Mayo 
Clinic after these cells had been expanded by 2 passages in T25 flasks and frozen 
down in liquid nitrogen.
Primary human trabecular meshwork cells were treated and propagated in analogy to 
293T cells except that the passage time was twice as long. These cells were used 
primarily to test for transduction differences of various vector types. One day prior to 
titration, 2.5 x 10  ^cells were seeded into each well of a 6-well plate. On day 0, 4 h 
before transduction, old media was replaced with 2 mL fresh media per well.
7.2.2.1.2. Culture Techniques
Cells were thawed in a 37C waterbath, washed with DMEM containing 10% PCS and 
antibiotic, spun down at 300 rpm for 3 minutes and seeded again in a T25 flask. Cells 
were grown again to confluency, DMEM was removed, cells were washed with 
phosphate buffered saline (PBS) and trypsinized with 1 ml of tissue culture grade 
trypsin for 3 minutes at 37 C in an incubator. Cells were then suspended in 8 ml of 
PBS, pipetted up and down while resting the tip of the pipette agains the bottom of the 
T25 flask to break up cell clumps. Cells were then spun down again with the above 
settings, supernatant was decanted and the cell pellet was suspended in DMEM with 
10% PCS and antibiotic.
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7.2.2.1.3. Transduction Techquiques
7.2.2.1.3.1. Transduction of Primary Human Trabecular 
Meshwork Cells
Cells were then transduced with 300 ml o f unconcentrated supernatant containing a 
2.5 X 10^-TU/ml concentration of MuLV or FIV lacZ vectors with or without 24 hr of 
prior growth arrest with aphidicolin (15 mg/ml). The transduction was carried out for 
6 hr before replacement with fresh medium. Aphidicolin (15 mg/ml) was maintained 
in all media overlying growth-arrested cells throughout the experiment, and was 
replenished daily until fixation and staining for p-galactosidase activity at 48 hr after 
transduction. G l/S growth arrest was verified by flow cytometric analysis with 
propidium iodide. Percent transduction was calculated by counting 10 visual fields per 
well at 340 magnification. No background p-galactosidase activity was detected in 
TM cells at any time point.
7.2.2.I.3.2. Cultured TM Cell Transduction
Primary human TM cells {gift o f  T. Borras, University of North Carolina Chapel Hill) 
were transduced with an escalating multiplicity o f infection (m.o.i) o f GINWF to test 
for potential GFP toxicity in vitro prior to in vivo experimentation. Doses were 
chosen to have an equivalent m.o.i to that in a feline eye injected with a bolus of 10^, 
10 ,^ 10  ^and 10  ^j u  747,748 medium was replaced weekly and TM cell layers were 
photographed (Nikon Coolpix 990 and Nikon Eclipse TE300, Nikon, Melville, NY) at 
the experimental endpoint of one month.
7.2.2.I.3.3. Human Eyes
Pairs of human eyes were obtained from the Minnesota Lions Eye Bank 
(Minneapolis, MN). Eyes were from individuals without any known eye disease 
(median age, 65 years) and were cultured within 36 hr of death. Eyes were sectioned 
along the equator, dissected to remove retina, iris, and lens, and cultured as described 
prev iously .Briefly ,  the sectioned specimens were sealed at the equator into a 
custom-built culture vessel as shown (Figure 17). The culture vessel was placed in an 
incubator (37°C, 5% C02), and connected to a microinfusion pump that perfused the 
eye with medium at the normal human anterior chamber rate o f 2.5 ml/min. A dose of 
1x10^ TU, or a range of doses for the dose-response experiments, was injected as a
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bolus into the afferent perfusate. AZT (50 mM) was included in the perfusate in some 
control experiments. Generally, eyes were cultured for 3 to 21 days. For the initial 
characterization of transduction by FIV, HIV, MuLV, adenoviral, and mock vectors, 
all eyes were injected and perfused with a randomly assigned vector, whereas the 
fellow eye was not injected and served as a control for potential endogenous P- 
galactosidase activity. Pairwise comparisons of FIV to MuLV vector and o f FIV to 
HIV vector were performed, using the left and right fellow eyes of human donors. 
Three pairs of randomly assigned eyes were transduced by injection of 1 x 10  ^TU of 
FIV vector in one eye and 1x10^ TU of MuLV vector in the other eye of the pair, 
and three pairs were transduced in a separate experimental set with 1x10^ TU of FIV 
and HIV vector, respectively. Eyes were fixed and stained for P-galactosidase activity 
on day 7 after transduction. The ratio of transduced to total TM cells was determined 
by counting all TM cells in each of four sections per eye (one from each quadrant).
7.2.2.2. Trypsinizing Cells
In order to propagate cells, media of established cell cultures in T75 bottles were 
removed by vacuum aspiration and washed twice with 5 ml of phosphate buffered 
saline (PBS). 2.5 ml trypsin solution was added and evenly spread across the cell 
monolayer by tilting. The culture bottles were placed back into the incubator to 
provide the ideal temperature for the enzymatic action of trypsin. At about 3 minutes 
the culture bottle was removed from the incubator, rocked to dislodge adherent cells, 
placed back in the incubator and trypsinization allowed to continue for another 2 
minutes. Bottles were removed from the incubator and opened in the tissue culture 
hood. The cell suspension was aspirated with an automatic pipette and forcefully 
ejected while creating a moderate seal with the counter pressure from the wall at the 
bottle end to break up remaining cell clumps that had not completely trypsinized. A 
volume of 7.5 ml Dulbecco’s modified Eagle medium with 10% fetal calf serum 
(DMEM-10), penicillin G sodium 100 units/mL, streptomycin sulfate 100 pg/mL and 
L-glutamine 2 mM (DMEM) was added to stop trypsinization and provide appropriate 
culture environment.
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7.2.2.S. Counting Cells
Figure 16: Hematocytometer counting 
chamber. Rulings cover 9 square 
millimeters. Boundary lines of the 
Neubauer ruling are the center lines of 
the groups o f three. (These are indicated 
in the illustration below.) The central 
square millimeter is ruled into 25 groups 
o f 16 small squares, each group 
separated by triple lines, the middle one 
of which is the boundary. The ruled 
surface is 0.10mm below the cover glass, 
so that the volume over each of the 16 
small squares is .00025 cubic mm.
After trypsinization as described above, suspended cells were counted with an 
improved Neubauer hemocytometer (cat. No. 3100, Hausser Scientific, Horsham, PA, 
USA) and a counter. This device has two separate cell counting areas, one of which is 
shown above (Figure 16). The volume above each square contains 0.1 mm^ of sample 
when covered by a cover slip ( 1 x 1  x 0.1 mm^). A cover slip mounts on two ground 
glass bars to form the top of the two chambers. The cell suspension that had to be 
counted was transferred to each chamber with a pipette resulting in the suspension 
being drawn into the chamber by capillary action. For proper counting both sides of 
the chamber have to be filled and counted. Fine rulings on the floor of each chamber 
provide grids to help count the number o f cells in suspension. There are nine large 
squares on each side of the hemocytometer. Cells were counted in three big squares. 
The number of cells per milliliter was calculated as the average number per square 
times l o t  Cells that were lying at the top and left hand lines of each box were 
included in the count but not the ones on the lower and right hand line. On average, 
100 to 300 cells were counted per chamber to increase accuracy. The same procedure 
was repeated in the second chamber. The appropriate volume was then added to the 
desired culture vessel and filled up with DMEM to the recommended volume as 
described below.
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7.2.2.4. Seeding and Growing Cells
7.2.2.4.1. 293T Cell Cultures for Retroviral Vector 
Production by Transfection
1. 293T cells.
2. Adherent fibro-epithelial cell lines for titration: CrFK cells.
3. Dulbecco’s modified Eagle medium with 10% fetal calf serum (DMEM-10), 
penicillin G sodium 100 units/mL, streptomycin sulfate 100 pg/mL and L- 
glutamine 2 mM.
4. Trypsin, tissue culture grade.
5. PBS (phosphate-buffered saline), tissue culture grade.
6. Distilled water, sterile.
7. 70% isopropanol or ethanol.
8. 37°C humidified incubators, 5% C02.
9. Nikon Coolpix 990 camera for digital image capture (Nikon, Melville, NY)
10. Nikon Eclipse TE300 microscope (Nikon, Melville, NY)
7.2.2.4.1.1. T75Flask
On Day -1 of a respective experiment 3x10^  293T cells per T75 flask were seeded. 
On day 0, 4 h before transfection, old media was replaced with 10 mL fresh media
7.2.2.4.1.2. Cell Factory CF2
1. D ay-4: CF2: seeding each of 4 T75 flasks with 3 x 10  ^293T cells.
2. Day -2: Trypsinizing and seeding a CF2 with 5 x 10  ^of the above 293T cells.
3. Day -1 : Trypsinizing and reseeding 5 x 10  ^of the above 293T cells into a CF2s. If 
desired and if full doubling occurred over from day -2  to day -1 , a second CF2 can be 
seeded.
4. Day 0: Transfection.
7.2.2.4.1.3. Cell Factory CF10
1. D ay- 6 : Seeding of 4 x 10  ^293T cells into each of 4 T75 flasks.
2. D ay-4: Trypsinizing and seeding 6.3 x 10  ^o f the above 293T cells into a CF2.
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3. Day -2: Trypsinizing and seeding a CFIO with 2.5 x 10 of the above 293T cells.
4. Day -1 : Trypsinizing the CFIO and reseeding 2.5 x 10  ^of these 293T cells into the 
same CFIO (i.e., the original CFIO is reused).
5. Day 0: Transfection.
7.2.2.4.2. Human Ocular Anterior Segment Cultures
Human donor eyes from the local eye bank
Custom made anterior chamber segment perfusion equipment as described by 
Douglas H. Johnson^^^ consisting of:
1. Bottom chamber
2. Scleral sealing ring
3. Cover
4. Perfusion tubing
5. Pressure transducer
6. Pressure recording software
7. Microperfusion pump
7.2.3. Generation of Vectors
7.2.3.1. Feline Immunodeficiency Virus Vectors
I generated replication defective feline immunodeficiency viral (FIV) vectors with the 
technical help of Mary Peretz and Wu-Lin Teo. Several different derivatives were 
created in the course of this thesis as detailed in the cloning history. Plasmids used to 
generate initial FIV vectors were a minimal transfer vector (pCT25), packaging 
construct pCFlAenv,^ and a VSV-G expression construct, pCMV-G."^^^ pCT25 
contains, in series from 59 to 39, the hybrid U3-substituted promoter of pCT5*; the 
FIV R repeat, U5 element, and leader sequence; the first 311 bp of the gag open 
reading frame (ORF); the Rev response element; an internal cytomegalovirus (CMV)- 
lacZ cassette; and the 39 long terminal repeat (LTR).
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7.2.3.1.1. Transfection
The amount of DNA was adjusted to 1 pg pCMV-G"^^^, 3 pg of pCT25^^"  ^and 3 pg of 
packaging plasmid pCFlA env/ The volume was brought to 800 pi with 0.01 M Tris- 
HCl (pH 8.0) and 800 pi of 2.5 M CaClz were added while vortexing at middle speed. 
The mix was allowed to precipitate for exactly 3 min and then pipetted at once into 
media pooled at the end of the tilted T75. Further mixing was achieved by turning the 
tilted flask back and forth around its longitudinal axis without dislodging cells.
Bottles were placed in incubators and left undisturbed until the medium was changed 
18 h later.
7.2.3.1.2. Harvest
Supernatants were collected 48 h after removal of the transfection mix, filtered 
through a 0.22-pm filter and aliquoted into cryovials. Aliquots were frozen at -80 C.
7.2.3.2. Feline Immunodeficiency Virus Mock Vectors
Mock vectors are not vector particles but allow comparing true transduction with 
proteins expressed from transduced genes to proteins that are present in the collected 
supernatants. A false positive result from unintentionally transferred of proteins is 
also known as pseudotransduction. Mock vectors were made with omission of 
packaging plasmids. Because there negligible transduction of trabecular meshwork 
cells in vitro or in ex vivo organ cultures, no mock vectors were needed in the 
experiments discussed below. HIV mock vectors were not generated because no 
pseudotransduction was found with FIV mock vectors and studies were designed to 
compare FIV to HIV mediated transduction while excluding pseudotransduction. 
Experiments also had to be designed with a limited number of human donor eyes.
7.2.3.2.1. Transfection
The amount of DNA was adjusted to 1 pg pCMV-G"^^^, 3 pg of pCT25^^"  ^while 
packaging plasmid pCFlAenv,^ was left out. The volume was brought to 800 pi with
0.01 M Tris-HCl (pH 8.0) and 800 pi of 2.5 M CaClz were added while vortexing at 
middle speed. The mix was allowed to precipitate for exactly 3 min and then pipetted 
at once into media pooled at the end of the tilted T75. Further mixing was achieved by
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turning the tilted flask back and forth around its longitudinal axis without dislodging 
cells. Bottles were placed in incubators and left undisturbed until the medium was 
changed 18 h later.
7.2.Z.2.2. Harvest
Supernatants were collected 48 h after removal of the transfection mix, filtered 
through a 0.22-pm filter and aliquoted into cryovials. Aliquots were frozen at -80 C.
7.2.3.S. Adenovirus Vectors
The adenoviral vector used in this study was a generous gift by Robert D. Simari. It 
was generated as described before.^"^^’ Briefly, subconfluent 293 cells were infected 
with crude viral lysate, the supernatant was collected and purified twice by cesium 
chloride ultracentrifugation. The viral band was collected and desalted by dialysis, 
equilibrated with 0.01 M Tris pH 8, 0.01 M MgC12 and 10% glycerol. Viral titers 
were determined and recorded as transducing units by infecting Crandell feline kidney 
(CrFK) cells. The absence of replication-competent virus was confirmed by testing 
the vector preparation on 293 cells at a multiplicity of infection of 10.
7.2.3.4. Murine Leukemia Virus Vectors
I generated beta-galactosidase expressing murine leukemia virus (MLV) vector 
LZRNL^^^ as published"^^^’ and detailed in the following. Mary Peretz provided 
technical assistance with vector production. All materials as listed in the materials and 
reagents section were present in Eric Poeschla*s laboratory where I conducted my 
studies.
7.2.3.4.1. Transfection
The amount of DNA of VSV-G expressing plasmid was adjusted to 1 pg. The volume 
was brought to 800 pi with 0.01 M Tris-HCl (pH 8.0) and 800 pi of 2.5 M CaCli were 
added while vortexing at middle speed. The mix was allowed to precipitate for exactly 
3 min and then pipetted at once into media pooled at the end of the tilted T75. Further 
mixing was achieved by turning the tilted flask back and forth around its longitudinal
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axis without dislodging cells. Bottles were placed in incubators and left undisturbed 
until the medium was changed 18 h later.
7.2.S.4.2. Harvest
Supernatants were collected 48 h after removal of the transfection mix, filtered 
through a 0.22-pm filter and aliquoted into cryovials. Aliquots were frozen at -80 C.
7.2.3.5. Human Immunodeficiency Virus Vectors
I produced the replication defective human immunodeficiency viral (HIV) vectors^"^^’ 
with the technical help of Mary Peretz. Production was similar to that of MLV and 
HIV vectors.
7.2.3.5.1. Transfection
The amount of DNA was adjusted to 1 pg pCMV-G"^^^, 3 pg of pHR9CMVlacZ^"^^’ 
and 3 pg of packaging plasmid pCMVDR8.9.^"^^’ The volume was brought to 800 
pi with 0.01 M Tris-HCl (pH 8.0) and 800 pi of 2.5 M CaClz were added while 
vortexing at middle speed. The mix was allowed to precipitate for exactly 3 min and 
then pipetted at once into media pooled at the end of the tilted T75. Further mixing 
was achieved by turning the tilted flask back and forth around its longitudinal axis 
without dislodging cells. Bottles were placed in incubators and left undisturbed until 
the medium was changed 18 h later.
7.2.3.S.2. Harvest
Supernatants were collected 48 h after removal of the transfection mix, filtered 
through a 0.22-pm filter and aliquoted into cryovials. Aliquots were frozen at -80 C.
7.2.4. Scaled-up Lentiviral Vector Production
Use of larger animals in the course of this thesis required larger volumes of vector and 
made development of a protocol for scaled up lentiviral vector production necessary. I 
established this protocol with the technical help of Wu-Lin Teo which has been
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published.^^' Depending on the amount of vectors needed, either larger volume cell 
factories (CFIO) were used or smaller ones (CF2).
7.2.4.1. Production of High-Titer FIV Vector Stocks by 
Transient Transfection of 293T Cells
7.2.4.1.1. Transfection and Vector Production
1 .1 adjusted the DNA amount of the three plasmids pMD.G/pFP93/pGINWF to a 
ratio of 1/3/3. For CFIO, use 84.5/253.5/253.5 pg in a 500-mL sterile plastic bottle, 
bring volume to 60.5 mL with 0.01 M Tris-HCl (pH 8.0), add 6.5 mL of 2.5 M CaC12, 
and mix by bubbling air into transfection mix with pipette. For CF2, use 
16.9/50.7/50.7 pg in a 250-mL sterile plastic bottle, brought volume to 12.1 mL with
0.01 M Tris-HCl (pH 8.0), add 1.3 mL of 2.5 M CaC12, and bubbled with pipette.
2 .1 tilted the bottle to gather contents in comer of bottle and added 67 mL (CFIO) or 
13.4 mL (CF2) of 2X HBS by rapid pipetting. Bubbled air through the mix and shake 
for 10 s. Vortexing was found to be less desirable because contents were not mixed 
immediately. Set aside and let precipitate for exactly 3 min. I found that small DNA 
amounts used in this protocol resulted in fewer condensation nuclei during 
precipitation and faster growth of crystals than large DNA amounts.
3. While the precipitation continued, I emptied Cell Factory into waste beaker, wiped 
inlets again with 70% ethanol-soaked Kimwipe, and connect loading bottle with 
silicon tube and connector to Cell Factory. Filled loading bottle with 100 mL of fresh 
culture media per layer (total of 1000 mL in CFIO or 200 mL in CF2) without letting 
media mn into Cell Factory.
4. At 3 min, stopped precipitation by pouring transfection mix straight into media in 
loading bottle. Shook and bubbled vigorously for even distribution.
5 .1 placed the Cell Factory on its side and filled by elevating loading bottle. Made 
sure chambers of Cell Factory contain equal media levels; lifted Cell Factory at 
connector end while still placed on side to prevent media of upper chambers from 
leaking into lower chambers. Rolled back into horizontal orientation. Put Cell Factory 
back into incubator in a precisely horizontal orientation.
6. Removed media 18 h later and replaced with fresh media.
- 164 -
Materials and Methods
7.2.4.1.2. Vector Harvest
1. On day 3, i.e., 48 h after replacement of transfection mixed with fresh media, 
collected supernatant in large beaker, stirred, and let sit for 3 min to allow detached 
cells to settle.
2. Filtered through 0.22-pm filter into 500-mL filter units. Aliquoted filtered vector 
supernatant into appropriate number of 1.8-mL cryovials.
7.2.4.2. Concentration by Large Volume Ultracentrifugation
Generation of larger volumes of vector required new ways of concentration. 
Therefore, I developed a fixed, large volume rotor protocol. This was done by 
extrapolating and estimating parameters fi*om the swinging bucket rotor concentration 
protocol.
1. I washed insides of 250-mL centrifuge buckets and lids with 70% ethanol. 
Aspirated dry with vacuum. Always filled buckets to top mark and used 
additional PBS if necessary. Balanced tubes on scale together with lids and 
closed tightly.
2. Spun at 67,000grmax for 6 h at 4°C. A brownish vector pellet was visible at the 
outer bottom rim of the bucket.
3. Decanted buckets, placed on ice at 45° angle with pellet pointing upward, let 
sit on ice for 2 min, and sucked up collected liquid at bottom. Rotated pellet to 
bottom and add 5 mL PBS if two rounds of concentration were planned. Used 
smaller volume if only one round of centrifugation is desired.
4. Started re-suspension with 5-mL pipette by washing down the whole outer 
wall to which pellet was attached, along with the entire bottom and the outer 
rim. Directed the wash jet toward the pellet. This process took more than 5 
min per bucket. Undispersed fragments are pipetted into 25-mL tubes for 
second round of concentration together with fully dispersed vector.
5. Washed insides of 36-mL centrifuge tubes, as well as buckets and lids of 
swinging bucket rotor with 70% ethanol. Sucked dry with vacuum. Filled 
buckets to the maximum level with resuspended vector from first round.
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Added PBS if  necessary. Balanced tubes on scale together with lids and closed 
tightly.
6 .  Spun at 6 7 ,0 0 0 g r m a x ,  3 l , 0 0 0 g n n i n  for 1 h 3 0  min at 4°C. A brown vector pellet 
was visible at the bottom of the bucket.
7 .  Resuspended pellet in 500 pi PBS by washing the entire bottom with jets for 5 
min. Set pipette to 250 pL and kept tip submerged to prevent bubbles and 
foam. Pipetted resuspended vector into 1.5-mL microcentrifuge tube and spun 
for 3 min at 3000g to remove large unsuspended particles.
8. Aliquoted vector in 50-pL fractions in tubes with narrow bottoms; freeze at -  
80°C.
9. Washed Cell Factories twice with dH20 inside the hood. Seal and store at 4°C 
if reuse was desired for production of same vector in next days.
7.2.5. Titration of Transducing Units
1 .1 seeded 2.5 x 10  ^CrFK into each well of a 6-well plate.
2. Twenty-four hours later, thawed vector stocks and made 10-fold serial dilutions.
3. Removed media from 6-well plate and added each mixture to a well of the 6-well 
plate, either changing the tip each time or moving from most dilute to least dilute.
Left one well untransduced as a control.
4. After 6 h, replaced supernatant with fresh media.
7.2.5.1. Enhanced (eGFP) and Renilia (rGFP) Green 
Fluorescent Protein Transducing Units
CrFK and TM cells were transduced as described above with enhanced (eGFP) or
Renilia (rGFP) green fluorescent protein expressing vectors. Cells were trypsinized 48
h after start o f transduction following the same protocol as for “Seeding and Growing
Cells”, washed with PBS, resuspended in PBS, and fixed with 1% formalin in PBS.
The suspension was analyzed for the percentage o f transduced cells with
fluorescence-activated cell sorter flow cytometry (FACS).
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7.2.5.2. Beta-Galactosidase Transducing Units
48 h after transduction, fixed cells with 1% glutaraldehyde for 3 min, washed with 
PBS, and incubated overnight at 37°C with 5-bromo-4-chloro- 3-indoxyl-p-D- 
galactopyranoside (X-Gal) staining solution. Washed once with PBS and replaced 
with 1% glutaraldehyde. Used a transparent 2-mm x 2-mm-square counting grid and 
determined number of squares per well. Counted positive foci in 10 random squares at 
lOOx magnification and determined the number of positive colonies per well. 
Multiplied count by dilution factor to obtain TU/mL. E.g. for a volume of 1 mL the 
titer = total number of P-galactosidase positive colonies per well x dilution factor = 
transducing units per milliliter.
7.2.6. In Vitro and Ex Vivo Methods
7.2.6.1. In Vitro Human Trabecular Meshwork Cells
Human trabecular meshwork (TM) cells (gift from  T, Borras) were derived from a 
normal human eye obtained at autopsy and seeded as described above. Transduction 
was carried out for 6 hr before replacement with fresh medium. Half the 6 wells with 
TM cells were incubated with aphidicolin (15 mg/ml) to achieve growth arrest which 
was maintained in all media overlying growth-arrested cells throughout the 
experiment. Media was replenished daily until fixation and staining for P- 
galactosidase activity at 48 hr after transduction. G l/S growth arrest was verified by 
flow cytometric analysis with propidium iodide. Percent transduction was calculated 
by counting 10 visual fields per well at 340-fold magnification. Beta-galactosidase 
staining was performed as described in the section “Titration”. No background p- 
galactosidase activity was detected in TM cells at any time point.
For the experiments seeking to enable real-time non-invasive monitoring, GFP- 
expressing vectors were the principal focus. To preliminarily assess feasibility and 
potential toxicity of GFP expression, cultured primary human TM cells were 
transduced with a 4-log range of FIV vector input. Transduction was carried out for 6 
hours before replacement with fresh medium and subsequently changed every 3 days. 
Fluorescence and viability of cells was confirmed by observation for one month with 
a tissue culture microscope with fluorescence equipment.
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7.2.6.2. Ex Vivo Human Donor Eyes
7.2.6.2.1. Human Organ-Perfusion Culture
i
Figure 17: Anterior chamber perfusion model/^' Left: Schematic side view. Media 
enters hemidisected eye centrally and exits following the natural route through the 
TM and episcleral veins collecting in the well surrounding the eye. A pressure 
transducer to measure lOP is also connected to the anterior chamber and enters from 
underneath (not shown). Right: Top view of open culture chamber.
The Minnesota Lions Eye Bank (Minneapolis, MN) provided pairs of human eyes. 
Eyes were used in accordance with Mayo Clinic Institutional Review Board 
guidelines and according to the tenets of the Declaration of Helsinki. All were from 
donors (median age, 76.5 years, n = 6) without known eye disease and were placed in 
perfusion culture within 24 hours of death, as previously described.^^*’ In this 
system, a human eye is obtained shortly postmortem and hemisectioned at the 
equator, the entire posterior pole, retina and choroid, iris and lens are removed. The 
anterior half is sealed posteriorly with an apparatus that maintains the aqueous 
circulation with fidelity to natural parameters (Figure 17). Medium is perfused with 
DMEM and antibiotics at the physiological rate of 2.5 microliter per minute and 37 C 
through the anterior chamber and exits the eye through the normal conventional 
outflow pathway (trabecular meshwork, Schlemm’s canal, collector channels, and 
episcleral veins). The cultures were maintained in 5% C02 in an incubator. Eyes 
cultured in this fashion remain viable for up to 4 weeks, during which outflow tract 
structures and trabecular meshwork cells maintain normal morphology. Intraocular 
pressure was measured every 60 seconds for 5 days and recorded as averages per 
hour.
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7.2.6.2.2. Intraocular Application of Vectors
One anterior segment of each pair (n = 3) was injected with a bolus of 1 x 10  ^
transduction units (TU) CT26 vector in a volume of 500 pL DMEM, and the fellow 
eyes received an equivalent volume of CT26 mock vector. Similarly, 1x10^ TU of 
GiNWF vector in 500 pL DMEM was injected into one anterior segment of a pair (« = 
3), whereas the control fellow eye received the same volume of medium without 
vector.
For comparison of HIV, FIV and MLV vectors, a dose of 1 x 10  ^TU, or a range of 
doses for the dose-response experiments, was injected as a bolus into the afferent 
perfusate. AZT (50 mM) was included in the perfusate in some control experiments. 
Generally, eyes were cultured for 3 to 21 days. For the initial characterization of 
transduction by FIV, HIV, MuLV, adenoviral, and mock vectors, all eyes were 
injected and perfused with a randomly assigned vector, whereas the fellow eye was 
not injected and served as a control for potential endogenous p-galactosidase activity. 
Pairwise comparisons of FIV to MuLV vector and of FIV to HIV vector were 
performed, using the left and right fellow eyes of human donors. Three pairs of 
randomly assigned eyes were transduced by injection of 1 x 10  ^TU of FIV vector in 
one eye and 1x10^ TU of MuLV vector in the other eye of the pair, and three pairs 
were transduced in a separate experimental set with 1x10^ TU of FIV and HIV 
vector, respectively. Eyes were fixed and stained for p-galactosidase activity on day 7 
after transduction. The ratio of transduced to total TM cells was determined by 
counting all TM cells in each of four sections per eye (one from each quadrant).
7.2.6.2.3. Time course of Expression
To evaluate the time course of expression, the TM of eyes in the vector comparison 
study (FIV, HIV, MLV) was biopsied 3 days after transduction, while the eyes were 
kept in culture for 16 days. For this, a standard surgical trabeculectomy was 
performed on two quadrants 90 degrees apart on day 3. Histological assessment of the 
entire meshwork was done at the end of the culture period, on day 16 after 
transduction.
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7.2.7. Tissue Processing and Marker Detection
7.2.7.1. Beta-Galactosidase Detection with the X-Gal Assay
7.2.7.1.1. X-Gal Assay in Human Eyes
Eyes were rinsed in phosphate-buffered saline (PBS) and cut into quadrants. From 
each quadrant, one corneoscleral wedge was taken for antibody labeling, while an 
adjacent wedge was fixed for 15 min in 4% paraformaldehyde, rinsed in PBS, and 
stained for 16 hr in X-Gal solution, rinsed with PBS, and embedded in paraffin or JB- 
4 plastic medium. Sections (6 mm) were obtained from unstained and stained paraffin 
blocks for antibody labeling. Nuclear fast red was used as a nuclear counterstain. JB4 
embedding and staining was performed by Cindy Bahler.
7.2.7.1.2. X-Gal Assay in Cat Eyes
Eyes of sacrificed animals that were injected with beta-galactosidase expressing FIV 
vector CT26 were enucleated. Only one random quadrant was removed from the 
anterior segment for X-Gal-staining, while the remaining 3 were used for eGFP 
detection because the in vivo study focused on detailed assessment o f a live marker. 
Eyes were X-Gal stained overnight, photographed with an operating microscope 
(Nikon, SMZ800, and DXM 1200, ACT-1 software), and embedded in paraffin by the 
Histopathology Core Facility of the Mayo Clinic. Sections were counterstained with 
fast nuclear red.
7.2.7.1.3. X-Gal Assay in Rat Eyes
To assess gene expression for the comparison of subretinal and intravitreal injection 
techniques, half of the neonatal rats in each litter injected with CT25 in right eyes, 
were sacrificed at 2 days post-injection and the other half at 7 days post-injection. 
Time points 2 and 7 days were chosen because neovascularization is maximal in the 
ROP model during this period.^^^ In the long-term expression/integration study 
comparing FIV WT integrase and mutant integrase vectors, 10 animals were 
sacrificed at 2 months, 10 animals at 3 months and the rest of 17 animals at the 
experimental endpoint of 7 months. After sacrifice and enucleation, eyes were fixed in 
10% formalin at 4°C for 90 minutes and cornea and lens were removed. To detect 
expression of the marker gene, eye cups were incubated in X-gal reagent overnight at
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37°C. Eyes were then send to the Histopathology core at the Mayo Clinic for paraffin 
embedding and counterstaining with nuclear fast red.
For cross-sectional histology o f eyes transduced with FIV or adenoviral vectors, two 
representative pairs o f eye cups from each time point were processed as above, 
embedded in paraffin, sectioned at 6 pm through the transduced area and 
counterstained with either neutral red or nuclear fast red. To assess the histology in a 
masked manner, all slides were examined by an ophthalmic pathologist (JDC) who 
was unaware of the experimental group.
7.2.7.2. Beta-Galactosidase Detection by Anti-Body Labeling
7.2.7.2.1. Antibody Labeling of Beta-Galactosidase in 
Human Eyes
For labeling with anti-p-galactosidase antibodies, 6- mm sections were mounted on 
slides at 60°C, deparaffinized with HemoD (Fisherbrand; Fisher Scientific, 
Pittsburgh, PA), rehydrated through stepped ethanol-water baths, and placed for 30 
min into a steamer with 0.1 M piperazine-N,N9-bis(2-ethanesulfonic acid) (PIPES, 
pH 8.0) to maximize antigen retrieval. Nonspecific binding was blocked by a 1-hr 
incubation with bovine serum albumin, followed by two 5-min washes with PBS, a 1- 
hr incubation with a polyclonal rabbit anti-p-galactosidase antibody (Molecular 
Probes, Eugene, OR) at a dilution of 1:50, washing, and a 30-min incubation with a 
secondary photostable, pH-independent, green fluorophore-conjugated goat anti­
rabbit antibody (Alexa Fluor 488, Molecular Probes; fluorescence absorption peak at 
495 nm, emission peak at 539 nm) at a concentration of 1:300. A 5-min incubation 
with diamidinophenylindole (DAPI; Molecular Probes) was used to stain nuclei.
7.2.7.2.2. Antibody Labeling of Beta-Galactosidase in Rat 
eyes
In the study comparing FIV WT and integrase mutant vectors, an additional expanded 
litter of 25 rats was used to assess localization of transgene expression using 
immunohistochemistry with anti-y^-galactosidase antibodies.^®"  ^All right eyes received 
subretinal injections of CT25 vector as described above. Left eyes were treated as one 
of three controls as described above. Prefixed eyecups were soaked in 20% sucrose 
overnight, embedded in OCT, and snap frozen in liquid nitrogen. 10 pm cryosections
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were rehydrated with PBS for 10 minutes and blocked with 3% bovine serum albumin 
and 0.1% Tween in PBS for 1 hour. Sections were then washed twice with PBS for 5 
minutes, exposed to the primary antibody (rabbit anti-/?-galactosidase antibody. 
Molecular Probes, A-11132) at a dilution of 1:100 in PBS for 60 minutes, washed 
twice with PBS for 5 minutes, incubated with the secondary antibody (goat anti-rabbit 
antibody Alexa Fluor 488 labeled. Molecular Probes, A-11008) at a dilution of 1:300 
in PBS for 90 minutes, and washed twice for 5 minutes each in PBS. Cell nuclei were 
stained with a 300 nM DAPI solution in PBS.
7.2.7.3. Antibody Labeling of Enhanced Green Fluorescent 
Protein (EGFP)
7.2.7.3.1. Antibody Labeling of EGFP in Human Eyes
Localization and extent of expression of eGFP were confirmed with specific antibody 
labeling in human eyes. Six micron paraffin-embedded sections from two quadrants of 
each eye were deparaffinized (22-143975; Citrisolv; Fisherbrand, Fair Lawn, NJ) and 
rehydrated with decreasing concentrations of ethanol, and antigens were retrieved for 
5 minutes in a steam chamber with piperazine-A-V-bis(2-ethanesulfonic acid)
(PIPES) buffer. Sections were incubated for 60 minutes with a primary rabbit anti- 
eGFP antibody (1:200 dilution, NB 600-303; Novus Biologicals, Littleton, CO) and 
for 30 minutes with a fluorescent phalloidin-labeled secondary goat anti-rabbit 
antibody (1:200 dilution, A-11088, Alexa 488; Molecular Probes). Nuclei were 
stained with a 1:1000 dilution of 4',6'-diamino-2-phenylindole (DAPI; D-1306; 
Molecular Probes).
7.2.7.3.2. Antibody Labeling of EGFP in Cat Eyes
For a more sensitive assessment of the extent of transduction with GINWF other eyes 
were labeled with an anti-GFP antibody following the exact same protocol as above.
7.2.7.3.3. Antibody Labeling of Feline Macrophages and I-  
Cells
7.2.7.3.3.1. Feline Macrophages
Anterior segment sections from cats that had developed an iritis after GFP over­
expression were analyzed for presence of feline macrophages with a primary murine
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anti-myeloid/histiocyte antibody (1:50 dilution, MAC 387, M0747, and
a secondary Alexa 488-labeled goat anti-mouse antibody (1:100 dilution, A-11001, 
Molecular Probes). Specifically, sections were pretreated with a pre-made solution of 
proteinase K (DAKO, product number S3020) for 10 minutes, blocked with DAKO 
blocking solution (DAKO, product number S200189) and incubated with MAC 387 
for 1 hour followed by washing with PBS for 5 minutes in the presence of blocking 
solution. Sections were then incubated with the secondary Alexa 488-labeled goat 
anti-mouse antibody for 1 hour followed by PBS washing for 10 minutes. MAC 387 
detects the myeloid/histiocyte antigen, a calcium-binding molecule, which 
predominantly consists of different polypeptide chains adding up to an Mr of -36  500 
protein complex.^^^ The complex contains at least two different subunits, which have 
molecular masses of 8 and 14 kDa.^^^ It belongs to the S I00 family,^^^ which is a 
large subfamily of EF-hand proteins.^^^ The myeloid/histiocyte antigen is expressed 
by circulating (and emigrated) neutrophils and monocytes, as well as a subset of 
reactive tissue macrophages and many tissue eosinophils.
7.2.7.3.S.2. Feline T-Cells
To detect feline T-cells,^^^’ sections were incubated with peroxidase-conjugated 
anti-CD3 (Anti-CD3/HRP, U0026, DAKO) according to manufacturer protocol. 
Tissue sections were deparaffinized (22-143975; Citrisolv; Fisherbrand, Fair Lawn, 
NJ) and rehydrated, followed by incubation with 3% hydrogen peroxide in distilled 
water for 5 minutes. Sections were then rinsed with Tris-buffered saline (TBS) for 5 
minutes and incubated with proteinase K (DAKO, product number S3020) for 5 
minutes. Sections were again rinsed in TBS for 5 minutes. Specimen were then 
covered with 2-3 drops of DAKO EPOS Anti-CD3/HRP and incubated for 60 minutes 
at room temperature. A horseradish peroxidase-labeled immunoglobulin mix (DAKO 
EPOS Negative Control solution, U0951) was used as a control: sections were rinsed 
in TBS for 5 minutes, incubated with DAKO Liquid DAB Plus (code Nos K 3467/K 
3468), a chromogenic substrate solution, for 5-15 minutes. Slides were rinsed with 
water and counterstained and mounted with a cover slip.
Sera of cats with proven iritis infiltrate were analyzed for antibodies against GFP and 
VSV-G. A 10% SDS-PAGE gel with a continuous well was loaded with GFP protein 
produced by transient transfection of 293T cells and transferred. Membrane strips
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were incubated with serum before transduction and 4 weeks after animals had 
developed an iritis. A rabbit anti-GFP antibody (1:1000 dilution, Novus Biologicals, 
NB 600-303) and a monoclonal mouse anti-VSV-glycoprotein antibody (1:1000 
dilution, protein clone P5D4, C-7706, Sigma, St. Louis, MO) served as a positive 
control. After washing, wells with cat serum as the primary incubation were incubated 
with a secondary peroxidase conjugated goat anti-cat antibody (1:1000 dilution, cat. 
55293, IGN Pharmaceuticals, Aurora, OH). A peroxidase conjugated goat anti-rabbit 
antibody (1:1000 dilution, Calbiochem, San Diego, CA) served as a secondary 
antibody for GFP detection and a peroxidase conjugated goat anti-mouse antibody 
(1:1000 dilution, Calbiochem) as the secondary antibody to the anti-VSV-G antibody. 
The same protocol was used to detect anti-VSV-G antibodies except that 293T cells 
were transfected with VSV-G expression plasmid pMD-G.
7.2.8. Animal Handling and Vector Application
7.2.8.1. Animals
All animals in used in this thesis were handled in accordance to the Institutional 
Animal Care and Use Committee and the ARVO Statement for the Use o f Animals in 
Ophthalmic and Vision Research.
7.2.8.1.1. Long-Term Outflow Tract Modification In the Cat
Because the anterior chamber perfusion model is artificial in many respects, such as 
short viability with consequent inability to assess long-term outcomes, substitution of 
the complex aqueous humor with synthetic medium, and the complete lack of a 
systemic immune response. In rodents, the outflow tract is too rudimentary to permit 
robust comparisons. I therefore proceeded to assess the possibility of long-term 
targeted gene expression with the required characteristics in the cat, a readily 
available larger animal with an outflow tract that is anatomically and physiologically 
similar to that of humans.
Experiments were conducted with specific pathogen-free domestic cats (Harlan, 
Indianapolis, IN). Ten days before vector application, cats were anesthetized with 10 
mg/kg intramuscular Tiletamine HCl/Zolazepam HCl (Telazol, Fort Dodge 
Laboratories Inc., Fort Dodge, lA) for ocular examination with slit lamp (Haag-Streit,
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Mason, OH) and a handheld pneumatonometer (Model 30 Classic, Medtronic,
Fridley, MN) to determine lOP. Fluorescence of transduced trabecular meshwork was 
observed with a standard gonioscope (Posner, Ocular Instruments, Bellevue, WA) and 
a microscope (Nikon Eclipse E400) equipped with a GFP-optimized filter (Nikon, EF- 
4 B-2E/C FITC, cat. 96107). Two days before vector application, two initial pilot cats 
received a bilateral conjunctival injection of 200 pi Kenalog-40 (Bristol-Myers 
Squibb, Princeton, NJ) to blunt nonspecific iritis during initial intraocular procedures 
as seen after saline injection in pilot studies. However, this procedure was abandoned 
in subsequent animals when no iritis occurred in two further cats.
Twelve subsequent animals were assigned to dosing groups (group 1:10^ TU, group 
2: 10  ^TU, group 3:10^ TU, group 4:10^ TU) in which each group o f 3 animals was 
transcomeally injected with different vectors (see Table 4 for vector identities) in 
each eye but without Kenalog.
7.2.8.1.2. Subretinal versus Intravitreal Injection Route 
Study In the Rat
To characterize transduction after different types of intraocular injection of FIV 
vectors, I chose subretinal and intravitreal routes in seven day old rats. Expanded 
litters were assembled that are commonly used in models o f oxygen-induced 
retinopathy resulting in retinal neovascularization similar to retinopathy of 
prematurity. For this, 100 newborn Sprague-Dawley rats (Harlan Laboratories, 
Indianapolis, IN) were randomly assigned at birth to 4 expanded litters of 25,^^ '^^^^’^^  ^
and raised in room air. 77 of the original 100 animals survived to the day o f injection 
(day 7), an expected attrition rate due to the expanded litter design.^^^ For comparison 
of injection techniques, right eyes of 39 rats received subretinal injections and right 
eyes of 38 rats intravitreal injections of CT25 on day 7 of life, while left eyes were 
assigned to one of three control groups: 1) FIV mock vector (n = 13 subretinal, n = 13 
intravitreal), 2) DMEM+10% FCS (n = 13 subretinal, n = 12 intravitreal) and 3) no 
injection (n = 26). DMEM+10%FCS was chosen as a control because vectors were 
produced in this medium. In the injection route study, 4 pi of 4.6 x 10  ^TU/ml (1.8 x 
10  ^TU total) of CT25 or control was delivered by either subretinal or intravitreal 
injection.
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7.2.8.1.3. Comparison of Long-Term Expression in the Rat 
with FIV and Adenoviral Vectors
In a second experiment, I tested whether genomic integration of FIV vectors is of 
advantage for long-term expression compared to non-integrating adenoviral vectors/^ 
In the long-term expression study, 60 five-day-old Sprague-Dawley rats received 
subretinal injections of 2 x 10  ^TU FIV vector into right eyes and 2 x10^  TU Ad 
vector into left eyes. An additional 10 animals served as non-injected grading 
controls. At 1 week, 1 month, 3 months and 6 months, 10 injected animals and 2 non­
injected controls were sacrificed for analysis of transgene expression. Ten injected 
animals and 1 non-injected control were sacrificed at 12 months. Deaths by normal 
senescence (n = 3) began to occur at 16 months, so the remaining animals (7 injected 
and one non-injected control) were sacrificed at that time point.
7.2.8.1.4. Retinal Long-Term Expression and Integration 
Study In the Rat with Wild-Type versus Mutant 
Integrase FIV Vectors
50 rats were raised in expanded litters as described above. At 7 days, right eyes of the 
37 surviving were injected subretinally with 2 pi of 4.6 x 10  ^TU/ml of CT25 and left 
eyes were injected with the integrase mutant vector (CT25.D66V).
7.2.8.2. Anesthesia
7.2.8.2.1. Cats
Cats were anesthetized with 10 mg/kg intramuscular Tiletamine HCl/Zolazepam HCl 
(Telazol, Fort Dodge Laboratories Inc., Fort Dodge, lA)
7.2.8.2.2. Neonatal Rats
In the FIV versus FIV integrase mutant vector study, seven-day-old pups underwent 
inhalation anesthesia with Metofane® (methoxy urane, Schering-Plough Animal 
Health Corp, Union, NJ) and were placed under an operating microscope. The 
anesthetic was delivered by placing a soaked sponge into the cover of a syringe and 
placing the open end over the nose of the animal. Metofane had the advantage that it 
did not require a vaporizer or doser. Although it has been very popular it is no longer 
available for use because of its carcinogenic and nephrotoxic potential in humans.
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In the study that compared FIV with adenoviral vectors, rat pups underwent inhalation 
anesthesia with isoflurane (isoflurane, USP; Abbott Laboratories, North Chicago, IL) 
and were placed under an operating microscope. Isoflurane was delivered as above 
metofane.
7.2.S.3. Intraocular Application of Vectors
7.2.8.3.1. Intracameral Vector Application Technique In the 
Cat
A 1 microliter syringe with a 30 gauge needle was used to inject anterior chambers of 
cat eyes under an operating microscope with a bolus of 50 pi of PBS (DPBS, Cellgro, 
Mediatech, Herndon, VA) containing 10  ^TU, 10  ^TU, or 10  ^TU of vectors RGWF, 
GINWF, CT26 or FGINSIN. Good vector circulation was achieved by aspirating 100 
microliter a total of 3 times. Circulation of the highly concentrated vector suspension 
was visualized and even distribution confirmed.
7.2.8.3.2. Subretinal and intravitreal Vector Application 
Technique In the Neonatal Rat
Harvested vector supernatant o f producer cells must be concentrated for subretinal or
intravitreal injection because of the limited volume that can be introduced (Figure
18). I developed a novel subretinal injection technique. Because of the small size of
the eye of newborn rats (Figure 19 A), subretinal injections are difficult and good
microsurgical skills are required.
The eyelid was cleaned with a cotton wool swap soaked with 70% alcohol. Alcohol 
must not contain any additional substances or be denatured to avoid remanescence 
and interference with the injected vector. After canthotomy with extension of the 
lateral palpebral lid fissure by 1 mm (Figure 19 B), a latex membrane with a 1 mm 
central slit was placed on top of the eye and spread open with curved forceps. The eye 
was prolapsed through the membrane with a gentle backward movement toward the 
orbit (Figure 19 C).
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Figure 18: Vector production, concentration, and injection. Supernatants of 
transfected 293T cells are collected, filtered, and concentrated by ultracentrifugation. 
For a subretinal injection, the needle is inserted through a sclera tunnel with the bevel 
of the needle facing the center of the eye (middle). An intravitreal injection requires a 
steeper angle and the bevel is rotated outwards (right). Injury of the large rodent lens 
must be avoided to prevent cataract formation.
7.2.8.3.2.1. Subretinal Injection
The subretinal injection was carried out in two steps: first, a 30ga needle was used to 
create a sclerotomy incision at the superior pars plana 1 mm back from the limbus 
(Figure 19 D). Because the latex membrane exercised slight pressure to the back of 
the eye, good hemostasis was achieved. A small volume of aqueous humor usually 
leaked and made room for the vector bolus. Precaution was taken not to injure the lens 
during the initial incision that aims toward the center of the eye. The 33ga needle of a 
custom made Hamilton syringe was advanced in a flat, tangential angle through the 
first incision, which directed the needle into the subretinal space (Figure 19 E). It was 
crucial to turn the needle with the open side and bevel facing the center o f the eye for 
proper guidance. Successful subretinal injection formed a detachment that could be 
seen through the translucent sclera of non- to medium pigmented animals (Figure 19 
F). In contrast, misplacement of the needle in the subconjunctival space caused 
outward bulging and could be recognized immediately. The needle was withdrawn, 
the latex membrane was stretched to open the central slit and removed.
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Figure 19: Subretinal injection technique. (A) Size of a 7 day old rat in comparison to 
the tip of a pen. (B) When full anesthesia is reached, lids are spread open with forceps 
and the lateral palpebral fissure is extended by 1 mm. (C) A latex membrane with a 
central cut of 2 mm is placed on top of the eye and the eye prolapsed with curved 
forceps in a backward motion while the slit is stretched open. (D) Creation of a sclera 
tunnel using a 30ga hypodermic needle. (E) Tangential insertion of a 33ga needle 
mounted on a custom made Hamilton syringe through the sclera tunnel. (F) A forming 
retinal detachment can be seen as a translucent crescent in animals without dark 
pigmentation.
7.2.8.3.2.2. Intravitreal Injection
Similar to subretinal injections, the intraretinal injection was carried out in two steps: 
first, a 30ga needle was used to create a sclerotomy incision at the superior pars plana 
1 mm back from the limbus (Figure 19 D). Because the latex membrane exercised 
slight pressure to the back of the eye, good hemostasis was achieved. Leakage of a 
small volume of aqueous humor was observed that made room for the vector bolus. 
Precaution was taken not to injure the lens during the initial incision that aims toward 
the center of the eye. The 33ga needle of a custom made Hamilton syringe was now 
directed into the vitreous, anterior to the optic nerve, the vector bolus was injected and 
the needle retracted.
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7.2.9. Ex Vivo and In vivo Imaging of Transduced Cells 
Expressing Fluorescent Proteins
7.2.9.1. Ex Vivo Imaging
7.2.9.1.1. Imaging of Anterior Human Segments
Transduction efficiency was determined as the mean percentage of transduced cells in 
four quadrants. Eyes in the eGFP group were divided into four quadrants, and 2-mm 
wedges were removed, rinsed in PBS, and placed into phenol red-free Dulbecco’s 
modified Eagle’s medium with 0.1% Hoechst 33342 (H-3570; Molecular Probes, 
Eugene, OR) for in vivo staining of nuclei. Expression of eGFP in freshly dissected, 
unfixed anterior segments was visualized by a frontal view toward the TM and a 
sagittal view of wedges mounted on their sides, by a microscope with a fluorescent 
light source (Eclipse E400; Nikon, Melville, NY) and by confocal microscopy (LSM 
510; Carl Zeiss, Thomwood, NY). To measure transduction efficiency with GiNWF, 
eGFP-positive TM cell bodies and stained nuclei were manually counted at 400x 
magnification in microscopic fields comprising an area of 0.24 mm^ in each of the 
four quadrants. Transduction efficiency is expressed as the mean percentage of eGFP- 
expressing cells versus stained nuclei ± SD. Medium-injected fellow eyes served as 
the control.
7.2.9.1.2. Imaging of Enucleated Cat Eyes
Cats were sacrificed with an injection of 175 mg/kg pentobarbital sodium IV 
(Sleepaway, Fort Dodge Laboratories, Sligo, Ireland) and eyes were enucleated. To 
correlate gonioscopic expression grades with transduction efficiency, 3 quadrants in 
one eye per expression grade were analyzed. One random quadrant was removed from 
the anterior segment for X-Gal-staining, while the remaining 3 were incubated with 
PBS and 1000-fold diluted Hoechst 33342 (Molecular Probes, Eugene, OR) to 
counter stain nuclei of living cells. The transduction efficiency was determined by 
counting GFP positive, living TM cells, and Hoechst 33342-positive nuclei in the 
same visual field at 100-fold magnification with a histology microscope (Nikon 
Eclipse E400). This required that the focus be moved up and down to count cells 
lining along the three-dimensional structure of the trabecular meshwork.
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7.2.9.2. Non-lnvasive In Vivo Monitoring of Enhanced (eGFP) 
and Renllla (rGFP) Green Fluorescent Protein 
Expression In the Cat Eye
mirror view
top view schematic side view
Figure 20: Top view of anesthetized cat on restrainer (A) and side view of restrainer 
under modified microscope (B). The trabecular meshwork can be seen as a black ring 
in the mirror of the gonioscope that is placed on the cornea (C).
Anesthetized cats were examined with slit lamp, pneumatonometer, and 
biomicroscopy at the day after arrival, 3 days before, at day of, and 3 days after vector 
application, then weekly for 2 months, bi-weekly for 4 months and monthly 
thereafter. lOP was always measured at the same time of the day, three readings per 
eye were taken and averaged. The entire TM circumference was inspected. 
Photographs of fluorescent TM were taken at each examination and grades 
determined in a masked manner by two observers rating independently, using the 
scale photographs shown in Fig. lb. A digital microscopy camera (DXM 1200,
Nikon, Melville, NY) was used, with 2 second exposures and image capture software 
(Automatic Camera Tamer (ACT-1), Nikon, Melville, NY).
During the examination, animals were secured in a bag (red bag in Figure 20 A) and 
placed on a custom made restrainer looking upwards. I designed this restrainer and 
had it manufactured by the Engineering Department of the Mayo Clinic. A Posner 
gonioscope mounted on a holder that could be moved around the head was positioned 
on top of the open eye without use of a contact gel.
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7.2.10. Quantification and Statistics
7.2.10.1.1. Quantification and Statistics of Human Eyes of 
Perfused Anterior Segment Cultures
The ratios of p-galactosidase-positive TM cells to total TM cells present in random 6-
mm sections from each quadrant o f an eye were determined by counting the labeled
and unlabeled cells and calculating the mean value for each quadrant. Colocalized
nuclear staining (nuclear fast red) and cytoplasmic P-galactosidase staining was
counted as a transduced cell. A paired Student t test was used for statistical analysis.
7.2.10.1.2. Quantification and Statistics of Expression in 
Feline Eyes
In vivo TM fluorescence as seen during gonioscopy was graded on a scale of 0 to 4, 
with representative photographs shown in Figure 23 B. Grade 0 was defined as no 
detectable fluorescence, graded as single fluorescent spots in the TM, grade 2 as 
numerous nonconfluent fluorescent spots with some confluent areas, grade 3 as 
extensive, mostly confluent, mid-level transduction and grade 4 as extensive, high 
level and completely confluent fluorescence. Because of the high linear correlation, 
expression grades were handled as continuous data during the statistical comparison 
of marker protein accumulation. To determine whether the rate of fluorescent marker 
protein accumulation (V f) influenced the duration o f expression, Vp was measured as 
the change from initial expression grade (gradei) to peak expression grade (grade?) 
over time from the first examination (ti) to the time point of peak expression (t?): Vp 
= Agrade/Atime = (grade? - gradei)/(t? - ti). Time was measured in days. A large 
increase in expression grade over a short period of time would result in a larger Vp 
than a small increase in the same period of time. lOP readings before vector injection 
were compared to peak pressures of the same eye as well as to the experimental 
endpoint using the paired student's t-test.
7.2.10.1.3. Blinded Assessment and Statistics of
Expression In Rat Eyes Transduced with Normal or 
Integrase Mutant Vectors
X-Gal-stained eye cups were graded in random order for transduction, and scored as
positive if p-galactosidase expressing cells could be identified in at least one retinal
quadrant by an independent observer in a masked manner using a Zeiss operating
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microscope. Eyes were finally scored before the random number code was broken.
The proportions of eyes transduced after intravitreal and subretinal injection were 
compared at 2 and 7 days post injection using a chi-square test. Statistical significance 
was defined as a p value < 0.05.
7.2.10.1.4. Assessment of Incidence and Extent of
Transduction of FIV and Adenoviral Vectors after 
Intravitreal or Subretinal Injection
control grade 1 grade 2 grade 3 grade 4 grade 5
Figure 21: Grading system for P-galactosidase expression. Grades were defined 
prospectively on a scale with a range from 0 to 5. Grade 5 = confluent transduction of 
entire retinal surface area, grade 4 = large confluent areas of at least half of retinal 
surface area, grade 3 = confluent areas with less than half the retinal surface area, 
grade 2 = large areas of non-confluent transduced cells, grade 1 = isolated, discrete 
transduced cells, grade 0 = no detectable p-galactosidase activity.
After sacrifice, eyes were enucleated and fixed for 90 minutes in 10% formalin at 4"’C. 
The cornea and lens were then removed and eye cups were stained overnight in X-gal 
solution to detect P-galactosidase expression. All eye cups were evaluated in a 
masked manner by an observer unaware of the experimental group for extent of 
transduction using a Zeiss stereo operating microscope (Zeiss OPMIMD; Carl Zeiss 
Surgical, Inc., Thomwood, NY). I used a prospectively defined grading scale to 
quantify the extent of retinal transgene expression, with a range from 0 to 5 (Figure 
21). Grade 5 was defined as confluent transduction of the entire retinal surface area, 
grade 4 as large confluent areas of transduction involving at least half of the retinal 
surface area, and grade 3 as confluent areas of transduction but involving less than 
half the retinal surface area. Grade 2 was defined as large areas of non-confluent 
transduced cells, grade 1 as the presence of isolated, discrete transduced cells and 
grade 0 as no detectable p-galactosidase activity.
Incidence and extent of transduction at each time point, and overall, were compared 
using McNemar's tests and Wilcoxon signed-rank tests.
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8. Results
8.1.Transgenesis of the Ocular Outflow Tract with Lentlvlral 
Vectors as a Basis for Gene Therapy of Glaucoma
8.1.1. FIV transfer vectors and Production Procedures
8.1.1.1. Transfer Vector Modification
The original beta-galactosidase expressing FIV vector, CTRZLb,^^^ was modified to 
minimize the risk of recombination with the packaging plasmids. The resulting 
minimal transfer vector, CT25, contained no sequences derived from viral coding 
regions except for the initial 311 nucleotides of the gag ORF, and a 250-nucleotide 39 
env fragment encoding the Rev response element. Reporter gene (lacZ) transcription 
was promoted internally by the human CMV immediate- early promoter-enhancer. 
Unconcentrated CT25 vector pseudotyped with VSV-G yielded mean titers of 1.6 
(±0.74) X 10  ^TU/ml (n = 12 preparations). After concentration by ultracentriftigation, 
mean titers were 2.2 (±1.8) x 10  ^TU/ml (n = 4 preparations). These were at least 
equivalent to titers obtained with FIV vector CTRZLb, which contained an additional 
938 nucleotides of gag that Iris Kemler found to be dispensable for efficient FIV 
genome encapsidation."^^^ Vectors with this truncated segment are in fact 
packaged into virions at higher efficiency than those with the longer gag  segment 
contained in the original vectors."^^  ^Reverse transcriptase (RT) measurements 
performed hy Iris Kemler confirmed equivalence: transducing units per counts per 
minute of RT activity for CT25 and CTRZLb vectors were 2.89 and 1.18, respectively 
(n = 3). Two rounds of concentration o f CT25 vector increased titer from 4.8 x 10  ^
TU/ml to 2.3 X 10^  ^TU/ml (79% yield).
Subsequent eGFP transfer vectors also contained new transgenes {eGFP and neoP^ 
and additional viral elements that are involved in reverse transcription and viral 
nuclear import (cPPT)"^^  ^or that enhance transgene mRNA levels (WPRE).^^^
8.1.1.2. Production Procedures
To enhance scalability of vector production, I developed a modified procedure that 
uses a much smaller amounts of plasmid DNA than in previously described 
protocols^"^® (10 times less in micrograms of DNA per square centimeter of 293T cell 
monolayer), as well as high-surface-area vessels (Cell Factory, Nunc) and large
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volume ultracentrifugation. Large-scale vector supernatants produced with these 
methods in cell factories averaged 2.8 ± 1.5 x 10  ^TU/mL {n = 8). The first round of 
ultracentrifugation resulted in vector recoveries of 60% to 80%, the second round in 
recovery of 40% to 60%, and maximum titers of 2.5 xlO* TU/mL. Vector 
preparations used for the organ perfusion experiments contained 6.83 x 10  ^TU/mL 
(GiNWF) and 2.5 x 10  ^TU/mL (CT26) and were diluted for injection of 1 x 10  ^TU 
in a volume o f500 pL. For bicistronic vector preparations, eGFP dinàneoR titers 
correlated within 50% of each other and more than 95% of G418-stable colonies 
expressed eGFP, indicating good function of the internal ribosomal entry site.
8.1.2. Transduction of Primary Human Trabecular Meshwork 
Cells with FIV LacZ Transfer Vector CT25
The CT25 FIV vector was tested for its ability to transduce primary TM cells derived
from human trabecular meshwork. CT25 was compared with an MuLV-based lacZ
vector also pseudotyped with VSV-G; for this and all comparisons in this study,
vector preparations were normalized to equal transducing units after titration under
identical conditions. The lentiviral vector transduced both proliferating cells and cells
growth-arrested in G l/S phase with aphidicolin (Figure 22). In contrast, growth arrest
prevented transduction by the MuLV vector. No background p-galactosidase activity
was detected in TM cells, no transduction was seen with a mock FIV vector, and
transduction by both vectors was completely blocked by 50 mM AZT, an inhibitor of
reverse transcriptase.
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MLV MLV + aphidocolin
FIV FIV + aphidocolin
percentage of transduced TM cells
no aphidocolin aphidocolin
MLV 31% 4%
FIV 40% 43%
Figure 22: Primary trabecular meshwork cell transduction and effect of growth arrest. 
Cells isolated from human trabecular meshwork and plated in 24-well plates were 
transduced with 300 m\ o f unconcentrated supernatant containing a 2.5 x 10^-TU/ml 
concentration of MuLV vector {top) or FIV lacZ vector {bottom). Growth arrest with 
aphidicolin (15 mg/ml, right-hand side) blocked MuLV but not FFV transduction. 
Percent transduction is shown at the bottom.
8.1.3. Transduction of Primary Human Trabecular Meshwork 
Cells with FIV eGFP Transfer Vector GINWF
Because enabling real-time non-invasive monitoring was a central goal, GFP-
expressing vectors were the principal focus of the study. To preliminarily assess
feasibility and potential toxicity of GFP expression, cultured primary human TM cells
were transduced with a 4-log range of FFV vector input (Figure 23a). Transduction at
the highest multiplicity o f infection (m.o.i), which I estimated to be the approximate
equivalent of ten times the maximum in vivo multiplicity used in the animal
experiments that follow, produced marked GFP over-expression in all TM cells
-186
Results: Transgenesis of the Ocular Outflow Tract with Lentlvlral Vectors
(Figure 23) without morphological change, detachment, vacuolization, change in 
doubling time, or other evidence of vector or transgene toxicity. The plateau of GFP 
fluorescence was reached within 24 to 48 hours. As shown by the one-month post­
transduction results in Figure 23, this transgene expression was stable. When Renilla 
GFP (from the sea pansy^^^’ ^^ )^ was substituted for Aequoria^^^’ GFP, cells 
transduced with equivalent m.o.i appeared paler and reached peak fluorescence later, 
at 48 to 72 hours. Unless otherwise specified below, GFP designates the Aequorea 
protein. Similar to in vivo TM cells, cultured primary TM cells experience strong 
contact inhibition and stop dividing when a certain culture density is reached. Cells 
were viable for at least 2 months under these conditions.
dose escalation with human TM cells in vitro
m.o.i. 4 
a 10® TU/eye
m.o.i. 40 
a 10^  TU/eye
m.o.i. 400 
a 10* TU/eye
m.o.i. 4000 
a 10* TU/eye
■:.â
Figure 23: Vector dose escalation experiments, (a) Dose-escalation experiment with 
GINWF in primary cultured human TM cells. Shown are contact-inhibited TM cells 
at 1 month post transduction. The vector encodes enhanced (codon-humanized) green 
fluorescent protein (GFP) under the transcriptional control of the human CMV 
promoter. No toxicity was observed at any dose.
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8.1.4. Transduction of Human TM
8.1.4.1. Transduction of Cuitured Human Eyes: Extent and
Time Course of Transgene Expression in the Trabecuiar 
Meshwork
Efficient transduction of growth-arrested primary human TM cells with the FIV 
vector provided a basis for proceeding to the human organ perfusion model. Initial 
experiments were performed to assess the comparative capabilities o f the MuLV 
vector, an adenoviral vector, and two different lentiviral vectors: the CT25 FIV vector 
and an HIV-1 vector, pHR9CMVlacZ.^"^^’ Vectors were administered as a single 
bolus injection of 1 x 10  ^TU into the afferent perfusion chamber. No polycations or 
other enhancers o f virion-cell binding were added, as Polybrene was highly toxic at 
concentrations (4 mg/ml) that enhanced transduction of cultured cell lines (data not 
shown). The MuLV vector produced minimal transduction of the TM at both days 3 
and 16 (Figure 24). Only occasional blue cells were seen in stained histological 
sections. In contrast, both FIV and HIV lentiviral vectors consistently transduced 
more than 60% of TM cells when examined on day 3; staining intensity was increased 
by day 16 (Figure 24). Transduction was distributed throughout the TM, including the 
juxtacanalicular portion, and extended to the endothelium of Schlemm’s canal. As 
previously s h o w n , t h e  adenoviral lacZ vector also transduced the majority of TM 
cells at both time points. The majority of lentiviral transduction was seen in the TM, 
although some lacZ-transduced cells could also be detected in portions of the ciliary 
body, comeal endothelium, Schlemm’s canal, and downstream collector channels. For 
example, day 3 trabecular biopsies and day 16 chamber angle views in lentivirally- 
transduced eyes in Figure 24 show patchy p-galactosidase activity in the comeal 
endothelium adjacent to the heavily transduced TM. The results were confirmed by 
the more sensitive method of antibody labeling, which detected p-galactosidase 
protein in TM cells after transduction with either of the lentiviral vectors, but not after 
oncoretroviral transduction (Figure 26). Controls using either preimmune rabbit semm 
as the primary antibody or only the secondary antibody were negative, as was an 
untransduced control eye using both antibodies. Furthermore, mock FIV vector- 
injected eyes showed no X-Gal staining or antibody labeling, and 50 mM AZT 
blocked TM transduction completely, confirming that both endogenous LacZ staining 
and pseudotransduction were absent.
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day 3; 
trabeculectomy
day 16: 
chamber angle
day 16: 
TM section
control sc
mock
sc
MLV
17-
FIV
HIV
Figure 24: Transduction of human trabecular meshwork. Left: Representative TM 
biopsies obtained on day 3 after transduction. Middle and right Representative 
chamber angles and histological sections, respectively, from eyes evaluated for 
reporter gene expression 16 days after transduction. TM, Trabecular meshwork; SC, 
Schlemm’s canal.
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c) d)
Figure 25: Fluorophore-labeled anti-p-galactosidase antibody labeling of the 
trabecular meshwork 16 days after injection of 10  ^TU of FIV vector (a), 10  ^TU of 
HIV-1 vector (b), or 10  ^TU of MuLV vector (c) or mock FIV vector (d). SC, 
Schlemm’s canal.
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Figure 26: Dose response and trabecular meshwork preservation. Percent 
transduction (a) and total trabecular cells (b) in four eye pairs perfused with the 
indicated doses of vector. A section from each quadrant of an eye was counted and the 
mean was compared with the simultaneously perfused and untransduced fellow eye. 
Bars represent the SD. (c and d) TMs from a pair of fellow eyes perfused with 
medium alone (c) or 10  ^TU of FIV vector (d).
8.1.4.2. Dose Response
A dose-response study for FIV vector was then performed (Figure 26). Significant 
transduction of TM cells was seen after administration of 10  ^and 10  ^TU, but not at 
lower vector doses (Figure 26). Fellow control eyes from each human donor in this 
series received no vector and displayed no p-galactosidase activity (data not shown). 
TM structure was intact in fellow eyes perfused with medium alone (Figure 26) or 
10  ^TU of FIV vector (Figure 26). TM lamellae, extracellular matrix, and cellularity 
were preserved after transduction. Thin, blue-staining cytoplasm extended along 
trabecular beams from counterstained TM cell nuclei (Figure 26). No significant 
differences in cellularity were found between transduced eyes and untransduced 
fellow eyes from the same donor (Figure 26).
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8.1.4.3. Pairwise Comparison of Trabecular Meshwork
Transduction by Oncoretroviral and Lentiviral Vectors
Direct, pairwise comparisons of FIV vector with MuLV vector and separately with
HIV vector were performed, using the left and right fellow eyes of human donors
(Table 3). Three pairs of eyes were used for each comparison. Quantitation o f the
meshwork cells expressing p-galactosidase showed that MuLV vector-perfused eyes
had no transduced TM cells, compared with transduction of 68 ± 3% of TM cells with
the FFV vector (p = 0.0005, n = 3). The separate, FFV/HIV-I vector comparison in
eyes from three donors resulted in 75 ± 4% transduced cells for the FIV eyes and 79 ±
11% for HIV eyes; this difference was not statistically significant (p = 0.67).
Transduction was uniform around the circumference of each TM (Table 3, standard
deviations for quadrant counts), indicating even dispersal of vector.
Paired comparison I
FIV HIV
Donor 1 79 ± 6  (R)“ 66 ±  3 (L)
Donor 2 71 ± 4  (L) 84 ±  7 (R)
Donor 3 74 ± 15 (L) 87 ±  3 (R)
Mean ±  SEM: 75 ±  2^ 79 ± 6
Paired comparison II
FIV MLV
Donor 4 70 ± 5 (L) <1 (R)
Donor 5 65 ±  22 (R) <1 (L)
Donor 6 69 ±  20 (L) <1 (R)
Mean ±  SEM: 68 ± 2 <1
Table 3: Paired comparison of retroviral vectors -  percent transduction after injection 
of 10  ^TU per eye. a) Percent transduction values for the individual eyes represent 
means 6 SD of counts from four TM sections, one from each eye quadrant, b) 
Aggregate mean 6 SEM was derived for each three-eye set.
8.1.4.4. Expression of eGFP and p-Galactosidase in Human 
Trabecuiar Meshwork
GiNWF vector injection into cultured anterior segments produced efficient TM
transduction, as determined by visualization of expression of eGFP (Figure 27).
Transduction was limited to the TM, with the exception of occasional eGFP-positive
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cells elsewhere within the outflow pathway (comeal endothelium in proximity to the 
TM, Schlemm’s canal, collector channels). Cell counts performed with nuclear 
counterstaining revealed that a mean of 82% ± 4% of TM cells were eGFP positive 
and no cell loss was apparent (P = 0.94 for comparison with control eyes, n = 2>). 
Staining of tissue sections with anti-cGFP antibodies confirmed the extent and 
location of expression of eGFP (data not shown). Plastic-embedded sections showed 
preserved TM morphology and cellularity. Transduction of two unpaired eyes with a 
version of GiNWF without the central DNA flap or WPRE (pGiN) showed less 
efficient transduction (data not shown).
a) GiNWF Control
frontal
sagittal
b)
Figure 27: (a) Confocal microscopy view with frontal and sagittal view of TM 5 days 
after transduction with GiNWF and the TM in the fellow control eye. Imaging depth 
of 20 pm with wide pinhole, (b) Conventional fluorescence microscopic view. 400x 
magnification.
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a)
b)
SC .
- ■ r . . . .
Figure 28: Chamber angles 5 days after injection of CT26 (a), and CT26.mock vector 
(b). Sections are stained with X-Gal to detect expression of p-galactosidase. SC, 
Schlemm’s canal.
Transduction with the /acZ-encoding CT26 vector also resulted in high-level 
transduction (79% ± 15%) of TM cells (Figure 28) The fellow eyes injected with the 
CT26.mock vector did not stain positively for B-galactosidase, confirming absence of 
pseudotransduction. Comparison of total cell numbers showed no significant cell 
loss (P = 0.18 for comparison with control eyes, « = 3) and the morphology was well- 
preserved (data not shown). Expression of B-galactosidase was mainly observed in 
TM, although a few comeal endothelial cells in proximity to the TM and occasional 
cells in the endothelia of Schlemm’s canal and the collector channels were also 
transduced.
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8.1.5. Effects on Outflow Facility
Despite the extensive transduction and high levels of marker gene expression in both 
sets of eye pairs, only slight and transient changes in outflow facility were observed 
(Figure 29). In six eyes with high (79% or greater) transduction of TM cells with lacZ 
or eGFP, a mean 30% ± 22% {P = 0.02) peak reduction in outflow facility was 
observed. This minimal decrease in outflow facility was followed by stable return to 
preinjection levels by approximately 48 to 72 hours. The experiments were terminated 
at 5 days. The mean peak decreases were not significantly different between the lacZ 
and eGFP groups (25% ± 30% and 36% ± 17%, respectively, P  = 0.6, « = 3 per 
group). CT26.mock vector-injected eyes did not show a significant change in outflow 
facility compared with medium-injected control eyes.
a) vector
.  control 
» CT26
-24 120
time (ttours)
b) 1.61.4
□ control
TT
Co/Cmln Co/C 72ti
Figure 29: Intraocular pressure, (a) Recording of eye injected with CT26 and 
CT26.mock vector control, (b) Ratio of outflow facility (1/R) before transduction ( C o )  
and at recorded minimum (Cmin) and CO and 72 hours after transduction (C72h). 
Outflow facility ratio of transduced eyes was significantly different from the control 
at the recorded minimum (* f  = 0.02), but returned to stable baseline at 72 hours.
8.1.6. Transgene Expression In Vivo
A total of 19 domestic cats were used in this study. 7 were used as pilot animals to 
establish techniques and assess feasibility of gene transfer with eGFP vector, using 
what was later established to be a highly effective dose (10^ TU per eye). When these 
animals showed extensive expression of GFP in the TM, 12 more cats were assigned 
to groups organized by dose level and marker gene in a design that utilized
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comparisons of different marker transgenes in right and left eyes of the same animal 
(see Methods and Table 1 for animal group assignments). Vectors were injected 
transcomeally into the anterior chambers of lightly anaesthetized animals via single 
50 pi bolus injections through a 27-gauge needle. Animals injected with lO^and 10  ^
TU of GFP-transducing vector developed high grade (grade 4; see Figure 23b for 
grading scale), persistent GFP expression in the TM that was readily visualized and 
photographed through a conventional gonioscope (Figure 31& 2). Notably, 
expression was confined to the TM. Numerical results are summarized by group in 
Table 1. GFP expression in the TM steadily increased after transduction, reaching a 
maximum within days to weeks. It then was observed in most animals to plateau at 
the same or a lower grade, where it persisted for at least ten months, at which time the 
animals were sacrificed (Figure 32a, Aequorea GFP panels). There was a high linear 
correlation (R^ = 0.9) of gonioscopic expression grade and histologically determined 
transduction efficiency, with antibody labeling for GFP confirming that expression 
was limited to the TM (Figure 33). Overlay with DAPI (nuclear) staining 
demonstrated normal cellularity in both highly transduced and untransduced TM in 
the same animal (Figure 33). Of note, the expression grade data in this study were 
scored in a masked manner by 2 independent observers who used the scale 
photographs shown in Fig. lb, did not participate in the experiments, and were 
blinded to vector assignments. The robustness of this rating scale is evident in the 
outcome that both of the masked observers agreed independently on each scored 
expression grade, except for one point in which a grade of 2 was assigned by one 
observer and 3 by the other. In this one instance, a grade of 2 was scored.
B gonioscopic in vivo expression grades
grade 1 grade 2 grade 3 grade 4
Figure 30: Gonioscopic in vivo expression grades. GFP fluorescence in the TM of 
living cats was serially photographed and graded by direct gonioscopy (a cornea- 
shaped lens with a mirror is used to enable visualization of the anterior chamber 
angle). There was a high linear correlation (R^ = 0.9) between expression grade and 
histological transduction efficiency (grade 1, 2% ± 0.3%; grade 2, 21% ± 1%; grade , 
39% ± 3%; and grade 4, 94% ± 5%).
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gonioscopic real-time view of TM in all quadrants
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Figure 31: View of trabecular meshwork in living animal in standard (top and 
bottom) and corresponding UV light gonioscopic views (center). All four quadrants 
from an eye with grade 4 expression after transduction with 10  ^TU are shown (SN = 
superonasal, IN = inferonasal, IT = inferotemporal, ST = superotemporal). 
Transduction was virtually complete and was confined to the TM.
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Temporal and spatial patterns of cats in Group 1, which were injected with 10  ^TU 
GFP vector in one eye and 10  ^TU Renilla GFP vector in the other eye were 
consistent with the human TM cell culture outcomes described above. Companion 
eyes were initially similar (Figure 32 and Figure 34 A). However, eyes expressing 
Renilla GFP showed smaller median expression (maximum grade 2 compared to 4 in 
the GFP injected eye of the same animal, p = 0.04, Table 1). Renilla GFP expression 
was also shorter lived than GFP expression (35±22 days versus more than 10 months). 
High level GFP expression remained stable in two of the three Group 1 animals 
(grade 2 in one, grade 3 in the other) to the endpoint of the study (i.e., sacrifice at 10 
months). The third animal also had grade 4 GFP expression initially. Strikingly 
however, the intense GFP fluorescence was observed to disappear abruptly on day 38, 
concurrent with a brief iritis (discussed further below). Rate of marker protein 
accumulation VF, expressed as Agrade/time was 0.2±0.1 grades/day for GFP and 
0.2±0.1 grades/day (p = 0.4) for Renilla GFP (Figure 32).
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3 days 8 days 10 months
right eye, 
Aequorea GFP
left eye, 
Renilla GFP
B
right eye, 
Aequorea GFP
3 days 8 days 13 days
left eye, 
beta-gal
Figure 32: Representative examples of reporter gene expression in animals in group 1 
and 2. (a) Renilla GFP (right eye) and GFP (left eye) expression in group 1. (b) Paired 
comparison of GFP (right eye) and B-galactosidase expression (left eye) in group 2. 
Shown are photos of TM as seen via UV light gonioscopy (the 13 day B-galactosidase 
eye was fixed and stained with X-gal after sacrifice). Detectable Renilla GFP 
expression was always shorter-lived than that of GFP, while B-galactosidase 
expression persisted longer than GFP only at the highest dose, when over-expression 
toxicity of GFP was observed.
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eGFP antibody labeling
o
0)
0_ 
?  +
eGFP control
Figure 33: Antibody labeling for GFP confirms gonioscopic extent of transduction. 
GFP expression was limited to the TM and collector channels. Comparison DAP I 
staining of transduced TM (left) and control TM (right) demonstrates preserved 
cellularity in GFP-expressing TM. AC = anterior chamber, P = plexus.
groL£3 r jmoe"" of ca:5 vector
medial 
expression grades 
max. f'lal
c jratioi V.= i f â E â  day
iCPuan VS. 
10=*,
1 1 = 3 R= IC^TU GFP i. 2’ > 13 moiths* C.2±3.1 0 = 3.93
L= 1Q®TL Reniiia GFP 2 C 35±22 days C.2±3.1 0 = 3.05
"Tl 1 = 3 R = ID® TU GFP i. C 12±5 days 1.1=3.E 0 = 3.8S
L = 1Q®TU 06t5-ga. r.a n.a. > 12±5 days r.a. 0 = 3.07
3 1 = 3 R = 1CTJ GPP
i 4 > 13 moiths D.2±3 D3 0 = 3.41
L = I C r  TU beta-ga' r.a i.a. > 13 moiths r.a. D = 3.0S
4 1 = 3 R = ID® TU GFP 3 2 > 13 mci'hs 0.1 ±3 1 0 = 3.23
L = 10® TU beta-gai r.a n.a > 13 moiths r.a. p = 3.03
' Ore a lirai *e'mlnated expression at 39 days.
Table 4: Characteristics of transgene expression imaged serially in vivo.
These results indicated that quite high level and sustained transgene expression 
focused to the TM was feasible after a single transcomeal injection, that it could be 
monitored gonioscopically, and that GFP (from Aequorea) was preferable to Renilla 
GFP. Because of the high level of GFP expression achieved with 10  ^TU, the loss o f 
expression in one of these maximally-transduced animals might be due to the 
previously reported phenomenon of GFP-specific over-expression toxicity.
™ I therefore proceeded to examine further the parameters affecting GFP expression
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in dose response studies, this time using B-galactosidase vector^^"  ^as a control in the 
companion eye rather than Renilla GFP vector (Table 4). In Group 2(10^ TU for each 
vector), the extent of GFP and B-galactosidase expression were comparable (Figure 
32), and all animals developed sustained grade 4 GFP expression. They attained the 
plateau of GFP expression 5-fold faster (Figure 32, Figure 34) than the animals of 
group 1 (p = 0.03). Here, the rate of marker protein accumulation VF was 1.1±0.5 
grades/day. Consistent with toxicity from rapid GFP over-expression, the intense 
fluorescence in all Group 2 animals was observed to terminate abruptly after a mean 
of 12±5 days, concurrent with a brief iritis. In contrast, and consistent with the results 
of B-galactosidase vector transduction in human eyes,^ "^ ’^ high-level B-galactosidase 
expression was found in the same animals at sacrifice after GFP expression had 
disappeared in the other eye (Figure 32). Thus, the cytotoxicity observed was marker 
protein-specific and the result of rapidly developing GFP over-expression. 
Immunolabeling with leukocyte lineage-specific antibodies in histological sections of 
eyes from cats experiencing this short-lived GFP over-expression showed numerous T 
cells, but not neutrophils or macrophages, in the TM, as well as loss o f TM cells 
(Figure 35). Sections of Renilla GFP expressing eyes also demonstrated occasional T- 
cells. No infiltrates were present in companion eyes expressing B-galactosidase. Sera 
of cats with short-term expression did not react in immunoblots with GFP, which was 
readily detected with commercial anti-GFP sera (data not shown).
These results were encouraging because they indicated that the method was effective 
enough to enable marked protein over-expression in the TM. Because of that, I 
injected reduced vector doses (animal groups 3 and 4, receiving 10  ^and 10  ^TUs 
respectively, again via single transcomeal injections). 10  ^TU also produced a median 
expression grade of 4, which was not significantly different fi-om group 2 (p = 0.37). 
Importantly, however, at this lower dose, the grade 4 GFP expression was reached 
noticeably slower than in group 2 (VF was G.2±G.Q3 grades/day. Table 1). A clear 
difference with Groups 1 and 2 was that GFP expression persisted until sacrifice at the 
IG month-post injection endpoint of the study, and remained Grade 4 throughout. 
Thus, IG  ^TUs emerged as the optimal dose for the GFP vector, while B-galactosidase 
was tolerated well at IG  ^TUs. Group 4 animals (IG^ TU GFP vs. B-galactosidase 
vector, or 2 logs less vector input than animals in groups 1 and 2) corroborated these 
results and clarified dose requirements. They had a maximum median expression
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grade of 3, with a VF of only 0 .1±0.1. The expression persisted at grade 2 until 
sacrifice at 10 months. The results indicate that an optimal GFP vector dose 
substantially below the peak of the achievable dynamic range can be selected (10^ 
TUs in the case of this GFP vector) to achieve long-term gene expression in the TM.
slow onset: long-term expression
W - = 0 .2
150 200 250 300
days
W - 0 . 1
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days
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rapid onset: short expression
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A grade _ 
A time
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Figure 34: Rate of initial GFP accumulation determines whether successful long-term 
GFP expression is established, (a) Expression slowly reached peak levels in two cats 
from group 1 transduced with 10  ^TU GFP vector (right eye) and Renilla GFP vector 
(left eye), resulting in stable fluorescence of GFP, but not Renilla GFP. (b) Rapid 
GFP over-expression in animals of group 3 that were also transduced with 10  ^TU 
GFP vector triggered an iritis that eliminated transduced cells. Dotted red line 
illustrates onset of expression. Inserted photos show actual gonioscopic view of TM 
as indicated.
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Figure 35: Antibody staining for T-cells (anti-CD3: a, b and c), macrophages (anti- 
myelomoncyte: d, e and f) and DAPI staining (g, h and i). Shown are sections from a 
TM transduced with eGFP (a, d and g) after loss of expression and the p-galactosidase 
transduced partner eye (b, e, h). Only the eGFP transduced TM is infiltrated by T- 
cells (a), but not macrophages (d), while there is no infiltrate in the other eye. Control 
c is an isotype control section from the same eGFP eye (c). Control f  the comeo- 
conjunctival junction where macrophages are expected (f and i).
8.1.6.1.1. Intraocular Pressure
The initial TOP of all transduced eyes was not different from lOP at the end of the 
study (p = 0.4). Days to weeks after application, cats had a brief increase in lOP 
(33±34%, p<0.01) followed by return to normal pressures, which may be consistent 
with corticosteroid induced ocular hypertension.^^’’ In support of this inference, 
lOP change in non-premedicated pilot animals was minimal with GFP vector (n = 3, 
lOP change = 3±5%, p = 0.4) or B-galactosidase vector (n = 3, lOP change = 1±1%, p 
= 0.4).
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8.1.6.1.2. SIN Modification
CMV.eGFP.IRES.neo
GINWF FGINSIN
eGFP TU/ml 1.6 xIO® 7.8 xIO®
cpm/ml 4.0 xIO® 1.5x10®
ratio 40:100 50:100
Table 5: Differences o f eGFP expression. SIN modification of the FIV-LTR slightly 
improves eGFP expression levels from internal CMV.eGFP.IRES.neo cassette. 
Cpm/ml = counts per minute per ml in RT assay, eGFP TU/ml = eGFP transducing 
units per ml determined with flow cytometry, GINWF = internal 
CMV.eGFP.IRES.neo cassette, FGINSIN = internal CMV.eGFP.IRES.neo cassette.
SIN vector FGINSIN had a slightly higher ratio of eGFP_TU per RTAhan,GINWF-__
G230 (50:100 vs. 40:100, Table 5). In conclusion, the SIN deletion o f the FIV 3'-LTR 
did not negatively affect vector function.
- 2 0 4 -
Results: Transgenesis of the Retinai Pigment Epithelium with FIV Vectors
8.2.Transgenesis of the Retinal Pigment Epithelium with 
FIV Vectors as a Basis for Gene Therapy of Retinal and 
Choroidal Diseases
8.2.1. Comparison of Wild-Type and Class I Integrase Mutant-FIV 
Vectors in the Retina Demonstrates Sustained Expression of 
Integrated Transgenes in Retinal Pigment Epithelium
8.2.1.1. Results
8.2.1.1.1. Eyes Analyzed
For the comparison of subretinal and intravitreal injections, all injected animals were 
available for analysis at the conclusion of the study (n = 39 in the subretinal group, 
and 38 in the intravitreal group). In the intravitreal group, six pairs of eyes were 
unreadable due to problems in tissue processing, leaving 32 pairs for analysis. 
Therefore, 39 right eyes subretinally injected with the p-galactosidase-encoding FIV 
vector, CT25, and 32 right eyes intravitreally injected with CT25 could be analyzed. 
Control left eyes were treated as follows: (1) FIV mock vector (n = 13 subretinal, n =
11 intravitreal), (2) DMEM+10% FCS (n = 13 subretinal, n = 10 intravitreal), and (3) 
no injection (n = 24). For the long-term expression/integration study, all 37 animals 
survived from injection to outcome. Ten animals injected subretinally were analyzed 
at 2 months, 10 at 3 months, and the remaining 17 at 7 months. All eyes in all groups 
were evaluated and scored in random sequence by an observer blinded to injection 
assignment.
8.2.1.1.2. Comparison of Subretinal and Intravitreal 
Injection
VSV-G-pseudotyped FIV vectors were injected either subretinally or intravitreally. 
Following subretinal injection, ^-galactosidase expression was found in 15 of 19 
retinae (79%) at 2 days and in 19 of 20 (95%) retinae at 7 days (Figure 36) and 
expression was widespread (Figure 37 a), with some eyes showing nearly complete 
transduction of the retina. Cross-sectional histology revealed extensive p- 
galactosidase activity in the retinal pigment epithelium (RPE) (eyes from 
representative animals are shown in Figure 38 a and 3b), with more than half o f RPE 
cells expressing the marker gene. Antibody labeling for p~ galactosidase in one 
additional litter confirmed transduction of the RPE in eyes injected subretinally 
(Figure 38 c and d). No transgene activity was detected in noninjected control eyes or 
control eyes injected subretinally with mock FIV vector or DMEM+10% FCS.
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Occasionally, endogenous ^-galactosidase activity was observed in the ciliary body 
(Figure 37); this was equivalent in uninjected and injeeted animals, and at a 
histological level was not confined to cell bodies. No other ocular tissues showed such 
endogenous activity, and no inflammation or virus-induced pathology was observed.
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Figure 36: Proportion of eyes transdueed 2 and 7 days after either subretinal or 
intravitreal injection.
In contrast to subretinal injeetions, reporter transgene expression was found in only 4 
of 12 eyes (33%) at 2 days following intravitreal injection of the same volume of 
vector and 6 of 20 (30%) eyes at 7 days (Figure 36). Also, in clear contrast, 
expression in eyes receiving intravitreal injections was limited to a small area of 
retina direetly adjacent to the injection site (Figure 37c). As in control eyes for 
subretinal injeetions, no reporter transgene activity was detected in control eyes 
intravitreally injected with moek vector or DMEM + 10% FCS, or in non-injected 
eyes, and no inflammation or pathological change was seen. In summary, subretinal 
injections resulted in a significantly greater proportion of transduced retinae than 
intravitreal injections at both 2 and 7 days following injection (p < 0.05 and <0.001, 
respectively). Subretinal injections also caused transduction of a larger retinal area 
eompared with intravitreal injections. Subretinal injections resulted in virtually 
eomplete RPE transduction, while only patchy transduction was observed near the 
injection site of intravitreally injected eyes.
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Figure 37: Representative eyes injected subretinally with (a) CT25 vector and (b) 
subretinal injection control, or injected intravitreally with (c) CT25 vector and (d) 
intravitreal injection control. Note the larger area of transduced retina with subretinal 
injection (a versus c, arrow). Endogenous P-galactosidase activity in the ciliary body 
was occasionally observed, and was equivalent in both uninjected and injected eyes, 
as seen in panels (b)-(d) (blue ring).
8.2.1.1.3. Long-term Expression and Integration
In the second group of experiments, I examined duration of expression, compared 
wild-type, and class I integrase-mutant vectors. Right eyes of 37 rats were injected 
subretinally with CT25 and left eyes were injected with CT25.D66V. Preparation of 
CT25.D66V was identical to the preparation of the integrase-competent CT25 with 
the exeeption of using paekaging plasmid CFlAenv.D66V, in which the only change 
from CFlAenv is the single amino acid in integrase. Class I properties (selective block 
to integrase eatalytie function without disruption of other Gag/Pol funetions, 
equivalent to those described for HIV-1 integrase D64V) have been systematically 
validated in tissue culture studies for this mutant of FIV integrase and were reported
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elsewhere.^^^ Reverse transcriptase (RT) activity was determined in triplicate as 
described for both CT25 and the integrase mutant CT25.D66V and animals were 
injected with equal RT units of each vector.
ONL ONL
RPE RPE
ONL
RPE
ONL
RPE
Figure 38: Examples of representative cross-sectional histology confirming 
transduction of the RPE. Paraffin sections (a and b) counterstained with neutral red 
showing P-galaetosidase activity as blue stain within the RPE at both low power (a, 
65x) and high power (b, 1 lOOx). Antibody labeling for p-galactosidase confirmed 
limitation of marker gene expression to the RPE (400x; INL = inner nuclear layer, 
ONL = outer nuclear layer, RPE = retinal pigment epithelium). CT25 injected eye 
with (c) anti-p-galactosidase antibody staining and (d) DAPI counter stain, (e, f) Non­
injected control eye.
10 animals were evaluated at 2 months, 10 were evaluated at 3 months, and 17 were 
evaluated at 7 months post-injection. All eyes injeeted subretinally with CT25 
demonstrated extensive, confluent areas of p-galaetosidase expression in the RPE
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(Figure 39). At the longest time period (7 months), 60% of eyes demonstrated such 
expression in more than half of the total area of the retina (Figure 39 e), with the 
remainder ranging from a punctate distribution in one quadrant up to 50% or less of 
the total retinal area. In addition, occasional cells in inner retinal layers expressed p- 
galactosidase at 3 and 7 months (Figure 39 a and d). In contrast to CT25- injected 
eyes, fellow eyes injected with CT25.D66V vector had no or only very rare cells 
expressing P-galactosidase (Figure 39 c and f). Incidence and extent of expression at 
2, 3, and 7 months were the same, with widespread areas of transduction after CT25 
injection and only very sparse, punctate staining with the integrase mutant 
CT25.D66V.
Figure 39: Cross-sectional histology (a and d) and whole eye cups (b, c and e, f) of 
representative eyes 3 (a-c) and 7 months (d-f) after subretinal injection with CT25 
vector (b and e), and CT25.D66V (c and f). Vector particles, which differ in only one 
amino acid, were normalized to equal RT units.
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8.2.2. Long-Term Retinal Transgene Expression with FIV versus 
Adenoviral Vectors
8.2.2.1. Results
8.2.2.1.1. Dose-Response Study
To determine the optimum vector dose for the subsequent long-term expression study, 
eyes injected subretinally with 3 different doses of FIV and Ad vectors were assessed 
at 2 days post injection for p-galactosidase expression.
At the highest dose of 2 x 10  ^TU, all animals survived to the study endpoint. All 14 
FIV vector injected eyes and 13 of 14 Ad vector injected eyes showed transduction 
with a median grade of 3 with each vector (p = 1). In contrast, at a dose of 2 x TU, 
9 of 13 (69%) FIV vector injected eyes showed expression, compared to 5 of 13 
(38%) Ad vector injected eyes. The median grade of transduction was greater in eyes 
injected with 2x10"^ TU FIV vector, but this was not statistically significant (median 
grade 2 versus 0; p = 0.22). Only 2 of 12 (17%) eyes injected with 2x10^  TU FIV 
vector and 4 o f 12 (33%) eyes injected with Ad vector showed expression. One rat 
injected with 2x10"^ TU, and two rats injected with 2x10^  TU, died prior to 
sacrifice, and therefore were not analyzed. None of eyes from non-injected control 
animals showed transduction. Based on these results, 2x10^  TU was chosen for the 
following long-term expression study.
8.2.2.1.2. Long-Term Expression Study
Nearly all eyes (96%) through all time points of the study showed some degree of 
transduction (Figure 40). Analyzing data from all eyes across the entire 16 month 
study, FIV vector produced a higher distribution of grade o f expression than Ad 
(Figure 40, p = 0.01, Wilcoxon signed-rank). Analyzing each time point separately, 
differences in expression grade were statistically significant at 6 months, when FIV 
vector transduced eyes had a higher grade than Ad eyes (p < 0.05) (Figure 40). At all 
other time points beyond one week, FIV vector transduced eyes had higher grades of 
transduction than Ad eyes (Figure 40), though these differences were not statistically 
significant due to low statistical power. For example, at sixteen months, 4 of 7 FTV 
vector transduced eyes were grades 3-4, while none of the Ad eyes achieved this 
degree o f transduction, but individual time point comparisons were limited by low 
statistical power.
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Grades of expression across the 16 months suggested that FIV vector expression 
increased to a maximal level at 3 months, with some subsequent reduction in extent 
(Figure 40). In contrast, Ad vectors appeared to yield more immediate expression, 
peaking at 1 week, with a decline thereafter (Figure 40).
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Figure 40: Time course of p-galactosidase expression. FIV is shown in panel A, and 
Ad vectors are shown in panel B. Circle sizes represent the number o f animals at each 
grade. FIV expression reached a maximum extent at 3 months and then decreased, 
while expression from Ad vectors reached its maximum extent at 1 week.
When cross-sectional histology was examined, the retinal pigment epithelium showed 
p-galactosidase expression with both vectors at day 2 (Figure 41). In eye cups that 
had lower grade of transduction the staining was greatest in the quadrant that 
corresponded to the site of injection. The retinae had multiple folds (not shown), 
similar to our findings in previous studies using subretinal injection. At day 7, 
expression was similar to day 2 (Figure 41).
At 1 month, extensive P-galactosidase staining could be seen throughout the retinal 
pigment epithelium, associated with staining of the adjacent photoreceptor outer 
segments (Figure 41). Some individual cells in the inner retinal layers in both FIV- 
and Ad vector injected eyes were transduced. In Ad injected eyes, there was evidence 
of infiltration by large cells morphologically consistent with macrophages (Figure 41, 
see insert shown in 16 month section) and extracellular p-galactosidase staining was 
prominent. The shallow retinal folds seen earlier with both FIV and Ad persisted, 
presumably secondary to subretinal injection and there were isolated areas of
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intraretinal microcyst formation (not shown). Retinae from both groups showed areas 
of attenuation, consistent with resolving focal traumatic retinopathy (not shown), 
while the remaining retinal architecture remained intact.
At 3 months, 6 months and 12 months, FIV vector-injected eyes were similar to those 
at 1 month with the exception of the time-dependent increase of cells in the outer 
nuclear layer staining positive for p-galactosidase. In Ad vector injected eyes, the 
intensity of RPE staining for p-galactosidase decreased over time. Transduced areas 
in Ad injected eyes often accumulated a focal cellular infiltrate and the previously 
normal retinal architecture appeared disrupted.
At the conclusion of the study (16 months), p-galactosidase positive cells were found 
in the RPE and occasionally in the inner and outer nuclear layers o f FIV vector- 
injected eyes. There was focal traumatic retinopathy, while the rest of the retina 
showed normal retinal morphology. Ad vector injected eyes still expressed p- 
galactosidase, but were less extensively transduced and had larger areas with 
disrupted retinal architecture (Figure 41).
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Figure 41: Representative eye cups and histological sections through the transduced 
retina of eye pairs from the same animal. Right eyes were injected with FIV, left eyes 
with Ad vector. When a retinal detachment was present in the section, images of 
neurosensory retina and RPE are shown in their normal spatial relationship. Insert; 
large, macrophage-like cells with abundant cytoplasm appeared to contain 
phagocytosed P-galactosidase positive material (arrows). Macrophage infiltrates were 
often seen in Ad transduced eyes after 3 months. Abbreviations (for control eye 
section): GCL = retinal ganglion cell layer, INL = inner nuclear cell layer, ONL = 
outer nuclear layer, PR = photoreceptor outer segments, RPE = retinal pigment 
epithelium.
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9. Discussion
9.1.Transgenesis of the Ocular Outflow Tract with Lentiviral 
Vectors as a Basis for Gene Therapy of Glaucoma
9.1.1. Genetic Modification of Human Trabecular Meshwork with 
Lentiviral and Adenoviral Vectors versus Type-C Retroviral 
Vectors
The results demonstrate that lentiviral vectors effectively transduce the human 
trabecular meshwork in situ. The direct, controlled comparisons of vector systems 
using normalized vectors in the present work also demonstrated for the first time that 
lentiviral vectors derived from FIV can perform as effectively as a well-validated 
vector derived from a human lentivirus for transduction of a mitotically quiescent, 
differentiated human tissue. The consistently efficient transduction of trabecular cells 
with two different lentiviral vectors but not with equal numbers of transducing units
of a murine leukemia virus vector establishes vector properties needed to achieve 
genetic modification of the meshwork, and is consistent with evidence that turnover 
of TM cells is minimal in vivo.^^ '^^"^ '^^^  ^For example, gross injury from laser 
trabeculoplasty stimulates thymidine labeling of TM cells, but processes often 
associated with decreased outflow facility and glaucoma (such as increased 
phagocytosis, inflammation, and hyphema) do not.^^^’ The finding that 
lentiretroviral vectors but not onco-retroviral vectors transduce the trabecular 
meshwork is additional evidence that trabecular cells are mitotically quiescent in vivo.
Anterior chamber injection is a routine ophthalmologic procedure that requires only 
local anesthesia. The present results suggest that administration of lentiviral vectors 
into the anterior chamber circulation has potential to deliver therapeutic genes to the 
trabecular meshwork. The preferential transduction of the TM over other outflow tract 
structures may be an in vivo correlate of the enhancement of transduction that is 
produced by perpendicular convective flow of retroviral vector supernatants through 
target cell monolayers grown on porous s ubs t r a t e s . Th i s  targeting effect was not 
completely selective, because a few p-galactosidase-expressing cells could also be 
detected in some eyes in the outflow pathway both downstream (Schlemm’s canal and 
collector channels) and upstream (comeal endothelium in proximity to the TM, and 
the transition zone between ciliary muscle and TM). Additional strategies, for 
example, transcriptional targeting, may be useful in this regard. This has been
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successfully demonstrated by Liton et al.^ "^  ^The authors used the chitinase 3-like 1 
(Ch3Ll) gene promoter after a comparative expression analysis o f trabecular 
meshwork and Schlemm’s canal cells to restrict adenoviral vector expression to the 
TM of adenoviral vectors that contained a Ch3Ll promoter driven lacZ cassette. 
Ch3Ll is a mammalian glycoprotein member of family 18 glycosyl hydrolases that is 
involved in tissue remodeling and inflammation and acts as a growth factor for 
connective tissue cells and as a potent migration factor for endothelial cells which 
could also play a role in both the normal physiology of the TM and the abnormalities 
that occur in glaucoma. Gonzales et al. found in a similar experiment by the same 
group that promoter fragments from the matrix Gla protein can specifically direct 
expression to the trabecular meshwork, while use of the vascular endothelin-cadherin 
gene promoter even allows differentiating between vascular and Schlemm’s canal 
endothelial cells.
Vectors that transduce nondividing cells but do not predictably integrate into the 
cellular genome also have potential to express transgenes in the human TM, as found 
here and previously.^"^"  ^However, glaucoma is a chronic disease. Aqueous outflow 
impairment requires long-term control, which is best addressed by a vector that stably 
integrates as an obligate part of the transduction process. In addition, adenovirus 
vectors can trigger marked inflammation, which could exacerbate glaucoma. The 
importance of investigating long-term expression is underscored by work that 
identified a stably abnormal gene expression profile in the glaucomatous TM.^^^ 
Although a gene mutation has been associated with g l a u c o m a , a  therapeutic gene 
has yet to be described. Lentiviral vectors will facilitate study of candidate genes in 
the human organ perfusion model and in animals.
9.1.2. Preservation of Aqueous Outflow Facility after FIV-
Mediated Transduction of Anterior Segments of Human Eyes
The goal of glaucoma gene therapy directed to the anterior chamber is to restore and
preserve aqueous outflow through the TM. For therapeutic transgenes to be validated
and for eventual clinical application to proceed, a method not only has to be stable but
non-toxic modification is needed that does cause intraocular pressure to be
dangerously high during or immediately after transduction. This capability is
necessary for experimental evaluation of candidate therapeutic genes and for eventual
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use of those genes in therapy. In particular, the method of gene transfer must not cause 
counterproductive disruption of aqueous outflow through the TM. My histological 
analyses in transduction experiments of human eyes with FIV, HIV, MLV and 
adenoviral vectors proved that cellularity is well preserved and that lentiviral vector 
transduction is minimally toxic. In the next set of experiments 1 extended these results 
by demonstrating that eGFP can also be used as an effective marker gene and that the 
extensive transduction observed with these vectors does not significantly impair 
outflow facility. 1 used more refined, second-generation vectors that incorporated the 
FIV central DNA flap that Todd Whitwam identifled'^^^ and cloned into the eGFP 
vector 1 had engineered and WPRE, as had been demonstrated to improve transgene 
expression levels in other lentiviral vector systems.
Aqueous humor outflow is a complex process that is not completely understood. The 
unique architecture oftheJTM, the phagocytic biology ofthe cells, theinarrangement— 
within a collagenous lattice and the extracellular matrix they populate are all believed 
to play important roles. A final regulatory step may occur at the interface of the TM 
with Schlemm’s canal, where bulk flow occurs through large outpouchings (giant 
vacuoles) in the endothelium.^^"^ A potential concern for gene therapy is that gene 
transfer methods might disrupt the physiology of this structure. Despite a high level of 
transgene expression, FIV vector-mediated gene transfer caused only transient, slight 
(mean of 30%) declines in outflow facility, with stable return to normal baseline 
levels from 48 to 72 hours after transduction until the end of the experiment at 5 days. 
These results compare favorably with those obtained by Borras et al.^ "^^  in the same 
model after injection of adenoviral vectors. After injection of 1 x 10  ^TU of adenoviral 
vectors, outflow facility declined 13% compared with control eyes within the first 4 
hours, and was reduced by 54% after 12 hours. Subsequently, baseline outflow facility 
was reached at 36 hours and continued to increase to approximately 20% higher than 
baseline until the end of the experiment at 48 hours.^^^ As in my previous 
e x p e r i m e n t s , 1 observed preferential transduction of TM. Targeted transduction 
prevents unwanted effects of transgene expression on neighboring structures. This is 
of particular importance in ocular gene therapy, in which anatomic structures in close 
proximity serve highly specialized functions.
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9.1.3. Long-Term Genetic Modification of the Outflow Tract 
Coupled with Non-lnvasive Imaging of Gene Expression In 
Vivo
Any gene therapy for glaucoma and the proper investigation of glaucoma associated 
genetic mutations requires a method that is simple to administer and can provide long­
term, stable, high-grade, and properly targeted transgene expression within the 
anterior chamber. The experiments with domestic cats demonstrated that long-term, 
serial in vivo imaging of transgene expression is possible and that transduction can 
lead to stable genetic modification in living animals for 10 months. The effectiveness 
of gene transfer was so high that at the highest doses rapidly accumulating GFP 
expression resulted in toxicity from overtransduction. In contrast, administration of 
equivalent b-galactosidase vector also produced high level expression but without 
toxicity. Toxicity of GFP is well-described, particularly at maximal expression levels, 
_and appears toJbe cell-type-dependent.^^^iZ^^i^^tZZ&Since_eGFP_is not amplifiable (one
molecule equals one fiuorophore, whereas enzymatic markers can convert many 
molecules of substrate to detectable dye), at least 10  ^molecules per cell are needed 
for the cell to yield twice the background f luorescence .Thi s  estimate is a lower 
boundary as it assumes perfect eGFP maturation; incomplete maturation would raise 
the threshold higher.^^^ Undoubtedly, many more than 10  ^molecules per cell are 
needed to image through the cornea and to produce the high grade fluorescence 
observed here. As the same applies to the titration of FIV vectors, it is possible that 
the same number of transducing units of eGFP expressing vectors is a much higher 
number of physical vectors particles and a higher m.o.i. than with B-galactosidase 
vectors. That lower doses circumvented this problem while resulting in GFP 
expression that was still readily imaged in the living animal makes clear that a high 
dynamic range of gene delivery and expression was achieved. Consistent with results 
of others,^^^ the use of Renilla GFP did not offer advantages in the TM. Renilla GFP 
was originally advertised as a fluorescent molecule with better biocompatibility but 
this has not been solidified in a stringent way and may represent company-intem 
findings by the vendor.
As seen in human eyes, 1 again observed preferential transduction of TM over other 
ocular structures in cats which is consistent with the results in perfused human 
anterior chambers.^^"^’ This targeting may be an in vivo correlate o f the 
enhancement produced by perpendicular convective flow of retroviral vector
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supernatants through target cell monolayers grown on porous substrates7^  ^In 
addition, the tropism of these VSV-G pseudotyped lentiviral vectors may favor certain 
cell types, as seen for example in the subretinal space where the retinal pigment 
epithelium is preferentially transduced. Thus aqueous humor flow dynamics and cell- 
specific permissiveness to transduction by these vectors may both be factors. Strict 
targeting in these larger eyes has not been seen by two other groups who used rodent 
eyes, the mouse^^^’ and the rat.^ "^  ^It is possible that this is a species specific 
observation and a result o f lentiviral restriction in comeal endothelial c e l l s . O n  the 
other hand, it is unlikely that the large amount of lentiviral vectors does not cause 
saturation of restricting factors^^^ in comeal endothelial cells but does so in trabecular 
meshwork cells. More likely, convection and flow are different in small rodent eyes; 
in the cat and in human eyes the central comea is further away firom the draining 
structure, the trabecular meshwork than in rodent eyes (Figure 17). Occasionally 
injected air bubbles may have contributed to protection of comeal endothelium as is 
commonly done prior to surgery of mature cataracts when trypan blue is injected 
undemeath air to only stain the anterior surface of the lens immediately before 
capsulorhexis. As of note, 1 observed some transduction of comeal endothelial cells 
directly adjacent to TM (Figure 24). Another possibility is that manipulation of small 
rodent eyes creates more comeal warping and stretching compared to the larger eyes 
which may induce endothelial cell cycling of this non-dividing cell. It is known that 
cell division facilitates lentiviral transduction^^^ although these vectors have a evolved 
a specialized mechanism that allows transduction of non-dividing cells, a feature that 
distinguishes them from type-C retroviral vectors.
As in human donor eyes,^ "^ ’^ high level transduction could be performed without 
detriment to aqueous humor outflow or the histological fine stmcture, indicating that 
these replication-defective lentiviral vectors have favorable toxicity profiles for 
further investigation of glaucoma gene therapy. This was reflected in an only 
moderate and transient change of intraocular pressure.
There is a critical need for a realistic animal model for glaucoma. The results establish 
that prolonged, targeted, and multi-grade expression of transgenes in the disease­
relevant tissue is possible. After completion of the studies for this thesis, we have 
explored this in the cat model that 1 developed here using myocilin and myocilin
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mutant expressing vectors.^"^* However, co-expression with enhanced GFP of 
myocilin or a juvenile glaucoma-associated mutant myocilin did not elevate lOP.
The association of myocilin gene mutations with familial glaucoma was recognized a 
decade ago;^ "^  ^a number of disease-associated mutations have been identified/
Since various studies suggest that the heterozygous state for many of these mutations 
is associated with POAG,^^^ we hypothesized that prolonged expression of a 
glaucoma-associated mutant (and possibly even additional wild-type protein 
expression) might produce elevated lOP in cats. It is possible that the feline outflow 
pathway may not be vulnerable to myocilin-related pathophysiology or the feline 
Y423H mutant chosen for study may differ from the human Y437H mutant protein in 
structure or other aspects. However, feline myocilin did behave similarly to human 
myocilin with respect to intracellular trafficking, with the Y423H mutant retained in 
the celFsimilar to humanAf437H and_theJwild^type_proteins undergoing-export.7fhe—
lack of significant lOP elevation we observed could be due to inadequate expression, 
or lack of uniform expression in all cells, since our immunofluorescence analyses 
using an epitope-tag do not establish the degree o f expression of the exogenous 
myocilins relative to endogenous levels. However, consistent with our study, 
transgenic mice with uniform Y423H expression also do not develop lOP elevation or 
glaucoma.^^^ Taken together with clinical and epidemiological data, existing animal 
data suggest that development of lOP elevation is dependent on other factors in 
addition to a mutant myocilin protein. Finally, since the clinical time course of human 
genetic glaucomas is quite variable, and disease can take many years to become 
evident, our study may simply lack the necessary duration for detecting an effect on 
lOP despite its relatively long follow-up period. Although the Y437H has a relatively 
early onset phenotype in humans, these individuals do not develop glaucoma at 1-2 
years of age (the term of our study) and the period of follow-up in the cats may well 
have been too short to detect an effect. The lentiviral vector feline model has the 
potential to produce a reliable, realistic animal model of POAG, but this will possibly 
also require alternative transgene approaches that can induce a realistic POAG-like 
state. While surgical or laser injuries to the full circumference of the TM can raise 
lOP,^^’ such approaches cannot recapitulate the subtle outflow resistance problem in 
POAG and the gross injury destroys the therapeutic target, the TM.
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The lack of a high fidelity full disease model of POAG with lOP elevation that can be 
followed to the endpoint o f retinal ganglion cell death, should not prove to be an 
impediment of any great degree to pre-clinical therapeutic transgene testing. Small 
molecule therapies in current practice appear to utilize physiological mechanisms that 
are also available in the normal outflow pathway (reviewed in^^ )^. Normotensive eyes 
are currently used for pre-clinical animal studies of candidate lOP-reducing POAG 
therapeutics which have often used the domestic cat; this is because lOP reductions in 
normotensive eyes are predictive of efficacy in POAG and the minimal variation 
between eyes at baseline facilitates paired left to right eye comparison designs.
9.1.4. Conclusions from Studies of Genetic Modification of the 
Outflow Tract and Future Directions
1 have shown that lenti-retrovirak but not oncoretroviral. vectors allow the specific
transduction of trabecular meshwork in human donor eyes and established a dose- 
response curve over 4 logs between injected vector number and transduction 
eff ic iency.Despi te  high transduction efficiencies the outflow facility was affected 
only transiently and to a minor d e g r e e . T h e  fine structure of the trabecular 
meshwork remained unaltered.^^"^’ In the cat, a similar transduction efficiency and 
effect on outflow facility was observed. Vector function could be followed in real 
time for the entire study of 10 months.^^^
FlV-mediated transgenesis is a highly effective method to reprogram the outflow tract 
permanently. This opens entirely new options to develop realistic glaucoma animal 
models by injecting vectors into the anterior chamber that transduce a desired 
genotype.
Our results with myocilin mutants cast doubt on the idea that mutations are 
responsible for intracellular deposits of proteins that are undegradable by the 
proteasome and are essentially the equivalent o f a neurodegenerative disease of the 
outflow tract. Ongoing in vivo experiments with feline myocilin mutants in the cat 
will help to better understand the pathomechanism that leads to the glaucoma 
phenotype.
Long-term genetic modifications for therapeutic purposes appear to be possible. This 
is the first basis for a gene therapy of glaucoma that can adequately address the
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chronicity o f glaucoma. Because transduction is targeted to the outflow structures, the 
choice of potential therapeutic transgene is also limited to proteins responsible for its 
regulation, which limits for instance regulation of aqueous humor production by the 
ciliary body. A variety o f transgenes has been suggested for the therapeutic 
modification of TM. Transduction of stromelysin^^^ to modify the extracellular matrix 
is attractive in theory, but will require well controlled expression to avoid 
autodigestion of the cellular network. Matrixmetalloproteinases also require activation 
by a complex system of other metalloproteinsases. Simple delivery of e.g. stromelysin 
cDNA ignores this fact^^  ^resulting in expression of inactive pro-stromelysin.
An attractive transgene for gene therapy is the small guanosine triphosphatase (GTP) 
Rho that regulates remodeling o f the actin cytoskeleton during cell morphogenesis 
and motility. Rao et al. investigated the role of Rho kinase in the modulation of 
aqueous-humor-outflowfacility.^^The-treatment-of human trabecular-meshwork and 
canal of Schlemm cells with a Rho kinase-specific inhibitor led to significant but 
reversible changes in cell shape and decreased actin stress fibers, focal adhesions, and 
protein phosphotyrosine staining. Based on the Rho kinase inhibitor-induced changes 
in myosin light chain phosphorylation and actomyosin organization, the authors 
suggested that cellular relaxation and loss of cell-substratum adhesions in the human 
trabecular meshwork and canal of Schlemm cells could result in either increased 
paracellular fluid flow across the canal of Schlemm or altered flow pathway through 
the juxtacanalicular tissue, thereby lowering resistance to outflow. Rho kinase is a 
potential target for the development of drugs to modulate intraocular pressure in 
glaucoma patients. However, adenoviral vector mediated transduction of TM with the 
Rho A gene's dominant-negative mutant protein showed only minor effects.
C3 transferase could be of use as a therapeutic transgene because it selectively ADP- 
ribozylates Rho in its effector-binding domain on asparagine residue 41 and thereby 
abolishes its biological fiinction.^^'^’
Caldesmon is another protein with therapeutic potential as an actomyosin regulatory 
protein found in smooth muscle and nonmuscle cells.^^^ Domain mapping and 
physical studies suggested that caldesmon is an elongated molecule with an N- 
terminal myosin/calmodulin-binding domain and a C-terminal 
tropomyosin/actin/calmodulin-binding domain separated by a 40-nm-long central 
helix.
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A different approach is the transduction of enzymes that produce pro-inflammatory 
substances, e.g. cyclooxygenase catalyzing the first two steps in prostaglandin, 
thromboxane, and prostacycline synthesis from arachnidonic acid. Some of the most 
successful intraocular pressure lowering drugs mimic the effect of prostaglandin p 2a 
(latanoprost).^^^ However, the effect of prostaglandins produced by cyclooxygenase, 
while potent, are not specific. It may be possible to cotransduce the appropriate 
receptor to make the effect specific. In order to create a production site of 
cyclooxygenase for the generation of prostaglandins, the jet during intracameral 
injection can be directed at different targets and repeatedly washed. The receptor 
should be expressed by the outflow structures and intraocular injection techniques 
would not have to be modified.
A more radical idea that 1 would like to pursue and have recently submitted for 
funding is trabeculoablative genejherapy toJmprove outflow.and to-create a model to-
study repopulation dynamics o f the trabecular meshwork. The site of the highest 
resistance to outflow of aqueous humor is the juxtacanalicular trabecular meshwork^^’ 
and the principal site of pathology in primary open angle glaucoma (POAG).*^^’ 
Traditional therapies for advanced glaucoma attempt to lower intraocular pressure 
surgically by circumventing the outflow resistance of the TM by shunting aqueous 
humor to the subtenon space (e.g. trabeculectomy, glaucoma drainage device)?^^ 
These filtering procedures have a high rate of complication and failure^^^ despite the 
introduction of antimetabolites and improvement of drainage device design, 
respectively. The complete disruption of the TM and wall of Schlemm’s canal has 
recently been achieved with the trahectome^^^ but this disruption is irreversible 
creating a permanently open connection to the downstream drainage system. Instead, 
trackable FIV vectors that co-express eGFP and herpes simplex virus thymidine 
kinase for selective ablation of the juxtacanalicular trabecular meshwork by 
ganciclovir^^^ may offer a solution. HSV-tk converts the antiviral prodrug of 
nucleotide analogs such as ganciclovir to the diphosphorylated form, which is then 
converted by endogenous cellular kinases to the toxic triphosphate form that competes 
with normal nucleosides for DNA replication. After incorporation into DNA 
elongation is inhibited leading to apoptosis.
HSV-tk suicide gene therapy^^^’ is a well established method of cytoreduction 
(reviewed in Yang et al. have recently demonstrated that an HFV vector co-
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expressing both HSV-tk and eGFP can be generated and is highly successful in killing 
human lens epithelial cells/^^ Because of selective transduction of the trabecular 
meshwork with FIV vectors and minimal bystander effect of HSV-tk, this approach 
will leave the supporting structures (trabecular beams, comeal endothelium, iris) 
intact and allow regeneration from adjacent tissues. This strategy has the advantage of
(a) being simple as it is using an already established model with proved transgenes,
(b) the chief pathology of POAG of an abnormally high outflow resistance is 
addressed in its core and (c) a new model to study TM regeneration and repopulation 
will be created. Another desirable safety feature for potential therapeutic application 
is that cells that were permanently genetically altered by an integrating vector can be 
visualized and reliably ablated.
Finally, trabecular meshwork transgenesis must be evaluated in eyes that are even
more similar to that of humans, e.g. that of macaques. Cats are different in thatth ey___
have a more wide-spread trabecular meshwork and a plexus of collector channels, 
while primates have a more confined, wedge-shaped TM and one occasionally 
doubled collecting Schlemm's canal. I have participated in studies with Dr. Paul 
Kaufman by setting up the imaging system, producing the vector and teaching vector 
application techniques. These findings have been presented at the 2006 meeting o f the 
Association for Research in Vision and Ophthalmology in Fort Lauderdale.
Preliminary results of trabecular meshwork transduction in macaques have 
demonstrated that the prior results in cultured human and live feline eyes can be 
replicated.
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9.2.Transgenesis of the Retinal Pigment Epithelium with 
FIV Vectors as a Basis for Gene Therapy of Retinal and 
Choroidal Diseases
9.2.1. Comparison of Wild-Type and Class I Integrase Mutant-FIV 
Vectors in the Retina Demonstrates Sustained Expression of 
Integrated Transgenes in Retinal Pigment Epithelium
My studies followed retinal transgene expression for the longest reported time.
Experiments with pseudotyped lentiviral vector systems in retina prior to mine
reported expression in rodents only up to post-injection day 42/^^ 84/^^' 140^^^
and 168.^^  ^My studies also involved the unbiased reporting of results from all
animals enrolled in a prospective design, and were scored by observers masked to
injection status minimizing observer influence.
Intravitreal injections resulted in relatively poor transduction efficiency compared to 
-subretinal injectionsrusing the same volume for delivery. In contrast, subretinal---------
injections of a similar volume caused extensive transduction of the RPE, indicating 
broad dissemination of the vector within the subretinal space. It is possible that the 
extent of transduction in eyes injected by the intravitreal route would be different at 
later time points, which were not examined in the injection route comparisons. 
However, most published studies agree with mine that the inner retinal layers block 
significant access of lentiviral vectors and other vectors to the RPE firom the 
vitreous."'^'
I found extensive transgene expression in the RPE, at 2, 3, and 7 months, and in only 
occasional cells of other inner and outer retinal layers. It was limited to the RPE at 
early time points (2 and 7 days). Transduction of neonatal rat neurosensory retina, in 
addition to the RPE, has been observed using subretinal injection of HIV vectors by 
other investigators.^^^ An important distinction is that the latter study was limited to 
rats injected earlier in post-partum development (2-5 days) than the rats in our study 
(7 days). The very rapid developmental changes occurring at these early time points 
are likely to influence permissivity. My findings are therefore consistent with the 
results of a number of studies that have found that in rodents older than 5 days post­
natal, and in adult rabbits, expression has been largely limited to the RPE, whether 
administered subretinally or intravitreally.^^^’ 3^6-338 y g y .Q  jg believed to 
mediate entry via ubiquitous plasma lemma lipid molecules, thereby giving the 
vectors broad entry specificity.^^^ Varying distribution of these molecules between
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cell types, and differential vector particle diffusion, might also contribute to 
preferential transduction of RPE. Duisit et al. saw only RPE transduction in a large 
series of rats injected with SIV vectors pseudotyped with 5 different viral envelopes, 
including VSV-G and Mokola-G,^^^ and a study with bovine immunodeficiency virus 
vectors showed targeted, high-level RPE expression in mice.^^^ One group saw 
reporter protein localization in both RPE and photoreceptors in 5-7 week old mice 
after HIV-1 vector injection; pseudotyping with the Mokola-G rather than VSV-G 
restricted transduction to the RPE.^^^ In contrast, in non-human primates injected at 
the macula, FIV vector-mediated expression was reported to be variably detectable in 
Müller cells and photoreceptors in some animals.^^^ Transduction of RPE cells is 
facilitated by vector uptake at their phagocytotically active, apical site.^^^ Other 
factors influencing differential expression between cell types include distance o f and 
barriers to diffusion as well as varying metabolism rates of neurosensory retina and 
RPE.
The class I integrase mutant vector data in my study suggests that integration is 
necessary for long-term transgene expression by this lentiviral vector. This has been 
confirmed in later collaborative studies with Dyana T. Saenz who has explored factors 
involved with integration^^^’ and species-dependent resistance o f transduction in 
more detail.^^^ I observed substantial, sustained transgene expression after subretinal 
injection of wild-type FIV vector (for at least 7 months); this was blocked when the 
D66V vector was used. D66 is the most amino-terminal of the three invariant acidic 
residues in the conserved catalytic core domain of integrases (DXsg.sgDXssE).^^^ The 
residues are highly conserved in eukaryotic retro-element integrases as well as in 
bacterial transposons.^^^"^^^ A D64V substitution in the HfV-1 integrase results in 
dramatically lower to undetectable transduction in rat brains^"^ ’^ and has been 
shown to be “class I" in that it specifically blocks the integration reaction while 
leaving all of the multiple other functions of Gag/Pol precursor-derived proteins 
undisturbed.^^^’ In contrast, simple deletions, frame shifts, and most other
point mutations in integrase yield "class 11" phenotypes in which particles are 
pleiotropically aberrant in non-integrase f u n c t i o n s . I n  vector experiments, this 
elegant control has the virtue of comparing particles that differ only in a single amino 
acid in a single enzyme that forms a very small molar fraction of the virion.
Class I integrase mutants had not been described for FIV, or tested in the eye for any
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lentiviral vector. My results with FIV vectors demonstrate long-term transgene 
expression in retina from an FIV vector and show that preventing integration prevents 
sustained expression. This single amino acid variant of FIV integrase provides a 
useful control for future studies using FIV vectors; pseudotransduction might in part 
account for some of the previously reported discrepancies in retinal layer targeting.
It is remarkable that Yanez-Munoz et al. found high level transduction with a non­
integrating HIV vector in mice."^ ^  ^My own studies employed a rat model and FIV 
vectors as did Naldini et al. in brain transduction experiments.^^® However, Park et al. 
transduced mouse liver and were unable to detect transduction with non-integrating 
v e c t o r s . I t  is possible that this is a species barrier or perhaps that the mode of 
application resulted in more cell cycling and attrition of non-integrated vector circles 
as the same author has demonstrated before.^^^
The^higi transgene expression seen at days 2"tô”7~âfterinjëction o f CT25 correlates 
temporally with the peak of neovascularization in HOP m o d e l s . I t  will be of interest 
to use FIV vectors to deliver candidate therapeutic genes to the retina o f neonatal rats 
under conditions of oxygen-induced retinopathy in a model for ROP. This may 
provide a tool to understand the pathogenesis of neovascular diseases and allow 
exploration of novel therapies for clinically approachable diseases such as age-related 
macular degeneration. The ability to obtain preferential gene expression in the RPE is 
desirable. Endogenous angiostatic factors, such as pigment epithelium derived factor 
(PEDF), are produced in these cells, and diffuse from the RPE into the adjacent retinal 
and choroidal layers.A deno-associated  virus vectors have shown promise for 
retinal expression of pigment epithelium derived factor; however, they do not limit 
expression of this protein to its physiological origin, the RPE.^^^ RPE-targeted gene 
therapy using FIV or other lentiviral vectors may be useful in treating diseases 
characterized by abnormal retinal angiogenesis. Other lentiviral vectors have now 
been successfully used to express anti-angiogenic substances: Igarashi et al. used HIV 
vectors expressing angiostatin to reduce neovascularization dramatically by 90%.^^^ 
EIAV vectors also achieved reduction of neovascularization in a laser model by 
expressing endostatin. Approximately 60% of the neovascularization area was 
reduced with endostatin versus 50% with angiostatin.^^®
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9.2.2. Long-Term Retinal Transgene Expression with FIV versus 
Adenoviral Vectors
I found similar location, extent and duration of transgene expression in neonatal rat
eyes subretinally injected with FIV and Ad vectors expressing P-galactosidase under
transcriptional control of the human CMV immediate-early promoter/enhancer.
Expression with each vector was present at 16 months post injection. There was a
higher overall extent of expression with FIV, which peaked later than Ad (3 months
vs. 1 week). Histology revealed greater cellular infiltrate and disruption of normal
retinal architecture with Ad.
Preferential transduction of RPE over other retinal cell types was again seen by VSV- 
G pseudotyped lentiviral vectors as reported.^®’ Ad vectors appear to
have a similar tropism within the r e t i n a . I n  contrast, only occasional 
expression in the post-mitotic, terminally differentiated, neurosensory retina occurred 
at 1 month post-injection and beyond with both FIV and Ad vectors. While this might 
limit applicability to neovascularization of inner retinal layers, choroidal 
neovascularization and degeneration of the RPE, as seen in wet macular degeneration, 
are good targets. Limiting expression to the RPE is desirable in degenerative diseases 
of the retinal pigment epithelium that result also in degeneration of photoreceptors 
from death of RPE cells.^^^ In wet macular degeneration, the combination of 
neuroprotective and anti-angiogenic action of PEDF would be highly desirable to 
prevent photoreceptor death and progressive vessel growth and exudation.
The extent and duration of expression with FIV vectors has implications for future 
therapy: lentiviral vectors are advantageous for long-term expression over other 
vectors because of their ability to integrate into the host cell genome. In my own 
studies, this was supported by the use of a single amino acid mutation in the catalytic 
core domain of the FIV integrase (D66V) blocked efficient transduction, while 
vectors with intact integrase expressed for 7 months.^®
The duration of expression from a first generation Ad vector was unexpected. Marker 
gene expression from subretinally injected Ad vector in an immunocompetent host 
often lasts between 1 to 3 m o n t h s . A d  vectors lack any mechanism for 
integration, leaving them more vulnerable to attrition by intracellular metabolism and 
dilution during cell division. Although adenoviral vectors may integrate in 0.1% to
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1% of infected c e l l s , t h i s  mechanism cannot explain the extent and duration 
observed in the present study. Most likely, the low mitotic rate of RPE cells 
contributes to long-term persistence of Ad vectors in this cell type.
Immunogenicity is a disadvantage of first generation Ad vectors.^^^’ I
confirmed that Ad vectors induce a long-term cellular response, associated with 
disruption of the normal retinal architecture in our model. This retinal disruption 
limits the clinical application of first generation Ad vectors in treating retinal disease. 
In contrast, retinal architecture was preserved in eyes injected with FIV vectors, with 
the exception of small areas of atrophy directly adjacent to the injection site.
Based on light microscopy, my experiments suggest minimal toxicity of FIV vectors 
following subretinal injection. Others have confirmed normal retina function with 
technically highly specialized assessment with electroretinography after lentiviral 
vector gene transfer to the subretinal space.^ "^ "^ ’^ ^^
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10. Conclusion
The central goal to engineer FIV vectors into a more modular platform for long-term 
ocular gene therapy could be accomplished by separating envelope, packaging and 
transfer function.^^* While this was a collaborative approach between several 
individuals (mostly Todd Whitwam, Iris Kemler, Roman Barraza) in Eric Poeschla’s 
laboratory, I contributed by transfer vector optimization. FIV mediated gene transfer 
to the aqueous humor outflow tract^ "^^ ’ and to the retina^^’ was established 
and long-term vector function and biocompatibility were assessed.^^’
Transduction of the outflow tract was highly efficient and resulted in genetic 
modification o f nearly the entire trabecular meshwork.^^"^’ I developed methods 
for administration and more sensitive monitoring of FIV vectors in the anterior 
chamber^^^ and a novel subretinal injection technique.^^’
Bicistronic FIV vectors generated high levels of two different transgenes eGFP and P- 
galactosidase, which allowed live in vivo tracking^^"^’ and sensitive yet specific 
cell labeling in tissue specimen, respectively.^^’ In eGFP vectors, I disabled the 
LTR promoter function of integrated vectors through a SIN modification in analogy to 
HIV vectors.^^^ ' "^^ ® This vector was used in later studies in which I participated to 
deliver myocilin mutants to the outflow tract in vivo to generate an in vivo glaucoma 
model.^"^  ^ The above studies and subsequent experiments that I have participated in 
and co-published published recently^"^  ^ establish that durable transgene expression is 
readily achievable and is well tolerated, exceeding 2 years. This model has been 
recreated by other investigators in other species^ "^ ®’ as well as with a collaborator, 
Paul Kaufman, in macaques. Future directions that I will pursue include development 
of trabeculoablative gene therapy and creation of a model to study trabecular 
meshwork repopulation dynamics and cell based therapy.
I also cloned an integrase mutant control vector that differed in only one amino acid 
while preserving all other biochemical properties.^^’^^® While I observed no 
transduction in vivo,^^ later studies have shown that there is significant transgene 
expression in non-dividing cells in vitro experiments.^®"  ^Unfortunately, more recent 
results with HIV integrase mutant vectors where full rescue could be achieved 
question the usefulness of this control unless the observed effect is HIV and rodent 
specific."^ ^^
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With the technical assistance of Teo Wu-Lin I developed a novel protocol for scaled- 
up production of these vectors using cell factories and large-volume concentration 
that proved useful in subsequent animal studies/^' Especially the
results achieved in the larger animal model, the domestic cat, validate the protocol for 
large-scale production. Transient transfection of 10 times less DNA in 293T cells 
within high surface area slides and high volume, fixed-angle ultracentrifugation 
resulted in high titer vectors that were effective in the eye. Standard protocols use 5 to 
10 times as much transfection DNA, which is expensive and time consuming to 
produce, and generally concentrate vectors in smaller volumes.^’ Although 
inducible vector production cell lines are very useful,^^ '^^^"  ^they do not have the 
versatility of transient transfection that allows readily adjustment and swapping of 
vector components.
Further preclinical studies will have to be conducted to evaluate vector safety and 
immunology. Although FIV is unable to actively infect and replicate in human cells, 
the domestic cat as the natural host will be used as a model to evaluate chances of 
generating replication competent retroviruses that could emerge in theory. For the 
actual clinical application, FIV vector producing cell lines will have to be generated 
and well characterized to fulfill regulations of Good Manufacturing Practices.
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